Purification of multispecific antibodies
Sequential capture and mixed-mode chromatography effectively purifies multispecific antibodies, addressing the challenge of removing product-specific impurities, achieving high purity suitable for therapeutic use.
Patent Information
- Application Number
- JP2024102664
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-06-17
- Filing Date
- 2024-06-26
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2037-06-16
AI Technical Summary
Conventional purification techniques are inadequate for effectively removing product-specific impurities such as misassembled antibodies and non-antibody arms from multispecific antibodies, which are challenging due to their unique production process involving multiple heavy/light chain subunits.
A method involving sequential capture chromatography followed by mixed-mode chromatography, including anion and hydrophobic interaction chromatography, is employed to purify multispecific antibodies, reducing product-specific impurities like non-opposed arms, homodimers, and aggregates.
The method achieves high purity multispecific antibodies with reduced impurities, reaching up to 99% purity with minimal non-opposed arms, homodimers, and other impurities, suitable for therapeutic applications.
Smart Images

Figure 2024156655000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 351,908, filed June 17, 2016, which is incorporated herein by reference in its entirety.
[0002] Submitting a sequence listing as an ASCII text file The following submission in an ASCII text file is incorporated by reference in its entirety herein: Sequence Listing in Computer Readable Form (CRF) (Filename: 146392036340SEQLIST.TXT, Recorded: Jun. 9, 2017, Size: 32KB).
[0003] Methods are provided for purifying a multispecific antibody from a composition comprising the multispecific antibody and at least one impurity, including at least one product-specific impurity. In some embodiments, the product-specific impurity is, for example, a precursor, aggregate, and / or variant of the multispecific antibody. Multispecific antibodies purified according to the methods, and compositions and formulations comprising such multispecific antibodies are also provided. [Background technology]
[0004] For recombinant biopharmaceutical proteins to be acceptable for administration to human patients, it is important that residual impurities resulting from the manufacturing and purification process are removed from the final biological product. These process components include culture media proteins, immunoglobulin affinity ligands, viruses, endotoxins, DNA, and host cell proteins (HCPs). The development of new antibody formats, such as multispecific antibodies, presents new challenges because traditional manufacturing and purification processes are inadequate to adequately remove product-specific impurities, including unpaired antibody arms and misassembled antibodies.
[0005] Compared to purification of standard antibodies, purification of multispecific antibodies from production media presents unique challenges. While standard mono-specific bivalent antibodies result from the dimerization of identical heavy / light chain subunits, production of multispecific antibodies requires the dimerization of at least two different heavy / light chain subunits, each containing a different heavy chain, as well as a different light chain. The production and purification of final and complete multispecific antibodies with minimal amounts of mispaired, misassembled, or incomplete molecules presents different challenges. Chain mispairing (e.g., homo-dimerization of identical heavy chain peptides or improper heavy / light chain association) is frequently observed due to incomplete protein assembly resulting from unbalanced host cell expression of different antibody chains. Commonly observed product-specific impurities include half (1 / 2) antibodies (containing a single heavy / light chain pair), three-quarter (3 / 4) antibodies (containing complete antibodies lacking a single light chain), and homodimers. Additional product-specific impurities may be observed depending on the multispecific format used. For example, if the variable domains of the multispecific antibody are constructed as single chain Fab (scFab), a product 5 / 4 antibody (containing an additional heavy or light chain variable domain) may be observed. Such corresponding product-specific impurities do not occur in standard antibody production.
[0006] Conventional purification techniques designed to remove process-related impurities such as HCP, DNA, endotoxins, and other substances with characteristics and properties very different from antibodies can be inadequate when implemented to remove impurities that are more similar to multispecific antibodies. Thus, there is a need to develop manufacturing and purification schemes that effectively remove product-specific impurities and yield sufficient quantities of the correct and intact multispecific antibodies.
[0007] All references cited herein, including patent applications and publications, are incorporated by reference in their entirety. Summary of the Invention
[0008] As described and exemplified herein, Applicants have discovered that the use of at least two mixed-mode (also referred to herein as multi-modal or multimodal) chromatography steps after an initial capture chromatography step results in greater removal of product-specific impurities and improves the process for purifying multispecific antibodies. Thus, in certain embodiments, a method is provided for purifying a multispecific antibody from a composition comprising the multispecific antibody and an impurity, wherein the multispecific antibody comprises a plurality of arms, each arm comprising a VH / VL unit, the method comprising the sequential steps of: a) subjecting the composition to capture chromatography to produce a capture chromatography eluate; b) subjecting the capture chromatography eluate to a first mixed-mode chromatography to produce a first mixed-mode eluate; c) subjecting the first mixed-mode eluate to a second mixed-mode chromatography to produce a second mixed-mode eluate; and d) collecting fractions comprising the multispecific antibody, wherein the method reduces the amount of product-specific impurities in the composition. In some embodiments according to (or as applied to) any of the above embodiments, the capture chromatography eluate is subjected to ion exchange chromatography (e.g., anion exchange) or hydrophobic interaction chromatography prior to the first mixed-mode chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the second mixed-mode eluate is subjected to ion exchange chromatography (e.g., anion exchange) or hydrophobic interaction chromatography.
[0009] In certain embodiments, a method is provided for purifying a multispecific antibody from a composition comprising the multispecific antibody and an impurity, the multispecific antibody comprising multiple arms, each arm comprising a VH / VL unit, each arm of the multispecific antibody being generated separately, the method comprising the sequential steps of: a) subjecting each arm of the multispecific antibody to capture chromatography to generate a capture eluate for each arm of the multispecific antibody, b) forming a mixture comprising the capture eluate of each arm of the multispecific antibody under conditions sufficient to generate a composition comprising the multispecific antibody, c) subjecting the composition comprising the multispecific antibody to a first mixed-mode chromatography to generate a first mixed-mode eluate, and d) subjecting the first mixed-mode eluate to a second mixed-mode chromatography to generate a second mixed-mode eluate; and e) collecting fractions comprising the multispecific antibody, the method reducing the amount of product-specific impurities in the composition. In some embodiments according to (or as applied to) any of the above embodiments, the capture chromatography eluate is subjected to ion exchange chromatography (e.g., anion exchange) or hydrophobic interaction chromatography prior to the first mixed-mode chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the second mixed-mode eluate is subjected to ion exchange chromatography (eg, anion exchange) or hydrophobic interaction chromatography.
[0010] In some embodiments according to (or as applied to) any of the above embodiments, the capture chromatography is affinity chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the affinity chromatography is Protein L chromatography, Protein A chromatography, Protein G chromatography, Protein A and Protein G chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the affinity chromatography is Protein A chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the capture chromatography is performed in bind and elute mode.
[0011] In some embodiments according to (or as applied to) any of the above embodiments, the first mixed mode chromatography and the second mixed mode chromatography are consecutive. In some embodiments according to (or as applied to) any of the above embodiments, the first mixed mode chromatography is mixed mode anion exchange chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the second mixed mode chromatography is mixed mode cation exchange chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the first mixed mode chromatography is mixed mode cation exchange chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the second mixed mode chromatography is mixed mode anion exchange chromatography.
[0012] In some embodiments according to (or as applied to) any of the above embodiments, the first mixed-mode chromatography is performed in bind-and-elute mode or in flow-through mode. In some embodiments according to (or as applied to) any of the embodiments in which the first mixed-mode chromatography is performed in bind-and-elute mode, the elution is a gradient elution.
[0013] In some embodiments according to (or as applied to) any of the above embodiments, the second mixed-mode chromatography is performed in bind-and-elute mode or in flow-through mode. In some embodiments according to (or as applied to) any of the embodiments in which the second mixed-mode chromatography is performed in bind-and-elute mode, the elution is a gradient elution.
[0014] In some embodiments according to (or as applied to) any of the above embodiments, the method further comprises ultrafiltering the second mixed-mode eluate. In some embodiments according to (or as applied to) any of the above embodiments, the ultrafiltration comprises, sequentially, a first ultrafiltration, a diafiltration, and a second ultrafiltration.
[0015] In some embodiments according to (or as applied to) any of the above embodiments, the Protein A chromatography comprises Protein A linked to agarose. In some embodiments according to (or as applied to) any of the above embodiments, the Protein A chromatography is MAbSelect™, MAbSelect™ SuRe and MAbSelect™ SuRe LX, Prosep-VA, Prosep-VA Ultra Plus, Protein A Sepharose Fast Flow, or Toyopearl Protein A chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the Protein A chromatography uses one or more of a Protein A equilibration buffer, a Protein A loading buffer, or a Protein A wash buffer, wherein the equilibration buffer, the loading buffer, and / or the wash buffer are at about pH 7 to about pH 8. In some embodiments according to (or as applied to) any of the above embodiments, the Protein A equilibration buffer is at about pH 7.7. In some embodiments according to (or as applied to) any of the above embodiments, the Protein A equilibration buffer comprises about 25 mM Tris and about 25 mM NaCl. In some embodiments according to (or as applied to) any of the above embodiments, the Protein A chromatography is washed with an equilibration buffer after loading. In some embodiments according to (or as applied to) any of the above embodiments, the multispecific antibody is eluted from the Protein A by applying a Protein A elution buffer having a low pH to the Protein A chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the Protein A elution buffer comprises about 150 mM acetic acid, about pH 2.9. In some embodiments according to (or as applied to) any of the above embodiments, the multispecific antibody is eluted from the Protein A chromatography by a pH gradient.
[0016] In some embodiments according to (or as applied to) any of the above embodiments, the anion exchange mixed mode chromatography comprises a quaternary amine and a hydrophobic moiety. In some embodiments according to (or as applied to) any of the above embodiments, the anion exchange mixed mode chromatography comprises a quaternary amine linked to agarose and a highly cross-linked hydrophobic moiety. In some embodiments according to (or as applied to) any of the above embodiments, the mixed mode chromatography is Capto™ Adhere chromatography or Capto™ Adhere ImpRes chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the cation exchange mixed mode chromatography comprises N-benzyl-n-methylethanolamine. In some embodiments according to (or as applied to) any of the above embodiments, the mixed mode chromatography is Capto™ MMC chromatography or Capto™ MMC ImpRes chromatography.
[0017] In some embodiments according to (or as applied to) any of the above embodiments, the first mixed-mode chromatography uses one or more of a mixed-mode pre-equilibration buffer, a mixed-mode equilibration buffer, a mixed-mode loading buffer, a mixed-mode wash buffer, wherein the mixed-mode pre-equilibration buffer, the mixed-mode equilibration buffer, the mixed-mode loading buffer, and / or the mixed-mode wash buffer are at about pH 6 to about pH 7. In some embodiments, the anionic mixed-mode equilibration buffer is at about pH 6.5 to about pH 8.
[0018] In some embodiments according to (or as applied to) any of the above embodiments, the second mixed mode chromatography uses a mixed mode pre-equilibration buffer, mixed mode equilibration buffer, mixed mode loading buffer, or mixed mode wash buffer, where the mixed mode pre-equilibration buffer, mixed mode equilibration buffer, and / or mixed mode wash buffer is from about pH 5 to about pH 8, optionally from about pH 5 to about pH 7, or from about pH 5 to about pH 6, or from about pH 6 to about pH 7.
[0019] In some embodiments according to (or as applied to) any of the above embodiments, the mixed-mode pre-equilibration buffer, the mixed-mode equilibration buffer, and / or the mixed-mode wash buffer are about pH 5.5. In some embodiments according to (or as applied to) any of the above embodiments, the mixed-mode pre-equilibration buffer comprises about 500 mM acetate. In some embodiments according to (or as applied to) any of the above embodiments, the mixed-mode equilibration buffer comprises about 50 mM acetate.
[0020] In some embodiments according to (or as applied to) any of the above embodiments, the first mixed-mode chromatography is washed with a wash buffer after loading. In some embodiments according to (or as applied to) any of the above embodiments, the second mixed-mode chromatography is washed with a wash buffer after loading. In some embodiments according to (or as applied to) any of the above embodiments, the multispecific antibody is eluted from the first mixed-mode chromatography by a salt gradient and / or a pH gradient or a pH step elution. In some embodiments according to (or as applied to) any of the above embodiments, the multispecific antibody is eluted from the first mixed-mode chromatography by applying a mixed-mode elution buffer having a low pH to the mixed-mode exchange chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the multispecific antibody is eluted from the second mixed-mode chromatography by a salt gradient and / or a pH gradient or a pH step elution. In some embodiments according to (or as applied to) any of the above embodiments, the multispecific antibody is eluted from the second mixed-mode chromatography by applying a mixed-mode elution buffer having a low pH to the mixed-mode exchange chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the mixed mode elution buffer comprises about 25 mM acetate, at about pH 5.5.
[0021] In some embodiments according to (or as applied to) any of the above embodiments, the anion exchange chromatography comprises a quaternary amine. In some embodiments according to (or as applied to) any of the above embodiments, the anion exchange chromatography comprises a quaternary amine linked to cross-linked agarose. In some embodiments according to (or as applied to) any of the above embodiments, the anion exchange chromatography is QSFF chromatography. In some embodiments according to (or as applied to) any of the above embodiments, the anion exchange chromatography uses one or more of anion exchange pre-equilibration buffer, anion exchange equilibration buffer, or anion exchange loading buffer, and the anion exchange pre-equilibration buffer, anion exchange equilibration buffer, and / or anion exchange loading buffer are at about pH 8 to about pH 9. In some embodiments according to (or as applied to) any of the above embodiments, the anion exchange pre-equilibration buffer, anion exchange equilibration buffer, and / or anion exchange loading buffer are at about pH 8.5. In some embodiments according to (or as applied to) any of the above embodiments, the anion exchange pre-equilibration buffer comprises about 50 mM Tris, 500 mM sodium acetate. In some embodiments according to (or as applied to) any of the above embodiments, the anion exchange equilibration buffer comprises about 50 mM Tris. In some embodiments according to (or as applied to) any of the above embodiments, the anion exchange chromatography is washed with anion exchange equilibration buffer after loading. In some embodiments according to (or as applied to) any of the above embodiments, the multispecific antibody is eluted from the anion exchange chromatography by a salt gradient. In some embodiments according to (or as applied to) any of the above embodiments, the multispecific antibody is eluted from the anion exchange chromatography by applying an anion exchange elution buffer having an increasing salt concentration to the anion exchange chromatography.In some embodiments according to (or as applied to) any of the above embodiments, the anion exchange elution buffer comprises about 50 mM Tris, 100 mM sodium acetate at about pH 8.5.
[0022] In some embodiments according to (or as applied to) any of the above embodiments, the arms of the multispecific antibody are produced in a cell. In some embodiments according to (or as applied to) any of the above embodiments, the cell is a prokaryotic cell. In some embodiments according to (or as applied to) any of the above embodiments, the prokaryotic cell is an E. coli cell. In some embodiments according to (or as applied to) any of the above embodiments, the cell is engineered to express one or more chaperones. In some embodiments according to (or as applied to) any of the above embodiments, the chaperone is one or more of FkpA, DsbA, or DsbC. In some embodiments according to (or as applied to) any of the above embodiments, the chaperone is an E. coli chaperone. In some embodiments according to (or as applied to) any of the above embodiments, the cell is a eukaryotic cell. In some embodiments according to (or as applied to) any of the above embodiments, the eukaryotic cell is a yeast cell, an insect cell, or a mammalian cell. In some embodiments according to (or as applied to) any of the above embodiments, the eukaryotic cell is a CHO cell.
[0023] In some embodiments according to (or as applied to) any of the above embodiments, the cells are lysed prior to capture chromatography to generate a cell lysate comprising the multispecific antibody or arms of the multispecific antibody. In some embodiments according to (or as applied to) any of the above embodiments, the cells are lysed using a microfluidizing agent. In some embodiments according to (or as applied to) any of the above embodiments, polyethyleneimine (PEI) is added to the cell lysate prior to chromatography. In some embodiments according to (or as applied to) any of the above embodiments, PEI is added to the lysate to a final concentration of about 0.4%. In some embodiments according to (or as applied to) any of the above embodiments, the cell lysate is clarified by centrifugation. In some embodiments according to (or as applied to) any of the above embodiments, the cell lysate of mammalian cells, e.g., CHO cells, is subjected to one or more of the following treatments by addition of agents: heat inactivation, low pH inactivation, viral inactivation.
[0024] In some embodiments according to (or as applied to) any of the above embodiments, the method reduces the amount of process specific impurities, such as any one of host cell proteins (HCPs), leached Protein A, nucleic acids, cell culture media components, or viral impurities in the composition.
[0025] In some embodiments according to (or as applied to) any of the above embodiments, the multispecific antibody is a bispecific antibody. In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody is a Knobs-in-Hole (KiH) antibody, e.g., a KiH bispecific antibody. In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody is a CrossMab bispecific antibody.
[0026] In some embodiments according to (or as applied to) any of the above methods, the fraction is collected after the last chromatography step and comprises at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% of the multispecific antibody. In some embodiments according to (or as applied to) any of the above embodiments, the fraction is collected after the last chromatography step and comprises a reduced amount of product-specific impurities, the product-specific impurities being one or more of unpaired antibody arms, antibody homodimers, high molecular weight species (HMWS), low molecular weight species (LMWS), or 3 / 4 antibodies. In some embodiments according to (or as applied to) any of the above embodiments, the fraction comprises less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% of unpaired antibody arms. In some embodiments according to (or as applied to) any of the above embodiments, the fraction comprises less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% of antibody homodimers. In some embodiments according to (or as applied to) any of the above embodiments, the fraction comprises about 1% or less or about 2% or less HMWS. In some embodiments according to (or as applied to) any of the above embodiments, the fraction comprises about 2% or less or about 1% or less LMWS. In some embodiments according to (or as applied to) any of the above embodiments, the fraction comprises about 5% or less, about 4% or less, about 3% or less, about 2% or less, or about 1% or less 3 / 4 antibodies.
[0027] In some embodiments according to (or as applied to) any of the above embodiments, the fraction comprises: a) at least about 95% to about 100% multispecific antibodies; b) about 1%-5% or less of the non-paired antibody arms; c) about 1% to less than about 5% antibody homodimers; d) about 1% or about 2% HMWS or less; e) LMWS of about 1% or about 2% or less; and / or f) Contains about 5% or less of 3 / 4 antibodies.
[0028] In certain embodiments, a composition is provided comprising a multispecific antibody purified by any one of the methods described above.
[0029] In some embodiments according to (or as applied to) any of the above methods, a composition comprising a multispecific antibody is provided, the composition comprising at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% multispecific antibody. In some embodiments according to (or as applied to) any of the above embodiments, a composition comprising a multispecific antibody is provided, the composition comprising a reduced amount of product-specific impurities, the product-specific impurities being one or more of unpaired antibody arms, antibody homodimers, high molecular weight species (HMWS), low molecular weight species (LMWS), or 3 / 4 antibodies. In some embodiments according to (or as applied to) any of the above embodiments, the composition comprises less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% unpaired antibody arms. In some embodiments according to (or as applied to) any of the above embodiments, the composition comprises less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% antibody homodimers. In some embodiments according to (or as applied to) any of the above embodiments, the composition comprises about 1% or less or about 2% HMWS. In some embodiments according to (or as applied to) any of the above embodiments, the composition comprises about 2% or less or about 1% LMWS. In some embodiments according to (or as applied to) any of the above embodiments, the composition comprises about 5% or less, about 4% or less, about 3% or less, about 2% or less, or about 1% or less 3 / 4 antibodies. In some embodiments according to (or as applied to) any of the above embodiments, the multispecific antibody in the composition is a bispecific antibody. In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody is a Knob-in-Hole (KiH) antibody, e.g., a KiH bispecific antibody. In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody is a CrossMab bispecific antibody. In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody binds ANG-2 and VEGF.In some embodiments according to (or as applied to) any of the above embodiments, a bispecific antibody that binds ANG-2 and VEGF comprises a) a heavy chain and a light chain of a first full-length antibody that comprises a first antigen-binding site, and b) a modified heavy chain and a modified light chain of a full-length antibody that comprises a second antigen-binding site, wherein the constant domains CL and CH1 are replaced by each other.
[0030] In some embodiments according to (or as applied to) any of the above embodiments, the composition comprises a) at least about 95% to about 100% multispecific antibodies, b) less than about 1% to about 5% unpaired antibody arms, c) less than about 1% to about 5% antibody homodimers, d) less than about 1% or 2% HMWS, e) less than about 1% or 2% LMWS, and / or f) less than about 5% 3 / 4 antibodies. In some embodiments according to (or as applied to) any of the above embodiments, the multispecific antibodies in the composition are bispecific antibodies. In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody is a Knob-in-Hole (KiH) antibody, e.g., a KiH bispecific antibody. In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody is a CrossMab bispecific antibody. In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody binds ANG-2 and VEGF. In some embodiments according to (or as applied to) any of the above embodiments, a bispecific antibody that binds ANG-2 and VEGF comprises a) a heavy chain and a light chain of a first full-length antibody that comprises a first antigen-binding site, and b) a modified heavy chain and a modified light chain of a full-length antibody that comprises a second antigen-binding site, wherein the constant domains CL and CH1 are replaced by each other.
[0031] In some embodiments according to (or as applied to) any of the above embodiments, a composition is provided comprising a multispecific or bispecific antibody (such as a bispecific antibody that binds ANG2 and VEGF) purified by any one of the methods described above for the treatment of cancer or eye disease.
[0032] In some embodiments according to (or as applied to) any of the above embodiments, there is provided a use comprising a multispecific or bispecific antibody (such as a bispecific antibody that binds ANG2 and VEGF) purified by any one of the methods described above for the manufacture of a medicament for the treatment of cancer or an eye disease.
[0033] In some embodiments according to (or as applied to) any of the above embodiments, the methods provided herein are used for the purification of an Fc-containing heterodimeric polypeptide.
[0034] In some embodiments according to (or as applied to) any of the above embodiments, there is provided the use of any of the methods provided herein for the reduction of Fc-containing heterodimeric polypeptide-related impurities in a composition.
[0035] In certain embodiments, a method is provided for purifying an Fc region-containing heterodimeric polypeptide with a multi-step chromatography method, the method comprising an affinity chromatography step followed by two different multimodal ion exchange chromatography steps, thereby purifying the Fc region-containing heterodimeric polypeptide. In some embodiments according to (or as applied to) any of the above embodiments, the multi-step chromatography method comprises (i) an affinity chromatography step followed by a multimodal anion exchange chromatography step followed by a multimodal cation exchange chromatography step, or (ii) an affinity chromatography step followed by a multimodal cation exchange chromatography step followed by a multimodal anion exchange chromatography step.
[0036] In some embodiments according to (or as applied to) any of the above embodiments, the multi-step chromatography method comprises an affinity chromatography step followed by a multimodal anion exchange chromatography step followed by a multimodal cation exchange chromatography step. In some embodiments according to (or as applied to) any of the above embodiments, the multi-step chromatography method comprises exactly three chromatography steps. In some embodiments according to (or as applied to) any of the above embodiments, the multimodal anion exchange chromatography step is performed in flow-through mode. In some embodiments according to (or as applied to) any of the above embodiments, in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity value of less than 7 mS / cm. In some embodiments according to (or as applied to) any of the above embodiments, in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity value in the range of about 6 mS / cm to about 2 mS / cm. In some embodiments according to (or as applied to) any of the above embodiments, in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity value of about 4.5 mS / cm. In some embodiments according to (or as applied to) any of the above embodiments, the multimodal anion exchange chromatography step is performed at a pH of about 7. In some embodiments according to (or as applied to) any of the above embodiments, in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity of about 4.5 mS / cm and a pH of about 7.In some embodiments according to (or as applied to) any of the above embodiments, in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in the range of about 100 g to about 300 g per liter of chromatography material.
[0037] In some embodiments according to (or as applied to) any of the above embodiments, the multimodal anion exchange chromatography material is a multimodal strong anion exchange chromatography material. In some embodiments according to (or as applied to) any of the above embodiments, the multimodal anion exchange chromatography material has a matrix of high-flux agarose, a multimodal strong anion exchange as the ligand, an average particle size of 36-44 μm, and an ionic capacity of the medium of 0.08-0.11 mmol Cl- / mL. In some embodiments according to (or as applied to) any of the above embodiments, the multimodal cation exchange chromatography medium is a multimodal weak cation exchange chromatography medium. In some embodiments according to (or as applied to) any of the above embodiments, the multimodal cation exchange chromatography medium has a matrix of high-flux agarose, a multimodal weak cation exchange as the ligand, an average particle size of 36-44 μm, and an ionic capacity of 25-39 μmol / mL. In some embodiments according to (or as applied to) any of the above embodiments, the multimodal anion exchange chromatography step is performed in bind and elute mode. In some embodiments according to (or as applied to) any of the above embodiments, the capture chromatography is performed by affinity chromatography. In some embodiments, the affinity chromatography is Protein A affinity chromatography, or Protein G affinity chromatography, or single chain Fv ligand affinity chromatography, or a chromatography step using CaptureSelect chromatography material, or a chromatography step using CaptureSelect FcXL chromatography material. In some embodiments according to (or as applied to) any of the above embodiments, the affinity chromatography step is a Protein A chromatography step.In some embodiments according to (or as applied to) any of the above embodiments, the affinity chromatography step is a chromatography step using CaptureSelect™ chromatography material.
[0038] In some embodiments according to (or as applied to) any of the above embodiments, the Fc region-containing heterodimeric polypeptide is an antibody, a bispecific antibody, or an Fc-fusion protein. In some embodiments according to (or as applied to) any of the above embodiments, the Fc region-containing heterodimeric polypeptide is a bispecific antibody. In some embodiments according to (or as applied to) any of the above embodiments, the Fc region-containing heterodimeric polypeptide is a CrossMab. In some embodiments according to (or as applied to) any of the above embodiments, the Fc region-containing heterodimeric polypeptide comprises a) the heavy and light chains of a first full-length antibody that specifically binds a first antigen, and b) a modified heavy and light chains of a full-length antibody that specifically binds a second antigen, wherein the constant domains CL and CH1 are replaced by each other.
[0039] In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody binds ANG2 and VEGF. In some embodiments according to (or as applied to) any of the above embodiments, CrossMab binds ANG2 and VEGF. In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody is vanucizumab. In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody comprises a first antigen-binding site comprising SEQ ID NO: 1 as the heavy chain variable domain (VH) and SEQ ID NO: 2 as the light chain variable domain (VL), and a second antigen-binding site comprising SEQ ID NO: 3 as the heavy chain variable domain (VH) and SEQ ID NO: 4 as the light chain variable domain (VL). In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody comprises a first heavy chain having the amino acid sequence of SEQ ID NO: 9, and a second heavy chain having the amino acid sequence of SEQ ID NO: 10, and a first light chain having the amino acid sequence of SEQ ID NO: 11, and a second light chain having the amino acid sequence of SEQ ID NO: 12.
[0040] In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody comprises a first antigen-binding site comprising SEQ ID NO: 5 as the heavy chain variable domain (VH) and SEQ ID NO: 6 as the light chain variable domain (VL), and a second antigen-binding site comprising SEQ ID NO: 7 as the heavy chain variable domain (VH) and SEQ ID NO: 8 as the light chain variable domain (VL). In some embodiments according to (or as applied to) any of the above embodiments, the bispecific antibody comprises a first heavy chain having the amino acid sequence of SEQ ID NO: 13, and a second heavy chain having the amino acid sequence of SEQ ID NO: 14, and a first light chain having the amino acid sequence of SEQ ID NO: 15, and a second light chain having the amino acid sequence of SEQ ID NO: 16.
[0041] In some embodiments according to (or as applied to) any of the above embodiments, the purified Fc region-containing heterodimeric polypeptide comprises about 5% or less of 3 / 4 antibody.
[0042] In certain embodiments, a method is provided for purifying a bispecific antibody that binds ANG2 and VEGF by a multi-step chromatography method, the method comprising a step of affinity chromatography followed by a step of multimodal anion exchange chromatography followed by a step of multimodal cation exchange chromatography, thereby purifying a bispecific antibody that binds ANG2 and VEGF, the bispecific antibody that binds ANG2 and VEGF comprising a first antigen-binding site comprising SEQ ID NO: 1 as the heavy chain variable domain (VH) and SEQ ID NO: 2 as the light chain variable domain (VL), and a second antigen-binding site comprising SEQ ID NO: 3 as the heavy chain variable domain (VH) and SEQ ID NO: 4 as the light chain variable domain (VL), or comprising a first antigen-binding site comprising SEQ ID NO: 5 as the heavy chain variable domain (VH) and SEQ ID NO: 6 as the light chain variable domain (VL), and a second antigen-binding site comprising SEQ ID NO: 7 as the heavy chain variable domain (VH) and SEQ ID NO: 8 as the light chain variable domain (VL). In some embodiments according to (or as applied to) any of the above embodiments, a bispecific antibody that binds ANG2 and VEGF comprises a) a heavy chain and a light chain of a first full-length antibody that comprises a first antigen-binding site, and b) a modified heavy chain and a modified light chain of a full-length antibody that comprises a second antigen-binding site, wherein the constant domains CL and CH1 are replaced by each other.
[0043] In some embodiments, there is provided the use of any of the methods according to (or as applied to) any of the above embodiments for the reduction of Fc-containing heterodimeric polypeptide-related impurities.
[0044] In some embodiments, there is provided an Fc-containing heterodimeric polypeptide obtained by a method according to (or as applied to) any of the above embodiments for the manufacture of a medicament for the treatment of cancer or an eye disease.
[0045] In some embodiments there is provided an Fc-containing heterodimeric polypeptide obtained by a method according to (or as applied to) any of the above embodiments for use in the treatment of cancer or eye disease.
[0046] In certain embodiments, a method for producing an Fc-containing heterodimeric polypeptide is provided, comprising: (i) culturing cells comprising a nucleic acid encoding an Fc-containing heterodimeric polypeptide; (ii) recovering the Fc-containing heterodimeric protein from the cells or the culture medium; and (iii) purifying the Fc-containing heterodimeric polypeptide using a method according to (or adapted to) any of the above embodiments, thereby producing the Fc-containing heterodimeric polypeptide.
[0047] In certain embodiments, a method is provided for producing a bispecific antibody that binds ANG-2 and VEGF, comprising: (i) culturing cells containing nucleic acid encoding the bispecific antibody; (ii) recovering the bispecific antibody from the cells or the culture medium; and (iii) purifying the bispecific antibody using a method according to (or as applied to) any of the above embodiments, thereby producing a bispecific antibody that binds ANG-2 and VEGF. [Brief description of the drawings]
[0048] [Figure 1A] 1 shows a first purification scheme used in Example 1. [Figure 1B] 1 shows a second purification scheme used in Example 1. [Figure 1C] 1 shows a third purification scheme used in Example 1. [Diagram 2]1 shows the purification scheme used in Example 2. [Figure 3A] 1 shows a first purification scheme used in Example 3. [Figure 3B] 1 shows a second purification scheme used in Example 3. [Figure 4] 1 shows the purification scheme used in Example 4. [Figure 5A] 1 shows a first purification scheme used in Example 6. [Figure 5B] 1 shows a second purification scheme used in Example 6. [Figure 6A] 1 shows a first purification scheme used in Example 7. [Figure 6B] 1 shows a second purification scheme used in Example 7. [Figure 7A] 1 shows a first purification scheme used in Example 8. [Figure 7B] 1 shows a second purification scheme used in Example 8. [Figure 7C] 1 shows a third purification scheme used in Example 8. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0049] A method for preparing a multispecific antibody (bispecific antibody or bivalent F(ab')) comprising the steps of: a) subjecting a composition comprising a multispecific antibody to capture chromatography; b) subjecting the composition to a first mixed-mode chromatography; and c) subjecting the composition to a second mixed-mode chromatography. 2Provided herein are methods for purifying multispecific antibodies, such as ribozymes, ribozymes, and ribozymes. In some aspects, methods for purifying multispecific antibodies are provided, in which each individual arm of the multispecific antibody is produced in a separate culture and each is purified separately by capture chromatography. The purified antibody arms are then assembled to produce the multispecific antibody. The assembled multispecific antibody is then subjected to a first mixed-mode anion exchange chromatography followed by a second mixed-mode chromatography. As described in more detail below, each of the capture chromatography, the first mixed-mode chromatography, and / or the second mixed-mode chromatography is optionally preceded and / or followed by one or more additional chromatography steps. The terms mixed-mode chromatography and multimodal chromatography are used interchangeably herein.
[0050] In some aspects, compositions are provided that include multispecific antibodies with reduced levels of one or more process-specific and / or product-specific impurities, such as unpaired antibody arms, homodimers, aggregates, low molecular weight species, acidic and basic variants. In some aspects, compositions are provided that include multispecific antibodies with reduced levels of one or more process-specific impurities, such as prokaryotic host cell proteins, eukaryotic host cell proteins (such as CHO proteins or "CHOP"), nucleic acids, and chaperones (such as prokaryotic chaperones, e.g., FkpA, DsbA, and DsbC). In certain embodiments, the compositions provided herein are obtained using the methods provided herein. In certain embodiments, the compositions provided herein have reduced levels of one or more process-specific and / or product-specific impurities than compositions obtained using methods known in the art.
[0051] In some embodiments, the use of the methods reported herein for the purification of Fc-containing heterodimeric polypeptides and the reduction of Fc-containing heterodimeric polypeptide-related impurities is provided. Improved reduction of product-specific impurities is achieved. In the case of CrossMab-specific impurities, for example, a reduction of 3 / 4 antibodies is achieved.
[0052] definition The terms "polypeptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. A polymer may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. These terms also encompass amino acid polymers that are modified naturally or by intervention, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. For example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art, are also included in this definition. The terms "polypeptide" and "protein" as used herein specifically encompass antibodies.
[0053] A "purified" polypeptide (e.g., an antibody or immunoadhesin) means that the purity of the polypeptide is increased such that the polypeptide exists in a purer form than it exists in its natural environment and / or when initially synthesized and / or amplified under laboratory conditions. Purity is a relative term and does not necessarily imply absolute purity. The terms "purify," "separate," or "isolate," as used interchangeably herein, refer to increasing the purity of a desired molecule (such as a multispecific antibody, e.g., a bispecific antibody) of a composition or sample that contains the desired molecule and one or more impurities. Typically, the purity of the desired molecule is increased by removing (completely or partially) at least one impurity from the composition.
[0054] A bispecific antibody that "binds an antigen of interest" is one that binds the antigen with sufficient affinity such that the bispecific antibody is useful as a diagnostic and / or therapeutic agent to target the protein, or cells or tissues expressing the protein, and does not significantly cross-react with other proteins. In such embodiments, the extent of binding of the bispecific antibody to a "non-target" protein is less than about 10% of the binding of the bispecific antibody to its specific target protein, as determined, for example, by fluorescence-activated cell sorting (FACS) analysis, radioimmunoprecipitation (RIA), or ELISA. With respect to the binding of a bispecific antibody to a target molecule, the term "specific binding" or "specifically binds" or "is specific" to a particular polypeptide or epitope on a particular polypeptide target refers to binding that is somewhat different from non-specific interactions (e.g., a non-specific interaction can be binding bovine serum albumin or casein). Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule. For example, specific binding can be determined by competition with a control molecule that is similar to the target, for example, an excess of unlabeled target. In this case, specific binding is indicated when the binding of labeled target to probe is competitively inhibited by excess unlabeled target.The term "specific binding" or "specific binding" or "specific" for a specific polypeptide or epitope on a specific polypeptide target as used herein can be indicated by a molecule having Kd for target with affinity of at least about 200nM, alternatively at least about 150nM, alternatively at least about 100nM, alternatively at least about 60nM, alternatively at least about 50nM, alternatively at least about 40nM, alternatively at least about 30nM, alternatively at least about 20nM, alternatively at least about 10nM, alternatively at least about 8nM, alternatively at least about 6nM, alternatively at least about 4nM, alternatively at least about 2nM, alternatively at least about 1nM or more.In one embodiment, the term "specific binding" refers to binding by a multispecific antigen-binding protein to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptides or polypeptide epitopes.
[0055] "Binding affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., a multispecific antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be expressed as a dissociation constant (Kd). For example, Kd can be about 200 nM or less, about 150 nM or less, about 100 nM or less, about 60 nM or less, about 50 nM or less, about 40 nM or less, about 30 nM or less, about 20 nM or less, about 10 nM or less, about 8 nM or less, about 6 nM or less, about 4 nM or less, about 2 nM or less, or about 1 nM or less. Affinity can be measured by common methods known in the art, including those described herein. Low affinity antibodies generally bind antigens slowly and tend to dissociate easily, whereas high affinity antibodies generally bind antigens faster and tend to remain bound longer. A variety of methods for measuring binding affinity are known in the art, any of which may be used for purposes of the methods and compositions provided herein.
[0056] In one embodiment, "Kd" or "Kd value" according to the present invention is measured using a surface plasmon resonance assay using a BIAcore™-2000 or BIAcore™-3000 (BIAcore, Inc., Piscataway, NJ) with an immobilized target (e.g., antigen) CM5 chip at 25°C with a response unit (RU) of -10. Briefly, a carboxymethylated dextran biosensor chip (CM5, BIAcore Inc.) is activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. The antigen is diluted to 5 μg / mL (approximately 0.2 μM) with 10 mM sodium acetate (pH 4.8) and then injected at a flow rate of 5 μL / min to obtain a coupled protein of approximately 10 response units (RU). After injection of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetic measurements, two-fold serial dilutions of Fab (e.g., 0.78 nM to 500 nM) are injected in PBS with 0.05% Tween 20 (PBST) at a flow rate of approximately 25 uL / min at 25°C. The association rate (k on ) and dissociation rate (k off The equilibrium dissociation constant (Kd) is calculated using a simple one-to-one Langmuir binding model (BIAcore Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensorgrams. off / k on The binding rate is calculated as a ratio of 10 to 10. See, for example, Chen et al., J. Mol. Biol. 293:865-881 (1999). 6 M -1 s -1If above 100 kDa, the binding rate can be determined by using a fluorescence quenching technique to measure the increase or decrease in fluorescence emission intensity (excitation = 295 nm, emission = 340 nm, 16 nm band pass) of 20 nM anti-antigen antibody (Fab form) in PBS (pH 7.2) at 25°C in the presence of increasing antigen concentrations as measured with a spectrometer such as a spectrophotometer equipped with stopped flow (Aviv Instruments) or an 8000 series SLM-Aminco spectrophotometer (ThermoSpectronic) equipped with a stirred red cuvette.
[0057] "Active" or "activity" herein refers to a form or forms of a polypeptide that retain the biological and / or immunological activity of the native or naturally occurring polypeptide, "biological" activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally occurring polypeptide other than the ability to induce the production of antibodies against an antigenic epitope possessed by the native or naturally occurring polypeptide, and "immunological" activity refers to the ability to induce the production of antibodies against an antigenic epitope possessed by the native or naturally occurring polypeptide.
[0058] "Biologically active" and "biological activity" and "biological characteristics" with respect to multispecific antigen binding proteins provided herein, such as antibodies, fragments, or derivatives thereof, mean, unless otherwise specified, having the ability to bind biological molecules.
[0059] The term "antibody" is used herein in the broadest sense and specifically includes monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies) formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity. The term "immunoglobulin" (Ig) is used synonymously herein with antibody.
[0060] Antibodies are naturally occurring immunoglobulin molecules with various structures, all of which are based on the immunoglobulin fold. For example, IgG antibodies have two "heavy" chains and two "light" chains that are disulfide-bonded to form a functional antibody. Each heavy and light chain contains its own "constant" (C) region and a "variable" (V) region. The V region determines the antigen-binding specificity of the antibody, while the C region provides structural support and functions in non-antigen-specific interactions with immune effectors. The antigen-binding specificity of an antibody or an antigen-binding fragment of an antibody is the ability of the antibody to specifically bind to a particular antigen.
[0061] The antigen-binding specificity of antibodies is determined by the structural features of the V regions. The variability is not evenly distributed across the 110 amino acid length of the variable domains. Instead, the V regions consist of relatively invariant stretches called framework regions (FRs) of 15-30 amino acids separated by shorter regions of extreme variability called "hypervariable regions" each 9-12 amino acids long. Naturally occurring heavy and light chain variable domains each contain four FRs that adopt a predominantly β-sheet configuration and are linked by three hypervariable regions that form loops that connect to, and in some cases form part of, the β-sheet structure. The hypervariable regions in each chain are held in close proximity to the hypervariable regions of the other chain by the FRs and contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participating in antibody dependent cellular cytotoxicity (ADCC).
[0062] Each V region typically contains three complementarity determining regions ("CDRs", each containing a "hypervariable loop") and four framework regions. Thus, an antibody combining site, which is the minimum structural unit required for binding with substantial affinity to a particular desired antigen, typically contains three CDRs and at least three, and preferably four, framework regions interspersed therebetween to hold and present the CDRs in the proper conformation. Classical four chain antibodies are composed of V H Domain and V L The domains cooperate to define an antigen-binding site. Certain antibodies, such as camel and shark antibodies, lack light chains and rely on binding sites formed exclusively by heavy chains. Single domain engineered immunoglobulins are H and V L In the absence of cooperation between the heavy and light chains, the binding site can be prepared so that it is formed only by the heavy or light chain.
[0063] The term "variable" refers to the fact that certain portions of the variable domains differ widely among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called hypervariable regions in both the light and heavy chain variable domains. The more highly conserved portions of the variable domains are called framework regions (FRs). Naturally occurring heavy and light chain variable domains each contain four FRs that adopt a predominantly β-sheet configuration and are connected by three hypervariable regions that form loops that connect to, and in some cases form part of, the β-sheet structure. The hypervariable regions in each chain are held in close proximity to the hypervariable regions of the other chain by the FRs, which contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participating in antibody dependent cellular cytotoxicity (ADCC).
[0064] The term "hypervariable region" as used herein refers to the amino acid residues of an antibody which are involved in antigen binding. Hypervariable regions include "complementarity determining regions" or "CDRs" (e.g., V L In the 1990s, residues 24–34 (L1), 50–56 (L2), and 89–97 (L3), as well as V H Approximately, 31-35B (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)) and / or those residues from the "hypervariable loops" (e.g., V LIn the , residues 26–32 (L1), 50–52 (L2), and 91–96 (L3), as well as V H In the H1 sequence, the H1 sequence may include amino acid residues 26-32 (H1), 52A-55 (H2), and 96-101 (H3) (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).
[0065] "Framework" or "FR" residues are those variable domain residues other than the hypervariable region residues as herein defined.
[0066] The "hinge region" in the context of an antibody or half antibody is generally defined as the stretch from Glu216 to Pro230 of human IgG1 (Burton, Molec. Immunol. 22:161-206 (1985)). Hinge regions of other IgG isotypes can be aligned with the IgG1 sequence by placing the first and last cysteine residues that form intra-heavy chain S-S bonds in the same positions.
[0067] The "lower hinge region" of an Fc region is usually defined as the stretch of residues immediately C-terminal to the hinge region, i.e., residues 233 to 239 of the Fc region. Prior to the present application, FcγR binding was generally attributed to amino acid residues in the lower hinge region of IgG Fc regions.
[0068] The "CH2 domain" of the human IgG Fc region usually extends from about residue 231 to about residue 340 of IgG. The CH2 domain is unique in that it is not tightly paired with another domain. Rather, two N-linked branched carbohydrate chains are interposed between the two CH2 domains in an intact native IgG molecule. It has been speculated that the carbohydrates provide an alternative for domain-domain pairing and may serve to stabilize the CH2 domain. Burton, Molec. Immunol. 22:161-206 (1985)
[0069] The "CH3 domain" comprises the stretch of residues from the C-terminus of the Fc region to the CH2 domain (ie, from about amino acid residue 341 to about amino acid residue 447 of IgG).
[0070] An "antibody fragment" comprises a portion of an intact antibody, preferably comprising the antigen-binding region thereof. Examples of antibody fragments include Fab, Fab', F(ab') 2 and Fv fragments; diabodies; tandem diabodies (taDbs), linear antibodies (e.g., Example 2 of U.S. Pat. No. 5,641,870; Zapata et al., Protein Eng. 8(10):1057-1062 (1995); one-arm antibodies, single variable domain antibodies, minibodies, single-chain antibody molecules; multispecific antibodies formed from antibody fragments (e.g., but not limited to, Db-Fc, taDb-Fc, taDb-CH3, (scFV)4-Fc, di-scFv, bi-scFv, or tandem (di, tri)-scFv); and bispecific T cell engagers (BiTEs).
[0071] Papain digestion of antibodies produces two identical antigen-binding fragments called "Fab" fragments and one residual "Fc" fragment, a designation reflecting the ability to crystallize readily. The Fab fragment consists of the entire L chain together with the variable region domain (VH) of the H chain and the first constant domain (CH1) of one heavy chain. Pepsin treatment of antibodies produces a single large F(ab')2 fragment, which generally corresponds to two disulfide-linked Fab fragments with bivalent antigen-binding activity and still capable of cross-linking antigen. Fab' fragments differ from Fab fragments in that they have several additional residues at the carboxy terminus of the CH1 domain, including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')2 antibody fragments were originally produced as pairs of Fab' fragments with hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
[0072] "Fv" is the minimum antibody fragment which contains a complete antigen-recognition and antigen-binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. In this configuration, the three hypervariable regions of each variable domain interact to form the V H -V L The six hypervariable regions define an antigen-binding site on the surface of the dimer. Collectively, the six hypervariable regions confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing only three antigen-specific hypervariable regions) has the ability to recognize and bind to an antigen, but with a lower affinity than the entire binding site.
[0073] Fab fragments also contain the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear at least one free thiol group. F(ab') 2 Antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
[0074] The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (κ) and lambda (λ), based on the amino acid sequences of their constant domains.
[0075] Antibodies can be assigned to different classes depending on the amino acid sequence of the constant domain of their heavy chains. There are five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy chain constant domains that correspond to the different classes of antibodies are called α, δ, ε, γ, and μ, respectively. The subunit structures and three-dimensional configurations of the different classes of immunoglobulins are well known.
[0076] "Single-chain Fv" or "scFv" antibody fragments are fragments of the V H and V L In some embodiments, the Fv polypeptide comprises V domains, where these domains are present in a single polypeptide. H Domain and V L The scFv further comprises a polypeptide linker between the domains, which enables the scFv to form the desired structure for antigen binding. For a general review of scFvs, see Pluckthun in The Pharmacology of Monoclonal Antibodies,, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
[0077] The term "diabody" refers to small antibody fragments with two antigen-binding sites, which are composed of a light chain variable domain (V L ) connected to a heavy chain variable domain (V H ) (V H -V L(The domains can be paired with the complementary domains of another chain and two antigen-binding sites can be created by using a linker that is too short to allow pairing between the two domains on the same chain. Diabodies are described in more detail in, for example, EP 404,097, WO 93 / 11161, and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).
[0078] As used herein, a "half antibody" or "hemimer" refers to a monovalent antigen-binding polypeptide. In certain embodiments, a half antibody or hemimer comprises a VH / VL unit and, optionally, at least a portion of an immunoglobulin constant domain. In certain embodiments, a half antibody or hemimer comprises one immunoglobulin heavy chain associated with one immunoglobulin light chain, or an antigen-binding fragment thereof. In certain embodiments, a half antibody or hemimer is mono-specific, i.e., binds a single antigen or epitope. One of skill in the art will readily appreciate that a half antibody can have an antigen-binding domain consisting of a single variable domain, e.g., derived from a Camelidae.
[0079] The term "VH / VL unit" refers to an antigen-binding region of an antibody that comprises at least one VH HVR and at least one VL HVR. In certain embodiments, a VH / VL unit comprises at least one, at least two, or all three VH HVRs, and at least one, at least two, or all three VL HVRs. In certain embodiments, a VH / VL unit further comprises at least a portion of a framework region (FR). In some embodiments, a VH / VL unit comprises three VH HVRs and three VL HVRs. In some such embodiments, a VH / VL unit comprises at least one, at least two, at least three, or all four VH FRs, and at least one, at least two, at least three, or all four VL FRs.
[0080] The term "multispecific antibody" is used in the broadest sense and specifically covers antibodies that contain antigen-binding domains that have multiple epitopic specificities (i.e., that can specifically bind to two or more different epitopes on one biological molecule or that can specifically bind to epitopes on two or more different biological molecules). In some embodiments, multispecific antibodies (bispecific antibodies or bivalent F(ab') 2The antigen-binding domain of a multispecific antibody (such as a VH / VL unit) comprises two VH / VL units, where a first VH / VL unit specifically binds a first epitope and a second VH / VL unit specifically binds a second epitope, and each VH / VL unit comprises a heavy chain variable domain (VH) and a light chain variable domain (VL). Such multispecific antibodies include, but are not limited to, full-length antibodies, antibodies with two or more VL and VH domains, antibody fragments (such as Fab, Fv, dsFv, scFv, diabodies, bispecific diabodies, and triabodies), and antibody fragments that are covalently or non-covalently linked. A VH / VL unit that further comprises at least a portion of a heavy chain constant region and / or at least a portion of a light chain constant region may also be referred to as a "hemimer" or "half antibody." In some embodiments, a half antibody comprises at least a portion of a single heavy chain variable region and at least a portion of a single light chain variable region. In some such embodiments, a bispecific antibody comprising two half antibodies and binding to two antigens comprises a first half antibody that binds to a first antigen or first epitope but not to a second antigen or second epitope, and a second half antibody that binds to a second antigen or second epitope but not to the first antigen or first epitope. According to some embodiments, the multispecific antibody is an IgG antibody that binds to each antigen or epitope with an affinity of 5M to 0.001 pM, 3M to 0.001 pM, 1M to 0.001 pM, 0.5M to 0.001 pM, or 0.1M to 0.001 pM. In some embodiments, the hemimer comprises a portion of a heavy chain variable region sufficient to allow an intramolecular disulfide bond to form with the second hemimer. In some embodiments, the hemimer comprises a knob or hole mutation that allows for heterodimerization, e.g., with a second hemimer or half antibody that comprises a complementary hole or knob mutation. Knob and hole mutations are discussed further below.
[0081] A "bispecific antibody" is a multispecific antibody that contains antigen-binding domains that can specifically bind to two different epitopes on one biological molecule or that can specifically bind to epitopes on two different biological molecules. Bispecific antibodies are also referred to herein as having "dual specificity" or being "bispecific". Unless otherwise indicated, the order in which the antigens bound by a bispecific antibody are listed in the bispecific antibody name is random. In some embodiments, a bispecific antibody comprises two half antibodies, each half antibody comprising a single heavy chain variable region and optionally at least a portion of a heavy chain constant region, and a single light chain variable region and optionally at least a portion of a light chain constant region. In certain embodiments, a bispecific antibody comprises two half antibodies, each half antibody comprising a single heavy chain variable region and a single light chain variable region, does not comprise more than one single heavy chain variable region, and does not comprise more than one single light chain variable region. In some embodiments, a bispecific antibody comprises two half antibodies, each half antibody comprising a single heavy chain variable region and a single light chain variable region, wherein the first half antibody binds to a first antigen and does not bind to a second antigen, and the second half antibody binds to the second antigen and does not bind to the first antigen.
[0082] As used herein, the term "knobs-into-holes" or "KiH" technology refers to a technology that directs the pairing of two polypeptides in vitro or in vivo by introducing a protuberance (knob) into one polypeptide and a cavity (hole) into the other polypeptide at the interface where they interact. For example, KiH has been introduced into the Fc:Fc binding interface, the CL:CH1 interface, or the VH / VL interface of an antibody (see, e.g., US2011 / 0287009, US2007 / 0178552, WO96 / 027011, WO98 / 050431, and Zhu et al., 1997, Protein Science 6:781-788). In some embodiments, KiH drives the pairing of two different heavy chains during the production of a multispecific antibody. For example, multispecific antibodies with KiH in their Fc region may further comprise a single variable domain linked to each Fc region, or may further comprise a different heavy chain variable domain paired with a similar or different light chain variable domain. KiH technology can also be used to pair two different receptor extracellular domains together, or any other polypeptide sequence that contains different target recognition sequences (including, for example, affibodies, peptibodies, and other Fc fusions).
[0083] As used herein, the term "knob mutation" refers to a mutation that introduces a protuberance (knob) into a polypeptide at the interface where the polypeptide interacts with another polypeptide. In some embodiments, the other polypeptide has a hole mutation (see, e.g., US5,731,168, US5,807,706, US5,821,333, US7,695,936, US8,216,805, each of which is incorporated herein by reference in its entirety).
[0084] As used herein, the term "hole mutation" refers to a mutation that introduces a cavity (hole) into a polypeptide at the interface where the polypeptide interacts with another polypeptide. In some embodiments, the other polypeptide has a knob mutation (see, e.g., US5,731,168, US5,807,706, US5,821,333, US7,695,936, US8,216,805, each of which is incorporated herein by reference in its entirety).
[0085] The term "single domain antibody" (sdAb) or "single variable domain (SVD) antibody" generally refers to an antibody in which a single variable domain (VH or VL) can confer antigen binding. In other words, the single variable domain does not need to interact with another variable domain to recognize the target antigen. Examples of single domain antibodies include antibodies derived from camelids (llamas and camels) and cartilaginous fish (e.g. nurse sharks), as well as antibodies obtained by recombinant methods from human and mouse antibodies (Nature (1989) 341:544-546, Dev Comp Immunol (2006) 30:43-56, Trends Biochem Sci (2001) 26:230-235, Trends Biotechnol (2003):21:484-490, WO2005 / 035572, WO03 / 035694, FEBS Lett (1994) 339:285-290, WO00 / 29004, WO02 / 051870).
[0086] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogenous antibodies, i.e., the individual antibodies comprising the population are identical and / or bind the same epitope, except for possible variants that may arise during the production of the monoclonal antibody, and such variants are generally present in minor amounts. In contrast to polyclonal antibody preparations, which typically contain different antibodies against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they are uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogenous population of antibodies and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies used in accordance with the methods provided herein may be produced by the hybridoma method first described by Kohler et al., Nature 256:495 (1975), or by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). Monoclonal antibodies can also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature 352:624-628 (1991), and Marks et al., J. Mol. Biol. 222:581-597 (1991), for example.
[0087] Monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and / or light chain is identical or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)). Chimeric antibodies of interest herein include "primatized" antibodies that contain variable domain antigen-binding sequences derived from a non-human primate (e.g., an Old World monkey such as a baboon, rhesus monkey, or cynomolgus monkey) and human constant region sequences (U.S. Pat. No. 5,693,780).
[0088] "Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. In most cases, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit, or non-human primate having the desired specificity, affinity, and capacity. In some cases, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are FRs of a human immunoglobulin sequence, except for the FR substitution(s) mentioned above. A humanized antibody optionally also comprises at least a portion of an immunoglobulin constant region, typically a human immunoglobulin constant region. For further details, see, e.g., Jones et al., Nature 321:522-525 (1986), Riechmann et al., Nature 332:323-329 (1988), and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).
[0089] As used herein, an "intact antibody" is one which comprises heavy and light variable domains, as well as an Fc region. The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof. Preferably, the intact antibody has one or more effector functions.
[0090] "Native antibodies" are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain contains at one end a variable domain (V H ) followed by several constant domains. Each light chain has a variable domain (V L ) at its other end and a constant domain, where the light chain constant domain is aligned with the first constant domain of the heavy chain and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light chain and the heavy chain variable domains.
[0091] A "naked antibody" is an antibody (as defined herein) that is not conjugated to a heterologous molecule, such as a cytotoxic moiety, or a radiolabel.
[0092] As used herein, the term "immunoadhesin" refers to a molecule that combines the binding specificity of a heterologous protein ("adhesin") with the effector functions of an immunoglobulin constant domain. Structurally, an immunoadhesin comprises an amino acid sequence with the desired binding specificity (which amino acid sequence is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous" compared to the constant region of an antibody)) and an immunoglobulin constant domain sequence (e.g., the CH2 and / or CH3 sequences of an IgG). Exemplary adhesin sequences include contiguous amino acid sequences that include a portion of a receptor or ligand that binds to a protein of interest. An adhesin sequence can also be a sequence that binds to a protein of interest but is not a receptor or ligand sequence (e.g., an adhesin sequence in a peptibody). Such polypeptide sequences can be selected or identified by a variety of methods, including phage display techniques and high-throughput selection methods. The immunoglobulin constant domain sequences in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD, or IgM.
[0093] In certain embodiments, the Fc region-containing heterodimeric polypeptide is an antibody, a bispecific antibody, or an Fc-fusion protein.
[0094] In certain embodiments, the Fc-fusion protein produced by the method provided herein is a targeting immunocytokine. In certain embodiments, the targeting immunocytokine is a CEA-IL2v immunocytokine. In certain embodiments, the CEA-IL2v immunocytokine is RG7813. In certain embodiments, the targeting immunocytokine is a FAP-IL2v immunocytokine. In certain embodiments, the FAP-IL2v immunocytokine is RG7461.
[0095] In certain embodiments, a multispecific antibody (such as a bispecific antibody) produced by the methods provided herein binds CEA and at least one additional target molecule. In certain embodiments, a multispecific antibody (such as a bispecific antibody) produced by the methods provided herein binds a tumor-targeting cytokine and at least one additional target molecule. In certain embodiments, a multispecific antibody produced by the methods provided herein is fused to IL2v (i.e., interleukin bivalent) and at least one additional target molecule. In certain embodiments, a multispecific antibody produced by the methods provided herein is a T-cell bispecific antibody (i.e., a bispecific T-cell engager or BiTE).
[0096] In some embodiments, an "effector function" of an antibody refers to a biological activity attributable to the Fc region of an antibody (either a native sequence Fc region or an amino acid sequence variant Fc region) and varies with the antibody isotype. Examples of antibody effector functions include C1q binding and complement dependent cytotoxicity, Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, and down-regulation of cell surface receptors.
[0097] "Complement-dependent cytotoxicity" or "CDC" refers to the ability of a molecule to lyse a target in the presence of complement. The complement activation pathway is initiated by the binding of the first component of the complement system (C1q) to a molecule (e.g., a polypeptide (e.g., an antibody)) complexed with a cognate antigen. To assess complement activation, for example, a CDC assay can be performed, as described in Gazzano-Santoro et al., J.Immunol.Methods 202:163 (1996).
[0098] "Antibody-dependent cell-mediated cytotoxicity" and "ADCC" refer to a cell-mediated reaction in which non-specific cytotoxic cells expressing Fc receptors (FcR), such as natural killer (NK) cells, neutrophils, and macrophages, recognize bound antibodies on target cells and subsequently cause lysis of the target cells. NK cells, the primary cells for mediating ADCC, express only FcγRIII, whereas monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). To assess the ADCC activity of a molecule of interest, an in vitro ADCC assay, such as that described in U.S. Pat. No. 5,500,362 or U.S. Pat. No. 5,821,337, may be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al., Proc. Natl. Acad. Sci. (USA) 95:652-656 (1998).
[0099] "Human effector cells" are leukocytes that express one or more FcR and perform effector function. In some embodiments, these cells express at least FcγRIII and perform ADCC effector function. Examples of human leukocytes that mediate ADCC include peripheral blood mononuclear cells (PBMCs), natural killer (NK) cells, monocytes, cytotoxic T cells, and neutrophils, with PBMCs and NK cells being preferred.
[0100] The term "Fc receptor" or "FcR" is used to describe a receptor that binds to the Fc region of an antibody. In some embodiments, the FcR is a native sequence human FcR. Additionally, preferred FcRs are those that bind IgG antibodies (gamma receptors), including receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA ("activating receptor") and FcγRIIB ("inhibiting receptor"), which have similar amino acid sequences that differ primarily in their cytoplasmic domains. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain (see Daeron, Annu. Rev. Immunol. 15:203-234 (1997)). FcR has been described by Ravetch and Kinet, Annu.Rev.Immunol9:457-92(1991), Capel et al., Immunomethods4:25-34(1994), and de Haas et al., J.Lab.Clin.Med. 126:330-41 (1995). Other FcRs, including those identified in the future, are encompassed by the term "FcR" herein. The term also includes the neonatal receptor FcRn, which is involved in the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)).
[0101] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and its progeny regardless of the number of passages. The progeny will not be completely identical in nucleic acid content to the parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
[0102] "Impurities" refer to substances that are different from the desired polypeptide product. Impurities may refer to product-specific polypeptides such as one-armed and misassembled antibodies, antibody variants including basic and acidic variants, and aggregates. Other impurities include host cell material such as host cell proteins (HCPs), process specific impurities including leached protein A, nucleic acids, other polypeptides, endotoxins, viral contaminants, cell culture media components, and the like. In some examples, impurities may be HCPs from bacterial cells, such as E. coli cells (ECPs), insect cells, prokaryotic cells, eukaryotic cells, yeast cells, mammalian cells, avian cells, fungal cells, and the like. In some examples, impurities may be HCPs from mammalian cells, such as CHO cells, i.e., CHO cell proteins (CHOPs). Impurities may refer to accessory proteins used to facilitate expression, folding, or assembly of multispecific antibodies, such as prokaryotic chaperones such as FkpA, DsbA, and DsbC.
[0103] As used herein, "complex" or "complexed" refers to an association of two or more molecules that interact with each other through non-peptide bonds and / or forces (e.g., van der Waals, hydrophobic, hydrophilic forces). In one embodiment, the complex is a heteromultimer. As used herein, the term "protein complex" or "polypeptide complex" should be understood to include complexes having non-protein entities that are protein-conjugated in the protein complex (e.g., including, but not limited to, chemical molecules such as toxins or detection agents).
[0104] An "isolated" nucleic acid refers to a nucleic acid molecule that is separated from a component of its natural environment. Isolated nucleic acid includes a nucleic acid molecule that is contained within a cell that ordinarily contains the nucleic acid molecule, but where the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
[0105] "Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence after aligning the sequences and introducing gaps as necessary to achieve the maximum percent sequence identity, and without considering any conservative substitutions as part of the sequence identity. Alignment to determine percent amino acid sequence identity can be achieved in a variety of ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment over the full length of the sequences being compared. In certain embodiments, percent amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program is written by Genentech, Inc., and the source code has been submitted, together with user documentation, to the U.S. Copyright Office, Washington DC, 20559, and is registered under U.S. Copyright No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or can be compiled from the source code. The ALIGN-2 program must be compiled for use with UNIX operating systems, including Digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
[0106] In situations where ALIGN-2 is used for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which may alternatively be expressed as a given amino acid sequence A having or containing a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 x fraction X / Y
[0107] where X is the number of amino acid residues scored as perfect matches by the sequence alignment program ALIGN-2 in its alignment of A and B, and Y is the total number of amino acid residues in B. It is understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, then the % amino acid sequence identity of A to B is not equal to the % amino acid sequence identity of B to A. Unless specifically indicated otherwise, all % amino acid sequence identity values used herein are obtained using the ALIGN-2 computer program as described in the immediately preceding paragraph.
[0108] The term "variable region" or "variable domain" refers to the domain of an antibody's heavy or light chain that is involved in binding the antibody to an antigen. The heavy and light chain variable domains of natural antibodies (VH and VL, respectively) generally have a similar structure, with each domain containing four conserved framework regions (FR) and three hypervariable regions (HVR). (See, for example, Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind to a particular antigen can be isolated from antibodies that bind to the antigen using a VH or VL domain to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
[0109] As used herein, the term "vector" refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors as self-replicating nucleic acid structures and vectors integrated into the genome of a host cell into which it is introduced. Certain vectors are capable of inducing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors."
[0110] The term "sequential" as used herein with respect to chromatography refers to chromatographic steps in a particular sequence, e.g., a first chromatographic step followed by a second chromatographic step followed by a third chromatographic step. Additional steps may be included between the sequential chromatographic steps.
[0111] The term "consecutive" as used herein with respect to chromatography refers to having two chromatographic materials connected directly or via some other mechanism that allows for continuous flow between a first chromatographic material and a second chromatographic material.
[0112] "Loading density" refers to the amount (e.g., grams) of a composition contacted with a volume (e.g., liters) of chromatographic material. In some examples, loading density is expressed in g / L.
[0113] A "sample" refers to a small portion of a larger amount of material. Generally, testing according to the methods described herein is performed on a sample. Samples are typically obtained, for example, from a cultured recombinant polypeptide-expressing cell line (also referred to herein as a "product cell line") or from a recombinant polypeptide preparation obtained from a cultured host cell. As used herein, a "host cell" does not contain genes for the expression of a recombinant polypeptide or product of interest. Samples can be obtained, for example, but are not limited to, from a harvested cell culture fluid, from an in-process pool at a certain step of a purification process, or from a final purified product. Samples also include diluents, buffers, detergents, and contaminant species, debris found mixed with the desired molecule (such as a multispecific antibody, e.g., a bispecific antibody), and the like.
[0114] Reference herein to "about" a value or parameter includes (and accounts for) the variation that surrounds the value or parameter itself. For example, a statement referring to "about X" includes the statement of "X."
[0115] It is understood that aspects and embodiments of the invention described herein include "comprising," "consisting," and "consisting essentially of" aspects and embodiments.
[0116] As used in this specification and the appended claims, the singular forms "a," "or," and "the" include plural referents unless the context clearly dictates otherwise. It is understood that aspects and variations of the invention described herein include "consisting of" and / or "consisting essentially of" aspects and variations.
[0117] All references cited herein, including patent applications and publications, are hereby incorporated by reference in their entirety.
[0118] Methods for purifying multispecific antibodies Methods for purifying multispecific antibodies are provided herein. In certain embodiments, the multispecific antibodies are bispecific antibodies. In certain embodiments, the multispecific antibodies are bivalent F(ab')s comprising a first F(ab) that binds a first target and a second F(ab) that binds a second target. 2 In certain embodiments, a multispecific antibody is a bispecific antibody, i.e., an antibody with two antigen-binding arms that are identical in amino acid sequence, and each Fab arm is capable of recognizing two antigens (such as a dual acting Fab antibody).
[0119] In some aspects, the purification of multispecific antibodies comprises sequentially a capture chromatography step, a first mixed-mode chromatography step, and a second mixed-mode chromatography step. In some embodiments, the multispecific antibodies are assembled prior to the capture chromatography. In some embodiments, the multispecific antibodies are assembled after the capture chromatography.
[0120] In some embodiments, a multispecific antibody (bispecific antibody or bivalent F(ab') 2 (e.g., comprise two or more antibody arms, where different antibody arms bind different epitopes. In certain embodiments, the different epitopes are on the same antigen. In certain embodiments, each epitope is on a different antigen. In certain embodiments, the antibody arms comprise a VH / VL unit. In certain embodiments, the antibody arms comprise a hemimer, also known as a half antibody. To facilitate assembly, in certain embodiments, the heavy chain of one antibody arm is modified to include a "knob" and the heavy chain of another antibody arm includes a "hole" such that the knob of the first heavy chain fits into the hole of the second heavy chain.
[0121] In certain embodiments, each arm of the multispecific antibody is produced in a separate cell culture. After expression of the antibody arms in the host cells, the whole cell broth is harvested and homogenized, and the antibody arms are extracted. In certain embodiments, polyethyleneimine (PEI) is added to the cell lysate prior to chromatography. In some embodiments, the cell lysate is centrifuged prior to chromatography. Each arm of the multispecific antibody is then purified by capture chromatography (such that each arm is purified on a separate chromatography column or membrane). In certain embodiments, the capture chromatography is affinity chromatography. In certain embodiments, the affinity chromatography is Protein A chromatography. In certain embodiments, the affinity chromatography is Protein G chromatography. In certain embodiments, the affinity chromatography is Protein A / G chromatography. In certain embodiments, the affinity chromatography is Protein L chromatography. After capture chromatography, the purified antibody arms can be analyzed, for example, by SDS-PAGE, SEC chromatography, mass spectrometry, etc. The purified arms of the multispecific antibody are then combined and allowed to assemble, as discussed in more detail elsewhere herein.
[0122] In other embodiments, each arm of the multispecific antibody is produced in a separate cell culture. After expression of the antibody arms in the host cells, the entire cell broth is harvested and homogenized. The cell homogenates of each culture are then mixed and the combined antibody arms are extracted. In some embodiments, polyethyleneimine (PEI) is added to the cell lysate prior to chromatography. In some embodiments, the cell lysate is centrifuged prior to chromatography. The combined arms of the multispecific antibody are then purified by affinity chromatography. In some embodiments, the affinity chromatography is Protein A chromatography. At this point, the purified antibody arms can be analyzed, for example, by SDS-PAGE, SEC chromatography, mass spectrometry, etc. The purified arms of the multispecific antibody are then combined and allowed to assemble by the methods described herein.
[0123] In other embodiments, each arm of the multispecific antibody is produced in the same cell culture. After expression of the antibody arms in the host cells, the whole cell broth is harvested and homogenized, and the antibody arms are extracted. In some embodiments, polyethyleneimine (PEI) is added to the cell lysate prior to chromatography. In some embodiments, the cell lysate is centrifuged prior to chromatography. The multispecific antibody arms are then purified by affinity chromatography. In some embodiments, the affinity chromatography is Protein A chromatography. At this point, the purified antibody arms can be analyzed, for example, by SDS-PAGE, SEC chromatography, mass spectrometry, etc. The purified arms of the multispecific antibody are then allowed to assemble by the methods described herein.
[0124] In some embodiments, the final concentration of PEI in the cell lysate is at least about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 2.0%, about 3.0%, about 4.0%, or about 5.0. In some embodiments, the final concentration of PEI in the cell lysate is about 0.1% to about 5%, about 0.1% to about 1%, about 0.1% to about 0.5%, about 0.5% to about 5%, about 0.5% to about 1%, or about 1% to about 5%. In some embodiments, the cell lysate containing PEI is held for more than about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 12 hours, about 14 hours, about 16 hours, about 18 hours, about 20 hours, or about 24 hours. In some embodiments, the cell lysate containing PEI is held for more than about 1 hour to 24 hours, 1 hour to 6 hours, 6 hours to 12 hours, 12 hours to 18 hours, or 18 hours to 24 hours. In some embodiments, the cell lysate containing PEI is held for more than about 10 hours to 14 hours. In some embodiments, the cell lysate containing PEI is held at about 4° C. to 37° C. In some embodiments, the cell lysate containing PEI is held at about ambient temperature.
[0125] In some embodiments, the cell lysate is clarified by centrifugation prior to chromatography. In some embodiments, the cell lysate is filtered prior to chromatography. In some embodiments, the cell lysate is filtered through a 0.22 μm filter prior to chromatography.
[0126] Examples of affinity chromatography include, but are not limited to, Protein A, Protein G, Protein A / G, or Protein L chromatography. Examples of affinity chromatography materials include, but are not limited to, ProSep®-vA, ProSep® Ultra Plus, Protein A Sepharose® Fast Flow, Toyopearl® AF-r Protein A, MabSelect™, MabSelect SuRe™, MabSelect SuRe™ LX, KappaSelect, CaptureSelect™, and CaptureSelect™ FcXL. In certain embodiments, the affinity chromatography material is in a column. In certain embodiments, the affinity chromatography is performed in a "bind and elute mode" (alternatively referred to as a "bind and elute process"). "Bind and elute mode" refers to a product separation technique in which products in a sample (such as multispecific antibodies) bind to an affinity chromatography material and are sequentially eluted from the affinity chromatography material. In some embodiments, the elution is a step elution, where the composition of the mobile phase is changed stepwise in one or several instances during the elution process. In certain embodiments, the elution is a gradient elution, where the composition of the mobile phase is changed continuously during the elution process. In certain embodiments, the affinity chromatography material is a membrane. In certain embodiments, the affinity chromatography is Protein A chromatography. In certain embodiments, the Protein A chromatography is MAbSelect SuRe chromatography. In certain embodiments, the affinity chromatography is CaptureSelect chromatography. In certain embodiments, the affinity chromatography is CaptureSelect FcXL chromatography.
[0127] In certain embodiments, the eluates of the affinity chromatography steps are sequentially applied to a first mixed-mode chromatography. In certain embodiments, the first mixed-mode material comprises functional groups capable of any one or more of the following functionalities: anion exchange, cation exchange, hydrogen bonding, pi-pi bond interaction, hydrophilic interaction, thiophilic interaction, and hydrophobic interaction. In certain embodiments, the first mixed-mode material comprises functional groups capable of anion exchange and hydrophobic interaction. In certain embodiments, the first mixed-mode material comprises functional groups capable of cation exchange and hydrophobic interaction. In certain embodiments, the first mixed-mode material comprises N-benzyl-N-methylethanolamine, 4-mercapto-ethyl-pyridine, 2-benzamido-4-mercaptobutanoic acid, hexylamine, or phenylpropylamine, or cross-linked polyallylamine. Examples of mixed-mode materials include Capto™ Adhere resin, Capto™ MMC resin, MEP HyperCel™ resin, HEA HyperCel™ resin, PPA HyperCel™ resin, Eshmuno® HCX, Capto™ Adhere ImpRes, Capto™ MMC Impres, Nuvia™ cPrime™ membrane. In some embodiments, the first mixed-mode material is Capto™ Adhere resin. In certain embodiments, the first mixed-mode material is Capto™ Adhere resin. In certain embodiments, the first mixed-mode material is Capto™ MMC. In certain embodiments, the first mixed-mode chromatography does not include ceramic hydroxyapatite chromatography. In certain embodiments, the first mixed-mode chromatography is performed in "bind and elute" mode. In some embodiments, the elution is step elution. In certain embodiments, the elution is gradient elution. In certain embodiments, the first mixed-mode chromatography is performed in "flow-through" mode. In certain embodiments above, the first mixed-mode material is in a column. In certain embodiments above, the first mixed-mode material is in a membrane.
[0128] In certain embodiments, the capture chromatography and the first mixed-mode chromatography are sequential, e.g., the capture chromatography material and the first mixed-mode material are either directly connected or connected by some other mechanism that allows for continuous flow between the capture chromatography material and the first mixed-mode material. In certain embodiments, the capture chromatography and the first mixed-mode chromatography are sequential, and the first mixed-mode chromatography is performed immediately after the capture chromatography.
[0129] In certain embodiments, the capture chromatography eluate is subjected to one or more additional chromatography steps before being applied to the first mixed-mode resin. For example, the capture chromatography eluate may be subjected to any one or more of the following chromatography steps, in any order and / or in any combination, before being subjected to the first mixed-mode chromatography: hydrophobic interaction (HIC) chromatography, anion exchange chromatography, cation exchange chromatography, size exclusion chromatography, affinity chromatography, ceramic hydroxyapatite (CHT) chromatography, hydrophilic interaction liquid chromatography (HILIC), etc.
[0130] Hydrophobic interaction chromatography is a liquid chromatography technique that separates biomolecules according to their hydrophobicity. Examples of HIC chromatography materials include, but are not limited to, Toyopearl® Hexyl-650, Toyopearl® Butyl-650, Toyopearl® Phenyl-650, Toyopearl® Ether-650, HiTrap® Sepharose, Octyl Sepharose®, Phenyl Sepharose®, and Butyl Sepharose®. In some embodiments, the HIC chromatography material comprises Phenyl Sepharose. In certain embodiments, the HIC chromatography is performed in a "bind and elute" mode. In some embodiments, the HIC chromatography is performed in a "flow-through" mode. In some of the above embodiments, the HIC chromatography material is in a column. In some of the above embodiments, the HIC chromatography material is in a membrane.
[0131] Anion exchange chromatography materials are solid phases that are positively charged and have free anions for exchange with anions in an aqueous solution (such as a composition containing a multispecific antibody and impurities) that passes through or is passed over the solid phase. In some embodiments of any of the methods described herein, the anion exchange material can be a membrane, a monolith, or a resin. In one embodiment, the anion exchange material can be a resin. In some embodiments, the anion exchange material can include primary amine, secondary amine, tertiary amine, or quaternary ammonium ion functional groups, polyamine functional groups, or diethylaminoaethyl functional groups. Examples of anion exchange materials are known in the art and include, but are not limited to, Poros® HQ50, Poros® PI50, Poros® D, Mustang® Q, Q Sepharose® Fast Flow (QSFF), Accell™ with quaternary methylamine (QMA) resin, Sartobind STIC®, and DEAE-Sepharose®. In some embodiments, the anion exchange chromatography is performed in "bind and elute" mode. In some embodiments, the anion exchange chromatography is performed in "flow-through" mode. In some of the above embodiments, the anion exchange chromatography material is in a column. In some of the above embodiments, the anion exchange chromatography material is in a membrane.
[0132] A cation exchange chromatography material is a solid phase that is negatively charged and has free anions for exchange with anions in an aqueous solution (such as a composition containing a multispecific antibody and impurities) that is passed through or through the solid phase. In some embodiments of any of the methods described herein, the cation exchange material can be a membrane, monolith, or resin. In some embodiments, the cation exchange material can be a resin. The cation exchange material can include carboxylic acid or sulfonic acid functional groups, for example, but not limited to, sulfonate, carboxyl, carboxymethylsulfonate, sulfoisobutyl, sulfoethyl, carboxyl, sulfopropyl, sulfonyl, sulfoxyethyl, or orthophosphate. In some embodiments above, the cation exchange chromatography material is a cation exchange chromatography column. In some embodiments above, the cation exchange chromatography material is a cation exchange chromatography membrane. Examples of cation exchange materials known in the art include, but are not limited to, Mustang® S, Sartobind® S, SO 3 Monolith (e.g., CIM®, CIMmultus®, and CIMac® SO 3 etc.), S Ceramic HyperD®, Poros® XS, Poros® HS50, Poros® HS20, Sulfopropyl-Sepharose® Fast Flow (SPSFF), SP-Sepharose® XL (SPXL), CM Sepharose® Fast Flow, Capto™ S, Fractogel® EMD Se Hicap, Fractogel® EMD SO 3 - , or Fractogel® EMD COO -In some embodiments, the cation exchange chromatography is performed in "bind and elute" mode. In some embodiments, the cation exchange chromatography is performed in "flow-through" mode. In some of the above embodiments, the cation exchange chromatography material is in a column. In some of the above embodiments, the cation exchange chromatography material is in a membrane.
[0133] Hydroxyapatite (Ca 10 (PO 4 ) 6 (OH) 2 The functional groups of the chromatographic material contain positively charged pairs of clusters of six negatively charged oxygen atoms associated with a triad of crystalline calcium ions (C-sites), and crystalline phosphate (P-sites). The C-sites, P-sites, and hydroxyls are distributed in a fixed pattern on the crystal surface. Proteins are typically absorbed to hydroxyapatite in low concentrations (e.g., 10-25 mM) of phosphate buffer, although certain acidic proteins may be absorbed when loaded in water, saline, or non-phosphate buffers. Proteins are usually eluted by increasing the phosphate gradient, but Ca 2+ , Mg 2+ , or Cl -Ion gradients may also be used, such as for selective elution of basic proteins. In some embodiments of any of the methods described herein, the hydroxyapatite chromatography material may be a resin. In some embodiments, the hydroxyapatite chromatography material may be a resin. In some embodiments above, the hydroxyapatite chromatography material is a column. Examples of hydroxyapatite chromatography materials known in the art include, but are not limited to, CHT™ ceramic hydroxyapatite, CHT ceramic hydroxyapatite type I carrier, CHT ceramic hydroxyapatite type II carrier. In some embodiments, the hydroxyapatite chromatography is performed in "bind and elute" mode. In some embodiments, the hydroxyapatite chromatography is performed in "flow-through" mode.
[0134] In one embodiment, the method reported herein may further comprise a method for separating the bispecific antibody comprising an Fc domain from a solution comprising the bispecific antibody, the method comprising: (a) contacting the solution with a hydroxyapatite chromatography medium; (b) absorbing the bispecific antibody into the hydroxyapatite chromatography medium; and (c) eluting the bispecific antibody from the hydroxyapatite chromatography medium in the presence of chloride ions, wherein the solution further comprises one or more fragments of the bispecific antibody, wherein the one or more fragments comprises an Fc domain, and / or the solution comprises one or more polypeptides having a molecular weight greater than the molecular weight of the bispecific antibody and wherein the one or more polypeptides comprise at least one of the two heavy chains of the bispecific antibody further comprising an Fc domain as referenced in WO2015 / 024896.
[0135] In certain embodiments, the eluate from the capture chromatography is subjected to anion exchange chromatography. In certain embodiments, the anion exchange chromatography material is Q Sepharose® Fast Flow (QSFF). In certain embodiments, the anion exchange chromatography is performed in "bind and elute" mode.
[0136] In certain embodiments, the eluate collected after the first mixed-mode chromatography is sequentially applied to a second mixed-mode chromatography. In certain embodiments, the second mixed-mode material comprises functional groups capable of any one or more of the following functionalities: anion exchange, cation exchange, hydrogen bonding, pi-pi bond interaction, hydrophilic interaction, thiophilic interaction, and hydrophobic interaction. In certain embodiments, the second mixed-mode material comprises functional groups capable of anion exchange and hydrophobic interaction. In certain embodiments, the second mixed-mode material comprises functional groups capable of cation exchange and hydrophobic interaction. In certain embodiments, the second mixed-mode material comprises N-benzyl-N-methylethanolamine, 4-mercapto-ethyl-pyridine, 2-benzamido-4-mercaptobutanoic acid, hexylamine, or phenylpropylamine, or cross-linked polyallylamine. Examples of mixed-mode materials include Capto™ Adhere resin, Capto™ MMC resin, MEP HyperCel™ resin, HEA HyperCel™ resin, Eshmuno® HCX, Capto™ Adhere ImpRes, Capto™ MMC Impres, Nuvia™ cPrime™ membrane. In some embodiments, the second mixed-mode material is Capto™ Adhere resin. In certain embodiments, the twelfth mixed-mode material is Capto™ Adhere resin. In certain embodiments, the second mixed-mode material is Capto™ MMC. In certain embodiments, the second mixed-mode chromatography does not include ceramic hydroxyapatite chromatography. In certain embodiments, the second mixed-mode chromatography is performed in a "bind and elute" mode. In some embodiments, the elution is a step elution. In certain embodiments, the elution is a gradient elution. In certain embodiments, the first mixed-mode chromatography is performed in a "flow-through" mode. In certain embodiments above, the second mixed mode material is in a column. In certain embodiments above, the second mixed mode material is in a membrane.
[0137] In certain embodiments, the first mixed mode chromatography and the second mixed mode chromatography are sequential, e.g., the capture chromatography material and the first mixed mode material are either directly connected or connected by some other mechanism that allows for continuous flow between the capture chromatography material and the first mixed mode material. In certain embodiments, the first mixed mode chromatography and the second mixed mode chromatography are sequential, with the second mixed mode chromatography occurring immediately after the first mixed mode chromatography.
[0138] In certain embodiments, the eluate of the first mixed-mode chromatography is subjected to one or more additional chromatographic operations before being applied to the second mixed-mode resin. For example, the eluate of the first mixed-mode chromatography may be subjected to one or more of the following chromatographic steps in any order and / or in any combination before being subjected to the second mixed-mode chromatography: hydrophobic interaction (HIC) chromatography, anion exchange chromatography, cation exchange chromatography, size exclusion chromatography, affinity chromatography, ceramic hydroxyapatite (CHT) chromatography, hydrophilic interaction liquid chromatography (HILIC), etc.
[0139] In certain embodiments of any of the methods described herein, the eluate of the second mixed-mode chromatography is subjected to one or more additional chromatographic steps. For example, the eluate of the second mixed-mode chromatography may be subjected to any one or more of the following chromatographic steps in any order and / or in any combination: hydrophobic interaction (HIC) chromatography, anion exchange chromatography, cation exchange chromatography, size exclusion chromatography, affinity chromatography, ceramic hydroxyapatite (CHT) chromatography, hydrophilic interaction liquid chromatography (HILIC), mixed mode chromatography, etc.
[0140] In certain embodiments of any of the methods described herein, the method includes using a buffer. A variety of buffers may be used during the purification of a multispecific antibody depending, for example, on the desired pH of the buffer, the desired conductivity of the buffer, the characteristics of the multispecific antibody to be purified, and the purification method. The buffer may be a loading buffer, an equilibration buffer, or a wash buffer. In certain embodiments, one or more of the loading buffer, the equilibration buffer, and / or the wash buffer are the same. In certain embodiments, the loading buffer, the equilibration buffer, and / or the wash buffer are different. In certain embodiments of any of the methods described herein, the buffer comprises a salt. In certain embodiments, the buffer comprises sodium chloride, sodium acetate, Tris HCl, Tris acetate, sodium phosphate, potassium phosphate, MES, CHES, MOPS, Bis Tris, arginine, arginine HCl, or a mixture thereof. In certain embodiments, the buffer is a sodium chloride buffer. In some embodiments, the buffer is a sodium acetate buffer. In certain embodiments, the buffer is a Tris, arginine, phosphate, MES, CHES, or MOPS buffer.
[0141] "Load" refers to a composition that is loaded onto a chromatographic material. A loading buffer is a buffer used to load a composition (e.g., a composition comprising a multispecific antibody and impurities, or a composition comprising an antibody arm and impurities) onto a chromatographic material (such as any one of the chromatographic materials described herein). The chromatographic material may be equilibrated with an equilibration buffer prior to loading of the composition to be purified. A wash buffer is used after loading the composition onto the chromatographic material. An elution buffer is used to elute the polypeptide of interest from the solid phase.
[0142] The loading of a composition comprising a multispecific antibody (such as a composition comprising a multispecific antibody and impurities) onto any of the chromatographic materials described herein may be optimized for purification of the multispecific antibody from impurities. In some embodiments, the loading of a composition comprising a multispecific antibody (such as a composition comprising a multispecific antibody and impurities) onto a chromatographic material is optimized for binding of the multispecific antibody to the chromatographic material when chromatography is performed in bind and elute mode (e.g., affinity chromatography, mixed mode chromatography, and ion exchange chromatography as designed herein).
[0143] Conductivity refers to the ability of an aqueous solution to conduct electric current between two electrodes. In a solution, electric current flows by ion transport. Thus, as the amount of ions present in an aqueous solution increases, the solution will have a higher conductivity. The base unit of measure for conductivity is siemens (mS / cm) or ohm (mho) and can be measured using a conductivity meter, such as the various models of Orion conductivity meters. Since electrolyte conductivity is the ability of ions in a solution to carry electric current, the conductivity of a solution can be altered by changing the concentration of ions therein. For example, the concentration of buffers and / or the concentration of salts (e.g., sodium chloride, sodium acetate, or potassium chloride) in the solution can be altered to achieve the desired conductivity. Preferably, the salt concentrations of the various buffers are modified to achieve the desired conductivity.
[0144] For example, in certain embodiments, a composition comprising a multispecific antibody (such as a composition comprising a multispecific antibody and an impurity) is loaded onto a chromatographic material, e.g., a chromatographic column comprising any one of the chromatographic materials described herein, in a loading buffer of several different pH values while the conductivity of the loading buffer is kept constant. Alternatively, a solution comprising a multispecific antibody can be loaded onto a chromatographic material in a loading buffer of several different conductivities while the pH of the loading buffer is kept constant. Upon loading a composition comprising a multispecific antibody (such as a composition comprising a multispecific antibody and an impurity) onto a chromatographic material and eluting the product from the chromatographic material in pooled fractions, the amount of impurities remaining in the pooled fractions provides information regarding the separation of the multispecific antibody from the impurities for a given pH or conductivity. Similarly, for chromatography, when the multispecific antibody flows through the chromatographic material, the loading buffer is optimized for a pH and conductivity such that the multispecific antibody flows through the chromatographic material, but the impurities are retained by the chromatographic material or flow through the chromatographic material at a different rate than the multispecific antibody.
[0145] In some embodiments, the loading density of a solution comprising a multispecific antibody or antibody arms is greater than any of about 10 g / L, about 20 g / L, about 30 g / L, about 40 g / L, about 50 g / L, about 60 g / L, about 70 g / L, about 80 g / L, about 90 g / L, about 100 g / L, about 110 g / L, about 120 g / L, about 130 g / L, about 140 g / L, or about 150 g / L of an affinity chromatography material (e.g., a Protein A chromatography material). In some embodiments, the loading density of the solution comprising the multispecific antibody or antibody arms is from about 10 g / L to about 20 g / L, from about 20 g / L to about 30 g / L, from about 30 g / L to about 40 g / L, from about 40 g / L to about 50 g / L, from about 50 g / L to about 60 g / L, from about 60 g / L to about 70 g / L, from about 70 g / L to about 80 g / L, from about 80 g / L to about 90 g / L, or from about 90 g / L to about 100 g / L of the capture chromatography material (such as an affinity chromatography material, e.g., a Protein A chromatography material, a Protein G chromatography material, a Protein A / G chromatography material, or a Protein L chromatography material).
[0146] In some embodiments of any of the methods described herein, the eluate obtained after capture chromatography is loaded onto an anion exchange chromatography material (e.g., Q Sepharose® Fast Flow (QSFF)). In some embodiments of any of the methods described herein, the eluate obtained after capture chromatography is loaded onto an anion exchange chromatography material at a loading density of the multispecific antibody of the anion chromatography material (e.g., Q Sepharose® Fast Flow (QSFF)) of greater than any of about 30 g / L, about 40 g / L, about 50 g / L, about 60 g / L, about 70 g / L, about 80 g / L, about 90 g / L, about 100 g / L, about 110 g / L, about 120 g / L, about 130 g / L, about 140 g / L, or about 150 g / L. In some embodiments, the eluate obtained after capture chromatography is loaded onto an anion exchange chromatography material (e.g., Q Sepharose® Fast Flow (QSFF)) at a loading density of the multispecific antibody of any of the following anion exchange chromatography materials (e.g., about 10 g / L to about 20 g / L, about 20 g / L to about 30 g / L, about 30 g / L to about 40 g / L, about 40 g / L to about 50 g / L, about 50 g / L to about 60 g / L, about 60 g / L to about 70 g / L, about 70 g / L to about 80 g / L, about 80 g / L to about 90 g / L, or about 90 g / L to about 100 g / L.
[0147] In some embodiments of any of the methods described herein, the eluate obtained after capture chromatography (optionally after capture chromatography and one or more additional chromatographic steps comprising any of the chromatographic procedures described herein) is loaded onto a first mixed-mode chromatography material at a multispecific antibody loading density of the first mixed-mode chromatography material (e.g., a Capto™ Adhere chromatography material or a Capto™ MMC chromatography material) of greater than any of about 30 g / L, about 40 g / L, about 50 g / L, about 60 g / L, about 70 g / L, about 80 g / L, about 90 g / L, about 100 g / L, about 110 g / L, about 120 g / L, about 130 g / L, about 140 g / L, or about 150 g / L. In some embodiments, the eluate obtained after capture mode chromatography is loaded onto a first mixed-mode chromatography material (e.g., Capto™ Adhere chromatography material or Capto™ MMC chromatography material) at a multispecific antibody loading density of about 10 g / L to about 20 g / L, about 20 g / L to about 30 g / L, about 30 g / L to about 40 g / L, about 40 g / L to about 50 g / L, about 50 g / L to about 60 g / L, about 60 g / L to about 70 g / L, about 70 g / L to about 80 g / L, about 80 g / L to about 90 g / L, or about 90 g / L to about 100 g / L of the first mixed-mode chromatography material.
[0148] In some embodiments of any of the methods described herein, the eluate obtained after the first mixed-mode chromatography is loaded onto a second mixed-mode chromatography material (e.g., a Capto™ Adhere chromatography material or a Capto™ MMC chromatography material) at a multispecific antibody loading density of greater than any of about 30 g / L, about 40 g / L, about 50 g / L, about 60 g / L, about 70 g / L, about 80 g / L, about 90 g / L, about 100 g / L, about 110 g / L, about 120 g / L, about 130 g / L, about 140 g / L, or about 150 g / L. In some embodiments, the eluate obtained after the first mixed-mode chromatography is loaded onto a second mixed-mode chromatography material at a multispecific antibody loading density of about 10 g / L to about 20 g / L, about 20 g / L to about 30 g / L, about 30 g / L to about 40 g / L, about 40 g / L to about 50 g / L, about 50 g / L to about 60 g / L, about 60 g / L to about 70 g / L, about 70 g / L to about 80 g / L, about 80 g / L to about 90 g / L, or about 90 g / L to about 100 g / L of any of the mixed-mode chromatography materials (e.g., Capto™ Adhere chromatography material or Capto™ MMC chromatography material).
[0149] In some embodiments of any of the methods described herein, the eluate obtained after the second mixed-mode chromatography is loaded onto a sequential chromatography material (such as a hydrophobic interaction (HIC) chromatography material, anion exchange chromatography material, cation exchange chromatography material, size exclusion chromatography material, affinity chromatography material, or additional mixed-mode chromatography material) at a loading density of multispecific antibodies on the sequential chromatography material of greater than any of about 30 g / L, about 40 g / L, about 50 g / L, about 60 g / L, about 70 g / L, about 80 g / L, about 90 g / L, about 100 g / L, about 110 g / L, about 120 g / L, about 130 g / L, about 140 g / L, or about 150 g / L. In some embodiments, the eluate obtained after the second mixed-mode chromatography is loaded onto a sequential chromatography material (such as a hydrophobic interaction (HIC) chromatography material, anion exchange chromatography material, cation exchange chromatography material, size exclusion chromatography material, affinity chromatography material, or additional mixed-mode chromatography material) at a multispecific antibody loading density of the sequential chromatography material of about 10 g / L to about 20 g / L, about 20 g / L to about 30 g / L, about 30 g / L to about 40 g / L, about 40 g / L to about 50 g / L, about 50 g / L to about 60 g / L, about 60 g / L to about 70 g / L, about 70 g / L to about 80 g / L, about 80 g / L to about 90 g / L, or about 90 g / L to about 100 g / L.
[0150] Elution, as used herein, is the removal of a product, e.g., a multispecific antibody or an antibody arm, from a chromatographic material. An elution buffer is a buffer used to elute a multispecific antibody or other product of interest from a chromatographic material. In many cases, the elution buffer has different physical characteristics than the loading buffer. For example, the elution buffer may have a different conductivity than the loading buffer or a different pH than the loading buffer. In some embodiments, the elution buffer has a lower conductivity than the loading buffer. In some embodiments, the elution buffer has a higher conductivity than the loading buffer. In some embodiments, the elution buffer has a lower pH than the loading buffer. In some embodiments, the elution buffer has a higher pH than the loading buffer. In some embodiments, the elution buffer has a different conductivity and a different pH than the loading buffer. The elution buffer may have any combination of higher or lower conductivity and higher or lower pH.
[0151] In certain embodiments, elution of the multispecific antibody from the chromatographic material is optimized for yielding product with minimal impurities and minimal elution or pooling volumes. For example, a composition comprising a multispecific antibody (e.g., bispecific antibody) or antibody arm can be loaded onto a chromatographic material, e.g., a chromatographic column, in a loading buffer. Once loading is complete, the multispecific antibody or antibody arm is eluted with a buffer of several different pH values, while the conductivity of the elution buffer is kept constant. Alternatively, the multispecific antibody or antibody arm can be eluted from the chromatographic material in an elution buffer of several different conductivities, while the pH of the elution buffer is kept constant. Once elution of the multispecific antibody (e.g., bispecific antibody) or antibody arm from the chromatographic material is complete, the amount of impurities in the pooled fractions provides information regarding the separation of the multispecific antibody or antibody arm from the impurities for a given pH or conductivity. Elution of the multispecific antibody or antibody arm in multiple column volumes (e.g., 8 column volumes) exhibits a "tailing" of the elution profile. In some embodiments, the tailing of the elution is minimized.
[0152] For example, various buffers may be used depending on the desired pH of the buffer, the desired conductivity of the buffer, the characteristics of the protein of interest, the chromatographic materials, and the purification process (e.g., "bind and elute" or "flow-through" mode). In some embodiments of any of the methods described herein, the method includes the use of at least one buffer. The buffer may be a loading buffer, an equilibration buffer, an elution buffer, or a wash buffer. In some embodiments, one or more of the loading buffer, the equilibration buffer, the elution buffer, and / or the wash buffer (such as the loading buffer, the equilibration buffer, and / or the wash buffer used for the capture chromatography, the first mixed-mode chromatography, the second mixed-mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed-mode chromatography, etc.) are the same. In some embodiments, the loading buffer, equilibration buffer, and / or wash buffer (such as the loading buffer, equilibration buffer, and / or wash buffer used for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) are different. In some embodiments of any of the methods described herein, the buffer comprises a salt. The loading buffer (such as the loading buffer, equilibration buffer, and / or wash buffer used for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) may comprise sodium chloride, sodium acetate, Tris, arginine, phosphate, MOPS, MES, CHES, BisTris, ammonium sulfate, sodium phosphate, citrate, succinate, or mixtures thereof.In certain embodiments, the buffer is a sodium chloride buffer. In some embodiments, the buffer is a sodium acetate buffer. In certain embodiments, the buffer is a Tris, arginine, phosphate, MES, CHES, or MOPS buffer. In some embodiments, the buffer comprises Tris. In some embodiments, the buffer comprises arginine.
[0153] In some embodiments of any of the methods described herein, the loading buffer (such as the loading buffer used for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) has a pH of about 1.0 mS / In some embodiments, the ion exchange polymer has a conductivity of greater than about 1.5 mS / cm, about 2.0 mS / cm, about 2.5 mS / cm, about 3.0 mS / cm, about 3.5 mS / cm, about 4.0 mS / cm, about 4.5 mS / cm, about 5.0 mS / cm, about 5.5 mS / cm, about 6.0 mS / cm, about 6.5 mS / cm, about 7.0 mS / cm, about 7.5 mS / cm, about 8.0 mS / cm, about 8.5 mS / cm, about 9.0 mS / cm, about 9.5 mS / cm, about 10 mS / cm, or about 20 mS / cm. The conductivity can be any of about 1 mS / cm to about 20 mS / cm, about 4 mS / cm to about 10 mS / cm, about 4 mS / cm to about 7 mS / cm, about 5 mS / cm to about 17 mS / cm, about 5 mS / cm to about 10 mS / cm, or about 5 mS / cm to about 7 mS / cm. In some embodiments, the conductivity is about 1.0 mS / cm, about 1.5 mS / cm, about 2.0 mS / cm, about 2.5 mS / cm, about 3.0 mS / cm, about 3.5 mS / cm, about 4 mS / cm, about 4.5 mS / cm, about 5.0 mS / cm, about 5.5 mS / cm, about 6.0 mS / cm, about 6.5 mS / cm, about 7.0 mS / cm, about 7.5 mS / cm, about 8.0 mS / cm, about 8.5 mS / cm, about 9.0 mS / cm, about 9.5 mS / cm, about 10 mS / cm, or about 20 mS / cm. In one aspect, the conductivity is that of a loading buffer, an equilibration buffer, and / or a wash buffer.In some embodiments, the conductivity of one or more of the loading buffer, equilibration buffer, and / or wash buffer (such as the loading buffer, equilibration buffer, and / or wash buffer used for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) is the same. In some embodiments, the conductivity of the loading buffer is different from the conductivity of the wash buffer and / or the equilibration buffer.
[0154] In some embodiments, the elution buffer (such as the elution buffer for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) has a conductivity less than the conductivity of the loading buffer. In some embodiments of any of the methods described herein, the elution buffer (such as the elution buffer for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) has a conductivity of less than any of about 0 mS / cm, about 0.5 mS / cm, about 1.0 mS / cm, about 1.5 mS / cm, about 2.0 mS / cm, about 2.5 mS / cm, about 3.0 mS / cm, about 3.5 mS / cm, about 4.0 mS / cm, about 4.5 mS / cm, about 5.0 mS / cm, about 5.5 mS / cm, about 6.0 mS / cm, about 6.5 mS / cm, or about 7.0 mS / cm. The conductivity can be any of about 0 mS / cm to about 7 mS / cm, about 1 mS / cm to about 7 mS / cm, about 2 mS / cm to about 7 mS / cm, about 3 mS / cm to about 7 mS / cm, or about 4 mS / cm to about 7 mS / cm, about 0 mS / cm to about 5.0 mS / cm, about 1 mS / cm to about 5 mS / cm, about 2 mS / cm to about 5 mS / cm, about 3 mS / cm to about 5 mS / cm, or about 4 mS / cm to about 5 mS / cm.In some embodiments, the conductivity of the elution buffer (such as the elution buffer for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) is any of about 0 mS / cm, about 0.5 mS / cm, about 1.0 mS / cm, about 1.5 mS / cm, about 2.0 mS / cm, about 2.5 mS / cm, about 3.0 mS / cm, about 3.5 mS / cm, about 4 mS / cm, about 4.5 mS / cm, about 5.0 mS / cm, about 5.5 mS / cm, about 6.0 mS / cm, about 6.5 mS / cm, or about 7.0 mS / cm.
[0155] In some embodiments, the elution buffer has a conductivity greater than that of the loading buffer. In some embodiments of any of the methods described herein, the elution buffer (such as an elution buffer for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) has a conductivity of about 5.5 mS / cm, about 6.0 mS / cm, about 6.5 mS / cm, about 7.0 mS / cm, about 7.5 mS / cm, about 8.0 mS / cm, about 8.5 mS / cm, about 9.0 mS / cm, about 10.0 mS / cm, about 11.0 mS / cm, about 12.0 mS / cm, about 13.0 mS / cm, about 14.0 mS / cm, about 15.0 mS / cm, about 16.0 mS / cm, about 17.0 mS / cm, about 18.0 mS / cm, about 19.0 mS / cm, about 20.0 mS / cm, about 21.0 mS / cm, about 22.0 mS / cm, about 23.0 mS / cm, about 24.0 mS / cm, about 25.0 mS / cm, about 26.0 mS / cm, about 27.0 mS / cm, about 28.0 mS / cm, about 29.0 mS / cm, about 30.0 mS / cm, about 31.0 mS / cm, about 32.0 mS / cm, about 33.0 mS / cm, about 34.0 mS / cm, about 35.0 mS / cm, about 36.0 mS / cm, about 37.0 mS / cm, about 38.0 mS / cm, about 39.0 mS / cm, about 20.0 mS / cm, about 21.0 mS / cm, about 22.0 mS / cm, about 23.0 mS / cm, about 24.0 mS / cm, about 25.0 mS / cm, about 26.0 mS / cm, about 27.0 mS / cm, about 28.0 mS / cm, about 29.0 mS / cm, or about 30.0 mS / cm. The conductivity can be any of about 5.5 mS / cm to about 30 mS / cm, about 6.0 mS / cm to about 30 mS / cm, about 7 mS / cm to about 30 mS / cm, about 8 mS / cm to about 30 mS / cm, about 9 mS / cm to about 30 mS / cm, or about 10 mS / cm to about 30 mS / cm.In some embodiments, the conductivity of the elution buffer is about 5.5 mS / cm, about 6.0 mS / cm, about 6.5 mS / cm, about 7.0 mS / cm, about 7.5 mS / cm, about 8.0 mS / cm, about 8.5 mS / cm, about 9.0 mS / cm, about 9.5 mS / cm, about 10 mS / cm, about 11 mS / cm, about 12 mS / cm, about 13 mS / cm, about 14 mS / cm, about 15 mS / cm, about 16 mS / cm, about 17 mS / cm, about 18 mS / cm, about 19 mS / cm, about 20 mS / cm, about 21 mS / cm, about 22 mS / cm, about 23 mS / cm, about 24 mS / cm, about 25 mS / cm, about 26 mS / cm, about 27 mS / cm, about 28 mS / cm, about 29 mS / cm, about 30 mS / cm, about 31 mS / cm, about 32 mS / cm, about 33 mS / cm, about 34 mS / cm, about 35 mS / cm, about 36 mS / cm, about 37 mS / cm, about 38 mS / cm, about 39 mS / cm, about 40 mS / cm, about 41 mS / cm, about 42 mS / cm, about 43 mS / cm, about 44 mS / cm, about 45 mS / cm, about 46 mS / cm, about 47 mS / cm, about 48 mS / cm, about 49 mS / cm, about 50 mS / cm, about 51 mS / cm, about 52 mS / cm, about 53 mS / cm, about 54 mS / cm, about 5 0 mS / cm, about 17.0 mS / cm, about 18.0 mS / cm, about 19.0 mS / cm, about 20.0 mS / cm, about 21.0 mS / cm, about 22.0 mS / cm, about 23.0 mS / cm, about 24.0 mS / cm, about 25.0 mS / cm, about 26.0 mS / cm, about 27.0 mS / cm, about 28.0 mS / cm, about 29.0 mS / cm, or about 30.0 mS / cm. In some aspects of any of the above embodiments, the conductivity of the elution buffer (such as the elution buffer for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) is changed from the load and / or wash buffer by a step gradient or a linear gradient.
[0156] In some embodiments, the solution comprising the multispecific antibody is loaded onto the first mixed-mode chromatographic material in a loading buffer having a conductivity of about <6.5 mS / cm and the polypeptide is eluted from the first mixed-mode chromatographic material in an elution buffer having a conductivity of about 1.5 mS / cm. In some embodiments, the loading buffer has a conductivity of about 6.5 mS / cm and the elution buffer has a conductivity of about 3 mS / cm. In some embodiments, the loading buffer has a conductivity of about 5.5 mS / cm and the elution buffer has a conductivity of about 2 mS / cm. In some embodiments, the loading buffer has a conductivity of about 5.5 mS / cm and the elution buffer has a conductivity of about 1 mS / cm. In further embodiments of the above embodiment, the first mixed-mode chromatographic material is Capto™ Adhere resin. In further embodiments of the above embodiment, the first mixed-mode chromatographic material is Capto™ MMC resin.
[0157] In some aspects of any of the above embodiments, the conductivity of the elution buffer is changed from the load and / or wash buffer by a step gradient or a linear gradient. In some embodiments, the composition comprising the multispecific antibody is loaded onto the first mixed-mode chromatography (e.g., Capto™ Adhere chromatography or Capto™ MMC chromatography) at <6.5 mS / cm and the multispecific antibody is eluted from the first mixed-mode chromatography by a step conductivity gradient up to about 1.5 mS / cm.
[0158] In some embodiments, the solution comprising the multispecific antibody is loaded onto the second mixed-mode chromatographic material in a loading buffer having a conductivity of about <6.5 mS / cm and the polypeptide is eluted from the second mixed-mode chromatographic material in an elution buffer having a conductivity of about 1.5 mS / cm. In some embodiments, the loading buffer has a conductivity of about 6.5 mS / cm and the elution buffer has a conductivity of about 3 mS / cm. In some embodiments, the loading buffer has a conductivity of about 5.5 mS / cm and the elution buffer has a conductivity of about 2 mS / cm. In some embodiments, the loading buffer has a conductivity of about 5.5 mS / cm and the elution buffer has a conductivity of about 1 mS / cm. In further embodiments of the above embodiment, the second mixed-mode chromatographic material is Capto™ Adhere resin. In further embodiments of the above embodiment, the second mixed-mode chromatographic material is Capto™ MMC resin.
[0159] In some aspects of any of the above embodiments, the conductivity of the elution buffer is changed from the load and / or wash buffer by a step gradient or a linear gradient. In some embodiments, the composition comprising the multispecific antibody is loaded onto the second mixed-mode chromatography (e.g., Capto™ Adhere chromatography or Capto™ MMC chromatography) at <6.5 mS / cm and the multispecific antibody is eluted from the second mixed-mode chromatography by a step conductivity gradient up to about 1.5 mS / cm.
[0160] In some embodiments, a composition comprising a multispecific antibody is loaded onto anion exchange chromatography (e.g., QSFF chromatography) at <2.5 mS / cm and the multispecific antibody is eluted from the anion exchange chromatography with a step conductivity gradient up to about 8.6 mS / cm.
[0161] In some embodiments, a composition comprising a multispecific antibody is loaded onto a cation exchange chromatography (e.g., POROS50HS chromatography) at about 5.0 mS / cm and the multispecific antibody is eluted from the cation exchange chromatography with a step conductivity gradient up to about 27.5 mS / cm.
[0162] In some embodiments of any of the methods described herein, the loading buffer (such as the loading buffer used for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) has a pH less than any of about 10, about 9, about 8, about 7, about 6, or about 5, including any ranges between these values. In some embodiments of any of the methods described herein, the loading buffer (such as the loading buffer used for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) has a pH greater than any of about 4, about 5, about 6, about 7, about 8, or about 9, including any ranges between these values. The loading buffer (such as the loading buffer used for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) has a pH of about 4 to about 9, about 4 to about 8, about 4 to about 7, about 5 to about 9, about 5 to about 8, about 5 to about 7, about 5 to about 6, including any range between these values.In some embodiments, the pH of the loading buffer (such as the loading buffer used for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) has a pH of any of about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, or about 8, including any ranges between these values. The pH can be the pH of the loading buffer, equilibration buffer, or wash buffer (such as the loading buffer, equilibration buffer, and / or wash buffer used for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.). In some embodiments, the pH of one or more of the loading buffer, equilibration buffer, and / or wash buffer are the same. In some embodiments, the pH of the loading buffer is different from the pH of the equilibration buffer and / or wash buffer.
[0163] In some embodiments, the elution buffer (such as the elution buffer for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) has a pH that is less than the pH of the loading buffer. In some embodiments of any of the methods described herein, the elution buffer has a pH that is less than any of about 8, about 7, about 6, about 5, about 4, about 3, or about 2, including any ranges between these values. The pH of the elution buffer can be any of about 4 to about 9, about 4 to about 8, about 4 to about 7, about 4 to about 6, about 4 to about 5, about 5 to about 9, about 5 to about 8, about 5 to about 7, about 5 to about 6, about 6 to about 9, about 6 to about 8, about 6 to about 7, including any ranges between these values. In some embodiments, the pH of the elution buffer (such as the elution buffer for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) is any of about 4.0, about 4.5, about 5.0, about 5.5, about 6.0, about 6.5, about 7.0, about 7.5, about 8.0, about 8.5, or about 9.0, including any range between these values.
[0164] In some embodiments, the elution buffer (such as an elution buffer for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) has a pH greater than the pH of the loading buffer. In some embodiments of any of the methods described herein, the elution buffer (such as an elution buffer for the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) has a pH greater than any of about 5, about 6, about 7, about 8, or about 9, including any ranges between these values. In some embodiments of any of the methods described herein, the elution buffer (such as an elution buffer for the capture chromatography) has a pH greater than any of about 2, about 4, or about 4, including any ranges between these values. The pH of the elution buffer (such as the elution buffer for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) can be any of about 2 to about 9, about 3 to about 9, about 4 to about 9, about 2 to about 8, about 3 to about 8, about 4 to about 8, about 2 to about 7, about 3 to about 7, about 4 to about 7, about 2 to about 6, about 3 to about 6, and about 4 to about 6, including any ranges between these values. In some embodiments, the pH of the elution buffer is any of about 2.0, about 2.5, about 3.0, about 3.5, about 4.0, including any ranges between these values.
[0165] In some embodiments, a solution containing the multispecific antibody or antibody arms is loaded onto affinity chromatography (e.g., Protein A chromatography) at about pH 7, and the multispecific antibody or antibody arms are eluted from the affinity chromatography with a step gradient to a pH of about 2.9.
[0166] In some aspects of any of the above embodiments, the pH of the elution buffer (such as the elution buffer for the capture chromatography, the first mixed mode chromatography, the second mixed mode chromatography, and / or any additional chromatography such as anion exchange chromatography, cation exchange chromatography, HIC chromatography, size exclusion chromatography, additional mixed mode chromatography, etc.) is changed from the load and / or wash buffer by a step gradient or a linear gradient.
[0167] In some embodiments of any of the methods described herein, the flow rate is less than about 50 CV / hr, about 40 CV / hr, or about 30 CV / hr. The flow rate can be about 5 CV / hr to about 50 CV / hr, about 10 CV / hr to about 40 CV / hr, or about 18 CV / hr to about 36 CV / hr. In some embodiments, the flow rate is about 9 CV / hr, about 18 CV / hr, about 25 CV / hr, about 30 CV / hr, about 36 CV / hr, or about 40 CV / hr. In some embodiments of any of the methods described herein, the flow rate is less than about 100 cm / hr, about 75 cm / hr, or about 50 cm / hr. The flow rate can be about 25 cm / hr to about 150 cm / hr, about 25 cm / hr to about 100 cm / hr, about 50 cm / hr to about 100 cm / hr, or about 65 cm / hr to about 85 cm / hr.
[0168] The bed height is the height of the chromatography material used. In some embodiments of any of the methods described herein, the bed height is greater than any of about 5 cm, about 10 cm, about 15 cm, about 20 cm, about 25 cm, about 30 cm, about 35 cm, about 40 cm, about 45 cm, or about 50 cm. In some embodiments, the bed height is between about 5 cm and about 50 cm. In some embodiments, the bed height is determined based on the amount of polypeptide or contaminants in the load.
[0169] In some embodiments, the chromatography is performed using a volume of about 1 mL, about 2 mL, about 3 mL, about 4 mL, about 5 mL, about 6 mL, about 7 mL, about 8 mL, about 9 mL, about 10 mL, about 15 mL, about 20 mL, about 25 mL, about 30 mL, about 40 mL, about 50 mL, about 75 mL, about 100 mL, about 200 mL, about 300 mL, about 400 mL, about 500 mL, about 600 mL, In a column or vessel having a volume of greater than about 700 mL, about 800 mL, about 900 mL, about 1 L, about 2 L, about 3 L, about 4 L, about 5 L, about 6 L, about 7 L, about 8 L, about 9 L, about 10 L, about 25 L, about 50 L, about 100 L, about 200 L, about 300 L, about 400 L, about 500 L, about 600 L, about 700 L, about 800 L, about 900 L, or about 1000 L.
[0170] In some embodiments, fractions are collected from the chromatography. In some embodiments, the collected fractions are greater than about 0.01 CV, about 0.02 CV, about 0.03 CV, about 0.04 CV, about 0.05 CV, about 0.06 CV, about 0.07 CV, about 0.08 CV, about 0.09 CV, about 0.1 CV, about 0.2 CV, about 0.3 CV, about 0.4 CV, about 0.5 CV, about 0.6 CV, about 0.7 CV, about 0.8 CV, about 0.9 CV, about 1.0 CV, about 2.0 CV, about 3.0 CV, about 4.0 CV, about 5.0 CV, about 6.0 CV, about 7.0 CV, about 8.0 CV, about 9.0 CV, or about 10.0 CV.
[0171] In certain embodiments, purified or partially purified products, such as multispecific antibodies (bispecific antibodies or bivalent F(ab') 2The fractions containing the OD or an arm or Fab of the antibody are pooled. The amount of polypeptide in a fraction can be determined by one of skill in the art, for example, the amount of polypeptide in a fraction can be determined by ultraviolet spectroscopy. In certain embodiments, the fractions are pooled at OD 280 In certain embodiments, fractions are collected when the OD exceeds any of about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, and about 1.0. 280 is any of about 0.5 to about 1.0, about 0.6 to about 1.0, about 0.7 to about 1.0, about 0.8 to about 1.0, or about 0.9 to about 1.0. In certain embodiments, fractions containing multispecific antibodies (e.g., bispecific antibodies) or antibody arms are pooled.
[0172] In certain embodiments of any of the methods described herein, the impurity is a product-specific impurity. Examples of product-specific impurities include, but are not limited to, unpaired half-antibodies, unpaired antibody light chains, unpaired heavy chains, antibody fragments, homodimers (e.g., paired half-dimers of bispecific antibodies containing the same heavy and light chains), aggregates, high molecular weight species (MHWS) (very high molecular weight species (vHMWS)), multispecific antibodies with mismatched disulfides, light chain dimers, heavy chain dimers, low molecular weight species (LMWS), and charge variants (such as acidic and basic variants of antibodies).
[0173] In certain embodiments, the methods provided herein remove or reduce the level of non-paired half antibodies from a composition comprising a multispecific antibody (e.g., a bispecific antibody) and a non-paired half antibody. Methods for measuring the presence or level of non-paired half antibodies in a composition are known in the art, for example, by mass spectrometry (such as liquid chromatography-mass spectrometry), CE-SDS, reverse phase HPLC, HIC HPLC. In certain embodiments of any of the methods described herein, the amount of non-paired half antibodies in a composition recovered from one or more purification step(s) (such as a chromatographic fraction) is reduced by more than any of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99%, including any range between these values. In certain embodiments, the amount of non-paired antibodies in a composition recovered from one or more purification step(s) (e.g., chromatographic fractions) is reduced to any of about 10% to about 95%, about 10% to about 99%, about 20% to about 95%, about 20% to about 99%, about 30% to about 95%, about 30% to about 99%, about 40% to about 95%, about 40% to about 99%, about 50% to about 95%, about 50% to about 99%, about 60% to about 95%, about 60% to about 99%, about 70% to about 95%, about 70% to about 99%, about 80% to about 95%, about 80% to about 99%, about 90% to about 95%, or about 90% to about 99%. In some embodiments, the amount of non-paired half antibodies in the composition (e.g., chromatographic fraction) is reduced by any of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 95%. In certain embodiments, the reduction in the presence or level of non-paired half antibodies is measured by comparing the amount of non-paired half antibodies in the composition recovered from the purification step(s) (e.g., chromatographic fraction) to the amount of non-paired half antibodies in the composition prior to the purification step(s).
[0174] In certain embodiments, the methods provided herein remove and reduce the level of homodimers from a composition comprising a multispecific antibody (e.g., a bispecific antibody) and a homodimer. Methods for measuring the presence or level of homodimers in a composition are known in the art, for example, by mass spectrometry (such as liquid chromatography-mass spectrometry), reverse phase HPLC, and HIC HPLC. In certain embodiments of any of the methods described herein, the amount of homodimers in a composition recovered from one or more purification step(s) (such as a chromatographic fraction) is reduced by more than any of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99%, including any range between these values. In certain embodiments, the amount of homodimer in a composition recovered from one or more purification step(s) (e.g., a chromatographic fraction) is reduced to any of about 10 to about 95%, about 10% to about 99%, about 20% to about 95%, about 20% to about 99%, about 30% to about 95%, about 30% to about 99%, about 40% to about 95%, about 40% to about 99%, about 50% to about 95%, about 50% to about 99%, about 60% to about 95%, about 60% to about 99%, about 70% to about 95%, about 70% to about 99%, about 80% to about 95%, about 80% to about 99%, about 90% to about 95%, or about 90% to about 99%. In some embodiments, the amount of homodimer in a composition (such as a chromatographic fraction) is reduced by any of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 95%. In certain embodiments, the reduction in the presence or level of homodimer is measured by comparing the amount of homodimer in a composition (such as a chromatographic fraction) recovered from a purification step(s) to the amount of homodimer in the composition prior to the purification step(s).
[0175] In certain embodiments, the methods provided herein remove or reduce the level of high molecular weight species (HMWS) proteins from a composition comprising a multispecific antibody (e.g., a bispecific antibody) and an HMWS protein. The HMWS protein may, for example, comprise an aggregated polypeptide (such as an aggregated multispecific antibody, an aggregated half-antibody, an aggregated homodimer, etc.). In certain embodiments, the aggregated polypeptide comprises a heavy chain multimer, a light chain multimer, and / or a multimer of a multispecific antibody. The HMWS protein may comprise 2, 3, 4, 5, 6, 7, or 8 or more monomers of heavy or light chains, or 2, 3, 4, 5, 6, 7, or 8 or more aggregated multispecific antibodies. Methods for measuring aggregated proteins (e.g., HMWS proteins) are known in the art and described, for example, in WO2011 / 150110. Such methods include, for example, size exclusion chromatography, capillary electrophoresis-sodium dodecyl sulfate (CE-SDS), and liquid chromatography-mass spectrometry (LC-MS). In certain embodiments of any of the methods described herein, the amount of HMWS protein in a composition recovered from one or more purification step(s) (e.g., a chromatography fraction) is reduced by greater than any of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99%, including any ranges therebetween. In certain embodiments, the amount of HMWS protein in a composition recovered from one or more purification step(s) (e.g., a chromatographic fraction) is reduced to any of about 10% to about 95%, about 10% to about 99%, about 20% to about 95%, about 20% to about 99%, about 30% to about 95%, about 30% to about 99%, about 40% to about 95%, about 40% to about 99%, about 50% to about 95%, about 50% to about 99%, about 60% to about 95%, about 60% to about 99%, about 70% to about 95%, about 70% to about 99%, about 80% to about 95%, about 80% to about 99%, about 90% to about 95%, or about 90% to about 99%.In some embodiments, the amount of HMWS protein in a composition (such as a chromatographic fraction) is reduced by any of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 95%. In certain embodiments, the reduction in the presence or level of HMWS protein is measured by comparing the amount of HMWS protein in a composition (such as a chromatographic fraction) recovered from a purification step(s) to the amount of HMWS protein in the composition prior to the purification step(s).
[0176] In certain embodiments, the methods provided herein remove or reduce the level of low molecular weight species (LMWS) protein from a composition comprising a multispecific antibody (e.g., a bispecific antibody) and a LMWS protein. The LMWS protein may comprise a fragmented polypeptide. In certain embodiments, the fragmented polypeptide is a fragment of a multispecific antibody, a fragment of an antibody arm, a heavy chain fragment, or a light chain fragment. Examples of LMWS proteins include, but are not limited to, Fab (i.e., fragment antigen binding), Fc (fragment, crystallizable), regions, or a combination of both, or any randomly fragmented portion of a multispecific antibody, heavy chain, or light chain of interest, or a 1 / 2 antibody (comprising one antibody light chain / heavy chain pair) or a 3 / 4 antibody (comprising a heterodimer or homodimer of an antibody heavy chain and an antibody light chain, also referred to herein as HHL). Methods for measuring fragmented proteins (e.g., LMWS proteins) are known in the art and described, for example, in WO2011 / 150110. Such methods include, for example, size exclusion chromatography, capillary electrophoresis-sodium dodecyl sulfate (CE-SDS), and liquid chromatography-mass spectrometry (LC-MS). In certain embodiments of any of the methods described herein, the amount of LMWS protein in a composition recovered from one or more purification step(s) (e.g., a chromatographic fraction) is reduced by greater than any of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99%, including any ranges therebetween.In certain embodiments, the amount of LMWS protein in a composition recovered from one or more purification step(s) (e.g., a chromatographic fraction) is reduced to any of about 10% to about 95%, about 10% to about 99%, about 20% to about 95%, about 20% to about 99%, about 30% to about 95%, about 30% to about 99%, about 40% to about 95%, about 40% to about 99%, about 50% to about 95%, about 50% to about 99%, about 60% to about 95%, about 60% to about 99%, about 70% to about 95%, about 70% to about 99%, about 80% to about 95%, about 80% to about 99%, about 90% to about 95%, or about 90% to about 99%. In some embodiments, the amount of LMWS protein in a composition (such as a chromatographic fraction) is reduced by any of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 95%. In certain embodiments, the reduction in the presence or level of LMWS protein is measured by comparing the amount of LMWS protein in a composition (such as a chromatographic fraction) recovered from a purification step(s) to the amount of LMWS protein in the composition prior to the purification step(s).
[0177] In certain embodiments, the methods provided herein remove or reduce the levels of acidic and / or basic variants from a multispecific antibody (e.g., bispecific antibody) and a composition comprising the acidic and / or basic variants. An acidic variant of an antibody (such as a multispecific antibody, e.g., a bispecific antibody) is a variant in which the pI of the antibody is less than the pI of the native intact antibody. A basic variant of an antibody (such as a multispecific antibody, e.g., a bispecific antibody) is a variant in which the pI of the antibody is greater than the pI of the native intact antibody. Such charge variants (e.g., acidic and basic variants) can be the result of natural processes such as oxidation, deamidation, C-terminal processing of lysine residues, N-terminal pyroglutamic acid formation, and glycosylation of antibodies. Methods for measuring charge variants are known in the art, for example, image capillary electrofocusing (iCIEF). In certain embodiments of any of the methods described herein, the amount of charge variants in a composition recovered from one or more purification step(s) (e.g., a chromatographic fraction) is reduced by greater than any of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99%, including any range between these values. In certain embodiments, the amount of charge variants in a composition recovered from one or more purification step(s) (e.g., a chromatographic fraction) is reduced to any of about 10% to about 95%, about 10% to about 99%, about 20% to about 95%, about 20% to about 99%, about 30% to about 95%, about 30% to about 99%, about 40% to about 95%, about 40% to about 99%, about 50% to about 95%, about 50% to about 99%, about 60% to about 95%, about 60% to about 99%, about 70% to about 95%, about 70% to about 99%, about 80% to about 95%, about 80% to about 99%, about 90% to about 95%, or about 90% to about 99%. In some embodiments, the amount of charge variants in a composition (such as a chromatographic fraction) is reduced by any of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 95%.In certain embodiments, the reduction in the presence or level of a charge variant is measured by comparing the amount of the charge variant in a composition recovered from a purification step(s) (such as a chromatographic fraction) to the amount of the charge variant in the composition before the purification step(s).
[0178] In certain embodiments of any of the methods described herein, the impurities are process-specific impurities. For example, the process-specific impurities may include one or more of leached protein A, host cell material, nucleic acid, other polypeptides, endotoxins, viral contaminants, cell culture medium components, carboxypeptidase B, gentamicin, etc. In certain embodiments, the process-specific impurities may be host cell proteins (HCPs) from, for example, prokaryotic cells, bacterial cells (such as E. coli cells), insect cells, eukaryotic cells, fungal cells, yeast cells, avian cells, or mammalian cells, for example, CHO cells.
[0179] In certain embodiments, the methods provided herein remove and reduce the level of leached protein A from a composition comprising a multispecific antibody (e.g., a bispecific antibody) and leached protein A. Leached protein A is protein A that has been separated or washed from the solid phase to which it is bound. For example, leached protein A can be leached from a protein A chromatography column. The amount of protein A can be measured, for example, by ELISA, as described in WO2011 / 150110. In certain embodiments, the reduction in the presence or level of leached protein A is measured by comparing the amount of leached protein A in a composition recovered from a purification step(s) (such as a chromatography fraction) to the amount of leached protein A in the composition before the purification step(s).
[0180] In certain embodiments, the methods provided herein remove and reduce the levels of host cell proteins (HCPs) from a composition comprising a multispecific antibody (e.g., a bispecific antibody) and an HCP. The HCP is a protein from a host cell in which the multispecific antibody (such as a bispecific antibody) was produced. In certain embodiments, the HCP protein is a protein from a prokaryotic cell. In certain embodiments, the HCP is a protein from an E. coli cell (i.e., E. coli protein or ECP). Examples of prokaryotic HCPs (such as ECPs) include, but are not limited to, prokaryotic chaperones such as FkpA, DsbA, and DsbC. In certain embodiments, the HCP is a protein from a eukaryotic host cell, such as those described elsewhere herein. In certain embodiments, the HCP is a protein from a mammalian cell, such as a CHO cell protein (i.e., Chinese Hamster Ovary Protein or CHOP). In certain embodiments, the amount of HCP (e.g., ECP, FkpA, DsbA, or DsbC, or, e.g., CHOP) is measured by enzyme-linked immunosorbent assay ("ELISA"). For example, antibodies can be raised against ultra-pure compositions of FkpA, DsbA, or DsbC. In certain embodiments, the amount of FkpA, DsbA, and / or DsbC is measured by mass spectrometry. In some embodiments of any of the methods described herein, the amount of HCP (e.g., ECP, FkpA, DsbA, or DsbC, or, e.g., CHOP). In certain embodiments of any of the methods described herein, the amount of HCP (e.g., ECP, FkpA, DsbA, or DsbC, or, e.g., CHOP) in a composition (such as a chromatographic fraction) recovered from one or more purification step(s) is reduced to less than about 100 ppm, about 75 ppm, about 50 ppm, about 25 ppm, about 20 ppm, about 10 ppm, about 5 ppm, about 2 ppm, or about 1 ppm, including any range between these values.In some embodiments, the HCP (e.g., ECP, FkpA, DsbA, or DsbC, or, e.g., CHOP) in the composition (such as a chromatographic fraction) is reduced to less than about 100 ppm, less than about 75 ppm, less than about 50 ppm, less than about 25 ppm, less than about 20 ppm, less than about 10 ppm, less than about 5 ppm, less than about 2 ppm, or less than about 1 ppm, including any ranges between these values. In certain embodiments, the reduction in the presence or level of the HCP (e.g., ECP, FkpA, DsbA, or DsbC, or, e.g., CHOP) is measured by comparing the amount of the HCP in the composition (such as a chromatographic fraction) recovered from the purification step(s) to the amount of the HCP in the composition prior to the purification step(s).
[0181] In certain embodiments, the methods provided herein remove or reduce levels of nucleic acid (such as host cell DNA and / or RNA) from multispecific antibodies (e.g., bispecific antibodies) and compositions incorporating the nucleic acid. Methods for measuring nucleic acid (such as host cell DNA and / or RNA) are known in the art and are described, for example, in WO2011 / 150110. Such methods include, for example, PCR of host cell DNA or RNA. In certain embodiments of any of the methods described herein, the amount of nucleic acid in a composition recovered from one or more purification step(s) (such as a chromatographic fraction) is reduced by more than any of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99%, including any range between these values. In certain embodiments, the amount of nucleic acid in a composition recovered from one or more purification step(s) (e.g., a chromatographic fraction) is reduced to any of about 10% to about 95%, about 10% to about 99%, about 20% to about 95%, about 20% to about 99%, about 30% to about 95%, about 30% to about 99%, about 40% to about 95%, about 40% to about 99%, about 50% to about 95%, about 50% to about 99%, about 60% to about 95%, about 60% to about 99%, about 70% to about 95%, about 70% to about 99%, about 80% to about 95%, about 80% to about 99%, about 90% to about 95%, or about 90% to about 99%. In some embodiments, the amount of nucleic acid in the composition (such as a chromatographic fraction) is reduced by any of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 95%. In certain embodiments, the reduction in the presence or level of nucleic acid is measured by comparing the amount of nucleic acid in the composition (such as a chromatographic fraction) recovered from the purification step(s) to the amount of nucleic acid in the composition prior to the purification step(s).
[0182] In certain embodiments, the methods provided herein remove or reduce the level of a cell culture medium component from a composition comprising a multispecific antibody (e.g., a bispecific antibody) and a cell culture medium component. "Cell culture medium component" refers to a component present in the cell culture medium. In certain embodiments, "cell culture medium" refers to the cell culture medium at the time the host cell(s) expressing the multispecific antibody (e.g., a bispecific antibody) or an arm thereof is harvested. In certain embodiments, the cell culture medium component is insulin, or tetracycline. In certain embodiments, the amount of insulin, or tetracycline is measured by ELISA. In certain embodiments of any of the methods described herein, the amount of cell culture media components in a composition recovered from one or more purification step(s) (such as a chromatographic fraction) is reduced by greater than any of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99%, including any ranges between these values.
[0183] In certain embodiments, the amount of cell culture media constituents in a composition recovered from one or more purification step(s) (e.g., chromatographic fractions) is reduced to any of about 10% to about 95%, about 10% to about 99%, about 20% to about 95%, about 20% to about 99%, about 30% to about 95%, about 30% to about 99%, about 40% to about 95%, about 40% to about 99%, about 50% to about 95%, about 50% to about 99%, about 60% to about 95%, about 60% to about 99%, about 70% to about 95%, about 70% to about 99%, about 80% to about 95%, about 80% to about 99%, about 90% to about 95%, or about 90% to about 99%. In some embodiments, the amount of the cell culture medium component in the composition (such as a chromatographic fraction) is reduced by any of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 95%. In certain embodiments, the reduction in the presence or level of the cell culture medium component is measured by comparing the amount of the cell culture medium component in the composition recovered from the purification step(s) (such as a chromatographic fraction) to the amount of the cell culture medium component in the composition prior to the purification step(s).
[0184] In certain embodiments, provided herein is a method for purifying a bispecific antibody comprising a first arm and a second arm, wherein the first and second arms are generated separately, the method comprising: subjecting the first and second arms to capture chromatography (such as any one or combination of the capture chromatography steps described elsewhere herein) operated in bind-and-elute mode to generate first and second capture eluates; forming a mixture comprising the first and second capture eluates under conditions sufficient to generate a composition comprising the multispecific antibody; subjecting the composition comprising the multispecific antibody to anion exchange chromatography (e.g., Q Sepharose® Fast Flow (QSFF) column in bind-and-elute mode) to generate a first and second capture eluate; ) chromatography) to produce an anion exchange eluate with gradient elution; subjecting the anion exchange eluate to anion exchange mixed mode chromatography (e.g., Capto™ Adhere chromatography) in a bind and elute mode to produce a first mixed mode eluate with gradient elution; and subjecting the first mixed mode eluate to cation exchange mixed mode chromatography (e.g., Capto™ MMC chromatography) in a bind and elute mode to produce a second mixed mode eluate with gradient elution, and collecting fractions comprising the bispecific antibody, wherein the method reduces the amount of impurities in the fractions relative to the mixture comprising the first and second arms.
[0185] In certain embodiments, provided herein is a method of purifying a bispecific antibody comprising a first arm and a second arm, wherein the first and second arms are produced separately, the method comprising: subjecting the first and second arms to capture chromatography (such as any one or combination of the capture chromatography steps described elsewhere herein) in a bind and elute mode to produce a first and a second capture eluate; forming a mixture comprising the first and the second capture eluate under conditions sufficient to produce a composition comprising the multispecific antibody; subjecting the composition comprising the multispecific antibody to cation exchange mixed mode chromatography (e.g., Capto™ MMC chromatography) in a bind and elute mode to produce a first mixed mode eluate, wherein the elution is a pH and salt step elution, and the method further comprises subjecting the first mixed mode eluate to anion exchange mixed mode chromatography (e.g., Capto™ Adhere chromatography) in a flow-through mode to produce a second mixed mode eluate; and collecting fractions comprising the bispecific antibody, wherein the method reduces the amount of impurities in the fractions relative to the mixture comprising the first and the second arms.
[0186] In certain embodiments, provided herein is a method of purifying a bispecific antibody comprising a first arm and a second arm, wherein the first and second arms are generated separately, the method comprising: subjecting the first and second arms to capture chromatography in bind and elute mode (such as any one or combination of the capture chromatography steps described elsewhere herein) to generate first and second capture eluates; forming a mixture comprising the first and second capture eluates under conditions sufficient to generate a composition comprising the multispecific antibody; subjecting the composition comprising the multispecific antibody to anion exchange mixed mode chromatography in bind and elute mode, where elution is step elution (e.g., and subjecting the first mixed mode eluate to cation exchange mixed mode chromatography (e.g., Capto™ Adhere chromatography) in a bind and elute mode to generate a second mixed mode eluate, wherein the elution is a step elution, and subjecting the second mixed mode eluate to hydrophobic interaction chromatography (e.g., Hexyl-650C chromatography) in a flow-through mode to generate a hydrophobic interaction eluate; and collecting fractions comprising the bispecific antibody, wherein the method reduces the amount of impurities in the fractions relative to the mixture comprising the first and second arms.
[0187] In certain embodiments, provided herein is a method of purifying a bispecific antibody (such as a bispecific F(ab')2) comprising a first arm and a second arm, wherein the first and second arms are generated separately, the method comprising: subjecting the first arm to capture chromatography operated in bind and elute mode (such as any one or combination of the capture chromatography steps described elsewhere herein) to generate a first capture eluate; subjecting the first capture eluate to cation exchange mixed mode chromatography (e.g., Capto™ MMC chromatography) in bind and elute mode to generate a first mixed mode eluate; subjecting the second arm to capture chromatography operated in bind and elute mode (such as any one or combination of the capture chromatography steps described elsewhere herein) to generate a second capture eluate. forming a mixture comprising a first mixed mode eluate and a second capture eluate under conditions sufficient to produce a composition comprising the multispecific antibody; subjecting the composition comprising the multispecific antibody to anion exchange mixed mode chromatography (e.g., Capto™ Adhere chromatography, etc.) to produce a second mixed mode eluate; and subjecting the second mixed mode eluate to cation exchange chromatography (e.g., POROS® 50 HS chromatography) in a bind and elute mode to produce a cation exchange eluate; subjecting the cation exchange eluate to sequential cation exchange mixed mode chromatography in a bind and elute mode to produce a third mixed mode eluate; and collecting fractions comprising the bispecific antibody, wherein the method reduces the amount of impurities in the fractions relative to the mixture comprising the first and second arms.
[0188] In certain embodiments, provided herein are methods of purifying a bispecific antibody (such as a bispecific F(ab')2) comprising a first arm and a second arm, wherein the first and second arms are generated separately, the method comprising: subjecting the first arm to capture chromatography (such as any one or combination of the capture chromatography steps described elsewhere herein) in bind and elute mode to generate a first capture eluate; subjecting the first capture eluate to cation exchange mixed mode chromatography (e.g., Capto™ MMC chromatography) in bind and elute mode to generate a first mixed mode eluate; subjecting the second arm to capture chromatography operated in bind and elute mode (such as any one or combination of the capture chromatography steps described elsewhere herein) to generate a first mixed mode eluate. forming a mixture comprising the first mixed mode eluate and the second capture eluate under conditions sufficient to produce a composition comprising the multispecific antibody; subjecting the composition comprising the multispecific antibody to anion exchange mixed mode chromatography (e.g., Capto™ Adhere chromatography) to produce a second mixed mode eluate; and subjecting the second mixed mode eluate to cation exchange chromatography (e.g., Capto™ MMC chromatography) in a bind and elute mode to produce a third mixed mode eluate; and collecting fractions comprising the bispecific antibody, wherein the method reduces the amount of impurities in the fractions relative to the mixture comprising the first and second arms.
[0189] In some embodiments, multispecific antibodies (such as bispecific antibodies) are further purified by viral filtration. Viral filtration is the removal of viral contaminants in a polypeptide purification feedstream. Examples of viral filtration include, for example, ultrafiltration and microfiltration. In some embodiments, the polypeptides are purified using a parvovirus filter.
[0190] In some embodiments, the multispecific antibody is concentrated after chromatography (e.g., after the second mixed-mode chromatography, or after one or more of the chromatographic steps performed after the second mixed-mode chromatography). Examples of concentration methods are known in the art and include, but are not limited to, for example, ultrafiltration and diafiltration (UFDF). In some embodiments, the multispecific antibody is concentrated by a first microfiltration, a diafiltration, and a second ultrafiltration. In some embodiments, the ultrafiltration and / or diafiltration uses a filter having a cutoff of less than about 5 kDal, about 10 kDal, about 15 kDal, about 20 kDal, or any of about 25 kDal or about 30 kDal. In some embodiments, the retentate of the first ultrafiltration is diafiltered into a pharmaceutical formulation.
[0191] In some embodiments, the concentration of the multispecific antibody after concentration is any of about 10 mg / mL, about 20 mg / mL, about 30 mg / mL, about 40 mg / mL, about 50 mg / mL, about 60 mg / mL, about 70 mg / mL, about 80 mg / mL, about 90 mg / mL, about 100 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, or about 300 mg / mL. In some embodiments, the concentration of the multispecific antibody is from about 10 mg / mL to about 20 mg / mL, from about 20 mg / mL to about 30 mg / mL, from about 30 mg / mL to about 40 mg / mL, from about 40 mg / mL to about 50 mg / mL, from about 50 mg / mL to about 60 mg / mL, from about 60 mg / mL to about 70 mg / mL, from about 70 mg / mL to about 80 mg / mL, from about 80 mg / mL to about 90 mg / mL, from about 90 mg / mL to about 100 mg / mL, from about 100 mg / mL to about 110 mg / mL, or from about 110 mg / mL to about 150 mg / mL. The concentration is any one of 0 mg / mL to about 120 mg / mL, about 120 mg / mL to about 130 mg / mL, about 130 mg / mL to about 140 mg / mL, about 140 mg / mL to about 150 mg / mL, about 150 mg / mL to about 160 mg / mL, about 160 mg / mL to about 170 mg / mL, about 170 mg / mL to about 180 mg / mL, about 180 mg / mL to about 190 mg / mL, about 190 mg / mL to about 200 mg / mL, about 200 mg / mL, or about 300 mg / mL.
[0192] In some embodiments of any of the methods described herein, the method further comprises combining the purified polypeptides of the purification method with a pharma- ceutically acceptable carrier, hi some embodiments, the multispecific antibodies are formulated into a pharmaceutical formulation by ultrafiltration / diafiltration.
[0193] In certain embodiments, the methods provided herein provide compositions comprising multispecific antibodies that are greater than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% pure. In certain embodiments, the multispecific antibodies in the compositions are greater than about 96%, 97%, 98%, or 99% pure.
[0194] In certain embodiments, the methods provided herein produce compositions comprising multispecific antibodies that contain no more than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, or about 10% of non-paired antibody arms. In certain embodiments, the methods provided herein produce compositions comprising multispecific antibodies that contain no more than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, or about 10% homodimers. In certain embodiments, the methods provided herein produce compositions comprising multispecific antibodies that contain no more than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, or about 5% aggregated protein. In certain embodiments, the methods provided herein produce compositions comprising multispecific antibodies that contain no more than about 0.1%, about 0.5%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% HMWS. In certain embodiments, the methods provided herein produce compositions comprising multispecific antibodies that comprise an LMWS of no more than about any of about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, or about 10%.In certain embodiments, the methods provided herein generate compositions comprising multispecific antibodies that contain no more than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% acidic variant. In certain embodiments, the methods provided herein produce compositions comprising multispecific antibodies that contain no more than about 0.1%, about 0.5%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% basic variants. In certain embodiments, the methods provided herein produce compositions comprising multispecific antibodies that contain no more than about any of about 0.1 ppm, about 0.2 ppm, about 0.3 ppm, about 0.4 ppm, about 0.5 ppm, about 0.6 ppm, about 0.7 ppm, about 0.8 ppm, about 0.9 ppm, about 1 ppm, about 1.5 ppm, about 2 ppm, about 2.5 ppm, about 3 ppm, about 3.5 ppm, about 4 ppm, about 4.5 ppm, about 5 ppm, about 5.5 ppm, about 6 ppm, about 6.5 ppm, about 7 ppm, about 7.5 ppm, about 8 ppm, about 8.5 ppm, about 9 ppm, about 9.5 ppm, or about 10 ppm of leached Protein A. In certain embodiments, the methods provided herein produce compositions comprising multispecific antibodies that contain no more than about 0.1 ppm, about 0.2 ppm, about 0.3 ppm, about 0.4 ppm, about 0.5 ppm, about 0.6 ppm, about 0.7 ppm, about 0.8 ppm, about 0.9 ppm, about 1 ppm, about 1.5 ppm, about 2 ppm, about 2.5 ppm, about 3 ppm, about 3.5 ppm, about 4 ppm, about 4.5 ppm, about 5 ppm, about 5.5 ppm, about 6 ppm, about 6.5 ppm, about 7 ppm, about 7.5 ppm, about 8 ppm, about 8.5 ppm, about 9 ppm, about 9.5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, or about 35 ppm of HCPs.In certain embodiments, the methods provided herein produce compositions comprising multispecific antibodies that contain no more than about 2 ppm, about 2.5 ppm, about 3 ppm, about 3.5 ppm, about 4 ppm, about 4.5 ppm, about 5 ppm, about 5.5 ppm, about 6 ppm, about 6.5 ppm, about 7 ppm, about 7.5 ppm, about 8 ppm, about 8.5 ppm, about 9 ppm, about 9.5 ppm, or about 10 ppm of nucleic acid. In certain embodiments, the compositions comprising multispecific antibodies contain no more than 0 ppm of nucleic acid. In certain embodiments, the nucleic acid in the compositions comprising multispecific antibodies is below the level of detection. In certain embodiments, the methods provided herein produce compositions comprising multispecific antibodies that contain no more than about 0.1%, about 0.5%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of cell culture medium components.
[0195] In certain embodiments, a composition is provided comprising a multispecific antibody purified according to any one of the methods described herein.
[0196] In certain embodiments, the multispecific antibodies in the composition are greater than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% pure. In certain embodiments, the multispecific antibodies in the composition are greater than about 96%, 97%, 98%, or 99% pure.
[0197] In certain embodiments, a composition comprising a multispecific antibody comprises no more than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, or about 10% of non-paired antibody arms. In certain embodiments, a composition comprising a multispecific antibody comprises no more than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, or about 10% homodimers. In certain embodiments, a composition comprising a multispecific antibody comprises no more than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, or about 5% aggregated protein. In certain embodiments, a composition comprising a multispecific antibody comprises no more than about 0.1%, about 0.5%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% HMWS. In certain embodiments, a composition comprising a multispecific antibody comprises an LMWS of no more than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, or about 10%.In certain embodiments, a composition comprising a multispecific antibody comprises no more than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% acidic variant. In certain embodiments, a composition comprising a multispecific antibody comprises no more than about 0.1%, about 0.5%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% basic variant. In certain embodiments, a composition comprising a multispecific antibody comprises no more than about 0.1 ppm, about 0.2 ppm, about 0.3 ppm, about 0.4 ppm, about 0.5 ppm, about 0.6 ppm, about 0.7 ppm, about 0.8 ppm, about 0.9 ppm, about 1 ppm, about 1.5 ppm, about 2 ppm, about 2.5 ppm, about 3 ppm, about 3.5 ppm, about 4 ppm, about 4.5 ppm, about 5 ppm, about 5.5 ppm, about 6 ppm, about 6.5 ppm, about 7 ppm, about 7.5 ppm, about 8 ppm, about 8.5 ppm, about 9 ppm, about 9.5 ppm, or about 10 ppm of leached Protein A. In certain embodiments, a composition comprising a multispecific antibody comprises no more than about 0.1 ppm, about 0.2 ppm, about 0.3 ppm, about 0.4 ppm, about 0.5 ppm, about 0.6 ppm, about 0.7 ppm, about 0.8 ppm, about 0.9 ppm, about 1 ppm, about 1.5 ppm, about 2 ppm, about 2.5 ppm, about 3 ppm, about 3.5 ppm, about 4 ppm, about 4.5 ppm, about 5 ppm, about 5.5 ppm, about 6 ppm, about 6.5 ppm, about 7 ppm, about 7.5 ppm, about 8 ppm, about 8.5 ppm, about 9 ppm, about 9.5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, or about 35 ppm of HCP.In certain embodiments, a composition comprising a multispecific antibody comprises no more than about 0.1 ppm, about 0.2 ppm, about 0.3 ppm, about 0.4 ppm, about 0.5 ppm, about 0.6 ppm, about 0.7 ppm, about 0.8 ppm, about 0.9 ppm, about 1 ppm, about 1.5 ppm, about 2 ppm, about 2.5 ppm, about 3 ppm, about 3.5 ppm, about 4 ppm, about 4.5 ppm, about 5 ppm, about 5.5 ppm, about 6 ppm, about 6.5 ppm, about 7 ppm, about 7.5 ppm, about 8 ppm, about 8.5 ppm, about 9 ppm, about 9.5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, or about 35 ppm of nucleic acid. In certain embodiments, a composition comprising a multispecific antibody comprises no more than about 0.1%, about 0.5%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of any of the following cell culture medium components.
[0198] In some embodiments, compositions comprising multispecific antibodies are provided, the compositions comprising: a) at least about 95% to about 100% multispecific antibodies; b) less than about 1% to about 5% unpaired antibody arms; c) less than about 1% to about 5% antibody homodimers; d) less than about 1% or about 2% HMWS; e) less than about 1% or about 2% LMWS; and / or f) less than about 5% 3 / 4 antibodies.
[0199] In certain embodiments, a composition is provided that comprises a bispecific antibody purified according to any one of the methods described herein.In certain embodiments, the bispecific antibody is a Knob-in-Hole (KiH) antibody, such as a KiH bispecific antibody.In some embodiments, the bispecific antibody is a CrossMab bispecific antibody.
[0200] In certain embodiments, compositions are provided that include a bispecific antibody that is greater than about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% pure. In certain embodiments, the bispecific antibody in the composition is greater than about 96%, about 97%, about 98%, or about 99% pure. In certain embodiments, the bispecific antibody is a Knob-in-Hole (KiH) antibody, e.g., a KiH bispecific antibody. In some embodiments, the bispecific antibody is a CrossMab bispecific antibody.
[0201] In certain embodiments, compositions are provided that comprise bispecific antibodies that contain no more than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, or about 10% of unpaired antibody arms. In certain embodiments, compositions are provided that comprise a bispecific antibody that comprises no more than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, or about 10% homodimers. In certain embodiments, compositions are provided that include a bispecific antibody that contains no more than about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% aggregated protein. In certain embodiments, compositions are provided that include a bispecific antibody that contains no more than about 0.1%, 0.5%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, or 35% HMWS. In certain embodiments, compositions are provided that comprise a bispecific antibody that comprises an LMWS of no more than about any of about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, or about 10%.In certain embodiments, compositions are provided that comprise a bispecific antibody that comprises no more than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% acidic variant. In certain embodiments, compositions are provided that comprise a bispecific antibody that comprises no more than about 0.1%, about 0.5%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% basic variant. In certain embodiments, compositions are provided that comprise a bispecific antibody comprising no more than about 0.1 ppm, about 0.2 ppm, about 0.3 ppm, about 0.4 ppm, about 0.5 ppm, about 0.6 ppm, about 0.7 ppm, about 0.8 ppm, about 0.9 ppm, about 1 ppm, about 1.5 ppm, about 2 ppm, about 2.5 ppm, about 3 ppm, about 3.5 ppm, about 4 ppm, about 4.5 ppm, about 5 ppm, about 5.5 ppm, about 6 ppm, about 6.5 ppm, about 7 ppm, about 7.5 ppm, about 8 ppm, about 8.5 ppm, about 9 ppm, about 9.5 ppm, or about 10 ppm of leached Protein A. In certain embodiments, compositions are provided that comprise a bispecific antibody that comprises no more than about 0.1 ppm, about 0.2 ppm, about 0.3 ppm, about 0.4 ppm, about 0.5 ppm, about 0.6 ppm, about 0.7 ppm, about 0.8 ppm, about 0.9 ppm, about 1 ppm, about 1.5 ppm, about 2 ppm, about 2.5 ppm, about 3 ppm, about 3.5 ppm, about 4 ppm, about 4.5 ppm, about 5 ppm, about 5.5 ppm, about 6 ppm, about 6.5 ppm, about 7 ppm, about 7.5 ppm, about 8 ppm, about 8.5 ppm, about 9 ppm, about 9.5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, or about 35 ppm of HCP.In certain embodiments, compositions are provided that include bispecific antibodies that contain no more than about 2 ppm, about 2.5 ppm, about 3 ppm, about 3.5 ppm, about 4 ppm, about 4.5 ppm, about 5 ppm, about 5.5 ppm, about 6 ppm, about 6.5 ppm, about 7 ppm, about 7.5 ppm, about 8 ppm, about 8.5 ppm, about 9 ppm, about 9.5 ppm, or about 10 ppm of nucleic acid. In certain embodiments, compositions that include bispecific antibodies contain no more than 0 ppm of nucleic acid. In certain embodiments, the nucleic acid in a composition that includes a bispecific antibody is below the level of detection. In certain embodiments, compositions are provided that include bispecific antibodies that contain no more than about 0.1%, about 0.5%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of cell culture medium components. In certain embodiments, the bispecific antibody is a Knob-in-Hole (KiH) antibody, e.g., a KiH bispecific antibody. In some embodiments, the bispecific antibody is a CrossMab bispecific antibody.
[0202] In some embodiments, a composition is provided comprising a bispecific antibody, the composition comprising: a) at least about 95% to about 100% bispecific antibody; b) less than about 1% to about 5% unpaired antibody arms; c) less than about 1% to about 5% antibody homodimers; d) less than about 1% or about 2% HMWS; e) less than about 1% or about 2% LMWS; and / or f) less than about 5% 3 / 4 antibody. In certain embodiments, the bispecific antibody is a Knobs-in-Hole (KiH) antibody, e.g., a KiH bispecific antibody. In some embodiments, the bispecific antibody is a CrossMab bispecific antibody.
[0203] One embodiment reported herein is a method for purifying an Fc region-containing heterodimeric protein / polypeptide in a multi-step chromatography method, the method comprising an affinity chromatography step followed by two different multimodal ion exchange chromatography steps, thereby purifying the Fc region-containing heterodimeric polypeptide.
[0204] In certain embodiments, the method comprises: i. an affinity chromatography step followed by a multimodal anion exchange chromatography step followed by a multimodal cation exchange chromatography step; or ii. an affinity chromatography step followed by a multimodal cation exchange chromatography step followed by a multimodal anion exchange chromatography step.
[0205] One aspect reported herein is a method for producing an Fc-region-containing heterodimeric protein / polypeptide, comprising: i. culturing cells comprising a nucleic acid encoding the Fc-region-containing heterodimeric protein / polypeptide; ii. recovering the Fc-region-containing heterodimeric protein / polypeptide from the cells or culture medium; and iii. purifying the Fc-region-containing heterodimeric protein / polypeptide by the method reported herein, thereby producing an Fc-region-containing heterodimeric protein. It has been found that the performance of an antibody purification process depends on the sequence of chromatographic steps used. By selecting a certain sequence / order of chromatographic steps, an improved process can be obtained.
[0206] The methods provided herein are based, at least in part, on the discovery that by performing a multimodal anion exchange chromatography step (directly) after the (first) affinity chromatography step and before the multimodal cation exchange chromatography step, the ultrafiltration / diafiltration step can be omitted, which is necessary if a multimodal cation exchange chromatography step is performed before a multimodal anion exchange chromatography step.
[0207] In certain embodiments, the multi-step chromatography method comprises an affinity chromatography step followed by a multimodal anion exchange chromatography step followed by a multimodal cation exchange chromatography step.
[0208] With the methods described herein, it has been found that good purity and yield can be achieved with only three chromatographic steps.
[0209] In certain embodiments, the multi-step chromatography method comprises exactly three chromatographic steps.
[0210] It has been found that the removal of host cell proteins can be improved when the multimodal anion exchange chromatography method / step is carried out in flow-through mode. In certain embodiments, the multimodal anion exchange chromatography method / step is carried out in flow-through mode.
[0211] It has been found that the pH of the load of the multimodal anion exchange chromatography step affects HCPs by product and DNA removal. In one preferred embodiment of all aspects, the multimodal anion exchange chromatography step is performed at a pH of about 7.0. Table 1 JPEG2024156655000002.jpg67170
[0212] The conductivity of the solution can have an impact on different parameters during the purification process. Here, it has been found that low conductivity values in the load of the multimodal anion exchange chromatography step (i.e., the solution containing the Fc region-containing heterodimeric polypeptide applied to the chromatographic material) result in improved HCP and DNA removal. Table 2 JPEG2024156655000003.jpg35170
[0213] In certain embodiments, in the step of multimodal anion exchange chromatography, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity value of less than 7 mS / cm. In certain embodiments, in the step of multimodal anion exchange chromatography, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity value of less than 6 mS / cm. In certain embodiments, in the step of multimodal anion exchange chromatography, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity value in the range of about 6 mS / cm to about 2 mS / cm. In certain embodiments, in the step of multimodal anion exchange chromatography, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity value in the range of about 5 mS / cm to about 4 mS / cm. In certain embodiments, in the step of multimodal anion exchange chromatography, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity value of about 4.5 mS / cm.
[0214] In certain embodiments, in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity of about 4.5 mS / cm and a pH of about 7.
[0215] The methods provided herein are based, at least in part, on the discovery that the protein load of the multimodal anion exchange chromatography step also impacts the performance of the purification process: when the load is in a defined range, the overall purification process is improved, e.g., the removal of DNA contamination. Table 3: Starting amount of DNA: 80 pg / mg JPEG2024156655000004.jpg35170
[0216] In certain embodiments, in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in the range of about 100 g to about 300 g per liter of chromatography material, i.e., the load is in the range of about 100 g / L to about 300 g / L. In certain embodiments, in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in the range of about 120 g to about 240 g per liter of chromatography material. In certain embodiments, in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in the range of about 160 g to about 200 g per liter of chromatography material.
[0217] Certain multimodal resin materials have been found to be particularly useful when applied in the methods reported herein.
[0218] In certain embodiments, the multimodal anion exchange chromatography material is a multimodal strong anion exchange chromatography material. In certain embodiments, the multimodal anion exchange chromatography material has a matrix of high flux agarose, multimodal strong anion exchange as the ligand, an average particle size of 36-44 μm, and an ionic capacity of 0.08-0.11 mmol Cl- / mL medium. In certain embodiments, the multimodal anion exchange chromatography material is "Capto adhere ImpRes".
[0219] In certain embodiments, the multimodal cation exchange chromatography medium is a multimodal weak cation exchange chromatography medium. In certain embodiments, the multimodal cation exchange chromatography medium has a high flux agarose matrix, a multimodal weak cation exchange as the ligand, an average particle size of 36-44 μm, and an ionic capacity of 25-39 μmol / mL. In certain embodiments, the multimodal cation exchange chromatography medium is "Capto MMC ImpRes".
[0220] In certain embodiments, the multimodal cation exchange chromatography method / step is performed in bind and elute mode.
[0221] In certain embodiments, the affinity chromatography step is a Protein A chromatography step, or a Protein G affinity chromatography step, or a single chain Fv ligand affinity chromatography step, or a chromatography step using KappaSelect chromatography material, or a chromatography step using CaptureSelect chromatography material, or a chromatography step using CaptureSelect FcXL chromatography material. In certain embodiments, the affinity chromatography step is a Protein A chromatography step. In certain embodiments, the affinity chromatography step is a CaptureSelect™ chromatography step. In certain embodiments, the affinity chromatography step is a Protein A chromatography step.
[0222] In certain embodiments, the Fc region-containing heterodimeric protein / polypeptide is an antibody, a bispecific antibody, or an Fc-fusion protein. In certain embodiments, the Fc region-containing heterodimeric protein / polypeptide is a bispecific antibody. In certain embodiments, the Fc region-containing heterodimeric protein / polypeptide is a CrossMab. In certain embodiments, the Fc region-containing heterodimeric protein / polypeptide is an Fc-fusion protein. In certain embodiments, the Fc region-containing heterodimeric protein / polypeptide is an Fc region-containing heterodimeric protein comprising a) a heavy chain and a light chain of a first full-length antibody that specifically binds a first antigen, and b) a modified heavy chain and a modified light chain of a full-length antibody that specifically binds a second antigen, wherein the constant domains CL and CH1 are replaced by each other.
[0223] In certain embodiments, the bispecific antibody is a bispecific antibody that binds ANG2 and VEGF. In certain embodiments, the Fc region-containing heterodimeric protein / polypeptide is a CrossMab that binds ANG2 and VEGF. In certain embodiments, the bispecific antibody is vanucizumab.
[0224] In certain embodiments, the bispecific antibody comprises a first antigen-binding site comprising SEQ ID NO: 1 as the heavy chain variable domain (VH) and SEQ ID NO: 2 as the light chain variable domain (VL), and a second antigen-binding site comprising SEQ ID NO: 3 as the heavy chain variable domain (VH) and SEQ ID NO: 4 as the light chain variable domain (VL). In certain embodiments, the bispecific antibody comprises a first heavy chain having the amino acid sequence of SEQ ID NO: 9, and a second heavy chain having the amino acid sequence of SEQ ID NO: 10, and a first light chain having the amino acid sequence of SEQ ID NO: 11, and a second light chain having the amino acid sequence of SEQ ID NO: 12. In certain embodiments, the bispecific antibody comprises a first antigen-binding site comprising SEQ ID NO: 5 as the heavy chain variable domain (VH) and SEQ ID NO: 6 as the light chain variable domain (VL), and a second antigen-binding site comprising SEQ ID NO: 7 as the heavy chain variable domain (VH) and SEQ ID NO: 8 as the light chain variable domain (VL). In certain embodiments, the bispecific antibody comprises a first heavy chain having the amino acid sequence of SEQ ID NO: 13, and a second heavy chain having the amino acid sequence of SEQ ID NO: 14, and a first light chain having the amino acid sequence of SEQ ID NO: 15, and a second light chain having the amino acid sequence of SEQ ID NO: 16. The amino acid sequences of SEQ ID NOs: 1-16 are provided in Table 4 below. Table 4 TIFF2024156655000005.tif255170TIFF2024156655000006.tif255170TIFF2024156655000007.tif23170
[0225] In certain embodiments, the purified Fc region-containing heterodimeric polypeptide comprises about 5% or less of 3 / 4 antibodies. In certain embodiments, the purified Fc region-containing heterodimeric polypeptide comprises about 4% or less of 3 / 4 antibodies. In certain embodiments, the purified Fc region-containing heterodimeric polypeptide comprises about 3% or less of 3 / 4 antibodies. In certain embodiments, the purified Fc region-containing heterodimeric polypeptide comprises about 2% or less of 3 / 4 antibodies. In certain embodiments, the purified Fc region-containing heterodimeric polypeptide comprises about 1% or less of 3 / 4 antibodies.
[0226] One aspect reported herein is a method for purifying a bispecific antibody that binds ANG2 and VEGF by a multi-step chromatography method, the method comprising a step of affinity chromatography followed by a step of multimodal anion exchange chromatography followed by a step of multimodal cation exchange chromatography, thereby purifying a bispecific antibody that binds ANG2 and VEGF, the bispecific antibody that binds ANG2 and VEGF comprising a first antigen-binding site comprising SEQ ID NO: 1 as the heavy chain variable domain (VH) and SEQ ID NO: 2 as the light chain variable domain (VL), and a second antigen-binding site comprising SEQ ID NO: 3 as the heavy chain variable domain (VH) and SEQ ID NO: 4 as the light chain variable domain (VL), or comprising a first antigen-binding site comprising SEQ ID NO: 5 as the heavy chain variable domain (VH) and SEQ ID NO: 6 as the light chain variable domain (VL), and a second antigen-binding site comprising SEQ ID NO: 7 as the heavy chain variable domain (VH) and SEQ ID NO: 8 as the light chain variable domain (VL).
[0227] In one embodiment, a bispecific antibody that binds ANG2 and VEGF comprises a) a heavy chain and a light chain of a first full length antibody that comprises a first antigen-binding site, and b) a modified heavy chain and a modified light chain of a full length antibody that comprises a second antigen-binding site, wherein the constant domains CL and CH1 are replaced by each other.
[0228] One aspect reported herein is the use of the method reported herein for the purification of an Fc-containing heterodimeric polypeptide.
[0229] One aspect reported herein is the use of the methods reported herein for the reduction of Fc-containing heterodimeric polypeptide-related impurities.
[0230] One embodiment reported herein is an Fc-containing heterodimeric polypeptide obtained by the method reported herein for the manufacture of a medicament for the treatment of cancer or an eye disease.
[0231] One embodiment reported herein is an Fc-containing heterodimeric polypeptide obtained by the method reported herein for use in the treatment of cancer or eye disease.
[0232] Polypeptides Monoclonal antibodies In some embodiments, the antibody is a monoclonal antibody. Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies within the population are identical and / or bind to the same epitope, but exclude possible variants that arise during production of the monoclonal antibody, such variants being generally present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of individual or polyclonal antibodies.
[0233] For example, the monoclonal antibodies may be made by the hybridoma method first described by Kohler et al., Nature 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).
[0234] In the hybridoma method, a mouse or other suitable host animal is immunized as described herein to elicit lymphocytes that produce or can produce antibodies that specifically bind to the polypeptide used for immunization. Alternatively, lymphocytes can be immunized in vitro. The lymphocytes are then fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form hybridoma cells (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)).
[0235] The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyltransferase (HGPRT or HPRT), the culture medium for the hybridomas typically contains hypoxanthine, aminopterin, and thymidine (HAT medium), which substances inhibit the growth of HGPRT-deficient cells.
[0236] In some embodiments, the myeloma cells are those that fuse efficiently, support stable high-level antibody production by selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, in some embodiments, the myeloma cell line is a mouse myeloma line such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Maryland USA. Human myeloma and mouse-human heteromyeloma cell lines have also been described for the production of human monoclonal antibodies (Kozbor, J. Immunol. 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications pp.51-63 (Marcel Dekker, Inc., New York, 1987)).
[0237] The culture medium in which the hybridoma cells grow is assayed for production of monoclonal antibodies directed against the antigen. In some embodiments, the binding specificity of the monoclonal antibodies produced by the hybridoma cells is measured by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
[0238] The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al., Anal. Biochem. 107:220 (1980).
[0239] After hybridoma cells producing antibodies of the desired specificity, affinity, and / or activity are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, Monoclonal Antibodies: Principles and Practice pp.59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, hybridoma cells may be grown in vivo as ascites tumors in animals.
[0240] The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, polypeptide A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity or ion-exchange chromatography.
[0241] DNA encoding monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of specifically binding to genes encoding the heavy and light chains of mouse antibodies). In some embodiments, hybridoma cells serve as a source of such DNA. Once isolated, the DNA can be placed into an expression vector, which can then be transfected into host cells, such as E. coli cells, monkey COS cells, human embryonic kidney (HEK) 293 cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin polypeptides, to obtain the synthesis of monoclonal antibodies in recombinant host cells. Review articles on recombinant expression of antibody-encoding DNA in bacteria include Skerra et al., Curr. Opinion in Immunol. 5:256-262 (1993) and Pluckthun, Immunol. Revs., 130:151-188 (1992).
[0242] In further embodiments, antibodies or antibody fragments can be isolated from antibody phage libraries generated using the techniques described in McCafferty et al., Nature 348:552-554 (1990). Clackson et al., Nature 352:624-628 (1991) and Marks et al., J. Mol. Biol. 222:581-597 (1991) describe the isolation of mouse and human antibodies, respectively, using phage libraries. Subsequent publications describe chain shuffling as a strategy for constructing very large phage libraries (Marks et al., Bio / Technology 10:779-783 (1992)), and the production of high affinity (nM range) human antibodies by combinatorial infection and in vivo recombination (Waterhouse et al., Nuc. Acids. Res. 21:2265-2266 (1993)). Therefore, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolating monoclonal antibodies.
[0243] The DNA may also be modified, for example, by substituting the coding sequence with human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison et al., Proc. Natl Acad. Sci. USA 81:6851 (1984)), or by covalently joining all or part of the coding sequence for a non-immunoglobulin polypeptide to the immunoglobulin coding sequence.
[0244] Typically, such non-immunoglobulin polypeptides are substituted for the constant domains of an antibody, or they are substituted for the variable domains of one antigen-binding site of an antibody to create a chimeric bivalent antibody comprising one antigen-binding site having specificity for an antigen, and another antigen-binding site having specificity for a different antigen.
[0245] In some embodiments of any of the methods described herein, the antibody is IgA, IgD, IgE, IgG, or IgM. In some embodiments, the antibody is an IgG monoclonal antibody.
[0246] antibody fragment In some embodiments, the antibody is an antibody fragment. Various techniques have been developed to produce antibody fragments. Traditionally, these fragments were obtained by proteolytic digestion of intact antibodies (see, for example, Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992) and Brennan et al., Science 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. For example, antibody fragments can be isolated from the antibody phage libraries discussed above. Alternatively, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab')2 fragments (Carter et al., Bio / Technology 10:163-167 (1992)). According to another approach, F(ab')2 fragments can be directly isolated from recombinant host cell culture. Other techniques for producing antibody fragments will be apparent to those skilled in the art. In other embodiments, the antibody of choice is a single chain Fv fragment (scFv). See WO 93 / 16185, U.S. Pat. No. 5,571,894, and U.S. Pat. No. 5,587,458. The antibody fragment may also be a "linear antibody", e.g., as described in U.S. Pat. No. 5,641,870. Such linear antibody fragments may be monospecific or bispecific.
[0247] In some embodiments, fragments of the antibodies described herein are provided. In some embodiments, the antibody fragment is an antigen-binding fragment. In some embodiments, the antigen-binding fragment is selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a scFv, an Fv, and a diabody.
[0248] Polypeptide variants and modifications In certain embodiments, amino acid sequence variants of the proteins herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the protein. The amino acid sequence variants of the protein can be prepared by introducing appropriate modifications into the nucleotide sequence encoding the protein or by peptide synthesis. Such modifications include, for example, deletions from, and / or insertions into, and / or substitutions of residues within the amino acid sequence of the protein. Any combination of deletions, insertions, and substitutions can be made to arrive at the final construct, provided that the final construct has the desired properties.
[0249] By "polypeptide variant" is meant a polypeptide, e.g., an active polypeptide, as defined herein, having at least about 80% amino acid sequence identity with the full-length native sequence of the polypeptide, the polypeptide sequence lacking a signal peptide, or the extracellular domain of the polypeptide with or without a signal peptide. Such polypeptide variants include, for example, polypeptides in which one or more amino acid residues are added or deleted at the N-terminus or C-terminus of the full-length native amino acid sequence. Typically, a polypeptide variant has at least about 80% amino acid sequence identity, or at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% amino acid sequence identity, with the full-length native sequence polypeptide sequence, the polypeptide sequence lacking a signal peptide, or the extracellular domain of the polypeptide with or without a signal peptide. Optionally, the variant polypeptide has no more than one conservative amino acid substitution compared to the native polypeptide sequence, or has any of the following conservative amino acid substitutions compared to the native polypeptide sequence: about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10.
[0250] The variant polypeptides may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, compared to the full-length native polypeptide. Certain variant polypeptides may lack amino acid residues that are not essential for the desired biological activity. These variant polypeptides with truncations, deletions, and insertions may be prepared by any of several conventional techniques. The desired variant polypeptide may be chemically synthesized. Another suitable technique involves isolating and amplifying a nucleic acid fragment encoding the desired variant polypeptide by polymerase chain reaction (PCR). Oligonucleotides that define the desired termini of the nucleic acid fragment are used at the 5' and 3' primers in the PCR. Preferably, the variant polypeptides share at least one biological and / or immunological activity with the native polypeptides disclosed herein.
[0251] Amino acid sequence insertions include amino- and / or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing 100 or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue or an antibody fused to a cytotoxic polypeptide. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme or a polypeptide which increases the serum half-life of the antibody.
[0252] For example, it may be desirable to improve the binding affinity and / or other biological properties of the polypeptide. Amino acid sequence variants of the polypeptide are prepared by introducing appropriate nucleotide changes into the antibody nucleic acid or by peptide synthesis. Such modifications include, for example, deletions from, and / or insertions into, and / or substitutions of residues within the amino acid sequence of the polypeptide. Any combination of deletions, insertions, and substitutions can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics. Amino acid changes can also modify post-translational processing of the polypeptide (e.g., antibody), for example, to change the number or location of glycosylation sites.
[0253] Guidance in determining which amino acid residues can be inserted, substituted, or deleted without adversely affecting a desired activity can be found by comparing the sequence of a polypeptide to the sequences of known polypeptide molecules of the same type, and minimizing the number of amino acid sequence changes in the areas of high homology.
[0254] A method useful for identifying certain residues or regions of a polypeptide (e.g., an antibody) that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" described by Cunningham and Wells, Science 244:1081-1085 (1989). Here, a residue or group of target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced with neutral or negatively charged amino acids (most preferably alanine or polyalanine) to affect the interaction of the amino acid with the antigen. The amino acid locations that demonstrate functional sensitivity to the substitution are then refined by introducing further or other variants at or in place of the substitution site. Thus, while the site for introducing amino acid sequence variation is predetermined, the nature of the mutation itself need not be predetermined. For example, to analyze the performance of a mutation at a given site, ala scanning or random mutagenesis is performed at the target codon or region, and the expressed antibody variants are screened for the desired activity.
[0255] Another type of variant is amino acid substitution variant. These variants have at least one amino acid residue in the antibody molecule replaced with a different residue. The most interesting site for substitution mutagenesis includes hypervariable region, but FR modification is also contemplated. If such substitution leads to a change in biological activity, more substantial changes can be introduced, as indicated in Table 5 as "exemplary substitutions" or as further described below with reference to amino acid class, and the product can be screened. Table 5 JPEG2024156655000008.jpg168170
[0256] Substantial modification of the biological properties of a polypeptide can be achieved by selecting substitutions that differ greatly in their effectiveness in maintaining (a) the structure of the polypeptide backbone in the region of substitution, e.g., sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Amino acids can be grouped according to the similarity of the properties of their side chains (ALLehninger, Biochemistry second ed., pp. 73-75, Worth Publishers, New York (1975)).
[0257] (1) Non-polar: Ala(A), Val(V), Leu(L), Ile(I), Pro(P), Phe(F), Trp(W), Met(M)
[0258] (2) Uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q)
[0259] (3) Acidic: Asp(D), Glu(E)
[0260] (4) Basic: Lys(K), Arg(R), His(H)
[0261] Alternatively, the naturally occurring residues can be grouped on the basis of common side chain properties.
[0262] (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile
[0263] (2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln
[0264] (3) Acidic: Asp, Glu
[0265] (4) Basic: His, Lys, Arg
[0266] (5) Residues that affect chain orientation: Gly, Pro
[0267] (6) Aromatic: Trp, Tyr, Phe
[0268] Non-conservative substitutions will involve the exchange of a member of one of these classes for another class.
[0269] Any cysteine residue not involved in maintaining the proper conformation of the antibody may also generally be substituted with serine to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) can be added to a polypeptide to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).
[0270] One example of a substitutional variant involves the substitution of one or more hypervariable region residues of a parent antibody (e.g., a humanized antibody). Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they were generated. A convenient method for generating such substitutional variants involves affinity maturation using phage display. Briefly, several hypervariable region sites (e.g., 6-7 sites) are mutated to generate all possible amino substitutions at each site. The antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle. The phage-displayed variants are then screened for their biological activity (e.g., binding affinity) as disclosed herein. To identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues that contribute significantly to antigen binding. Alternatively, or in addition, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the antibody and the target. Such contact and adjacent residues are candidates for substitution according to the techniques detailed herein. Once such variants are generated, the panel of variants can be subjected to screening as described herein, and antibodies with superior properties in one or more relevant assays can be selected for further development.
[0271] Another type of amino acid variant of the polypeptide modifies the original glycosylation pattern of the antibody. The polypeptide may contain non-amino acid moieties. For example, the polypeptide may be glycosylated. Such glycosylation may occur naturally during expression of the polypeptide in a host cell or host organism, or may be a deliberate modification resulting from human intervention. Modification refers to the deletion of one or more carbohydrate moieties found in the polypeptide and / or the addition of one or more glycosylation sites that are not present in the polypeptide.
[0272] Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are recognition sequences for enzymatic attachment of a carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine can also be used.
[0273] Addition of glycosylation sites to the polypeptide is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-mentioned tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).
[0274] Removal of carbohydrate moieties present on a polypeptide can be accomplished chemically or enzymatically, or by mutational substitution of codons that code for amino acid residues that serve as targets for glycosylation. Enzymatic cleavage of carbohydrate moieties on a polypeptide can be accomplished by the use of a variety of endo- and exo-glycosidases.
[0275] Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of the hydroxyl groups of seryl or threonyl residues, methylation of the γ-amino groups of lysine, arginine, and histidine side chains, acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.
[0276] Chimeric Polypeptides The polypeptides described herein can be modified in a way to form chimeric molecules that include the polypeptide fused to another heterologous polypeptide or amino acid sequence. In some embodiments, the chimeric molecule comprises a fusion of the polypeptide with a tag polypeptide that provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally located at the amino- or carboxyl-terminus of the polypeptide. The presence of such an epitope-tagged form of the polypeptide can be detected using an antibody against the tag polypeptide. The provision of an epitope tag also allows the polypeptide to be easily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag.
[0277] multispecific antibodies In certain embodiments, the antibody provided herein is a multispecific antibody, e.g., a bispecific antibody. A multispecific antibody is a monoclonal antibody that has binding specificity for at least two different sites. In certain embodiments, one of the binding specificities is for c-met, and the other is for any other antigen. In certain embodiments, a bispecific antibody can bind to two different epitopes of c-met. Bispecific antibodies can also be used to localize cytotoxic drugs to cells that express c-met. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.
[0278] Techniques for making multispecific antibodies include, but are not limited to, recombinant coexpression of two immunoglobulin heavy-light chain pairs with different specificities (see Milstein and Cuello, Nature 305:537 (1983)), WO 93 / 08829, and Traunecker et al., EMBO J. 10:3655 (1991)), and "knobs-in-holes" engineering (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can also be produced by manipulating electrostatic steering effects to create antibody Fc-heterodimeric molecules (WO 2009 / 089004 A1), cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan et al., Science, 229:81 (1985)), using leucine zippers to produce bispecific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)), using "diabody" technology to create bispecific antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)), and using single-chain Fv (sFv) dimers (see, e.g., Gruber et al., J. Immunol., 1999, 20:111-112 (1999)). al., J. Immunol., 152:5368 (1994)), as well as by preparing trispecific antibodies (e.g., Tutt et al. J. Immunol. 147:60 (1991).
[0279] The antibodies or fragments herein also include the multispecific antibodies described in WO2009 / 080251, WO2009 / 080252, WO2009 / 080253, WO2009 / 080254, WO2010 / 112193, WO2010 / 115589, WO2010 / 136172, WO2010 / 145792, and WO2010 / 145793.
[0280] Engineered antibodies with three or more functional antigen binding sites, including "octopus antibodies," are also included herein (see, eg, US 2006 / 0025576 A1).
[0281] The antibodies or fragments herein also include "dual-acting Fabs" or "dual-acting Fabs" (DAFs) that contain an antigen-binding site that binds to a first epitope (e.g., on a first antigen) as well as another, different epitope (e.g., on the first antigen or a second, different antigen) (see, e.g., US2008 / 0069820; Bostrom et al. (2009) Science, 5921, 1610-1614).
[0282] Methods for producing bispecific antibodies are known in the art. Traditionally, recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-light chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature 305:537 (1983)). Due to the random combination of immunoglobulin heavy and light chains, these hybridomas (quadromas) may produce a mixture of 10 different antibody molecules, only one of which has the correct bispecific structure. Purification of the correct molecule, usually performed by an affinity chromatography step, is somewhat laborious and the product yield is low. Similar procedures are disclosed in WO 93 / 08829 published May 13, 1993, and in Traunecker et al., EMBO J., 10:3655 (1991).
[0283] According to a different and more preferred approach, antibody variable domains (antibody-antigen binding sites) with the desired binding specificity are fused to immunoglobulin constant domain sequences. The fusion is preferably with an immunoglobulin heavy chain constant domain, including at least a part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy chain constant region (CH1) containing the site necessary for light chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain are inserted into separate expression vectors and co-transfected into a suitable host organism. This provides great flexibility in adjusting the mutual ratios of the three polypeptide fragments in embodiments where unequal ratios of the three polypeptide chains used in the construction provide optimal yields. However, it is possible to insert the coding sequences for two or all three polypeptide chains into one expression vector when expression of at least two polypeptide chains in equal ratios provides high yields or when their ratio is not particularly important.
[0284] In a preferred embodiment of this approach, the bispecific antibody is composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It has been found that this asymmetric structure facilitates the separation of the desired bispecific compound from undesired immunoglobulin chain combinations, since the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides an easy method of separation. This approach is disclosed in WO94 / 04690. For further details of the generation of bispecific antibodies, see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).
[0285] Nobu in Hall According to another approach, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers recovered from recombinant cell culture. A preferred interface comprises at least a portion of the CH3 domain of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of a first antibody molecule are replaced (knobs or protuberances) with larger side chains (e.g., tyrosine or tryptophan). A compensatory "cavity" (hole) of identical or similar size to the large side chain(s) is created on the interface of the second antibody molecule by replacing the large amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine). This provides a mechanism for increasing the yield of heterodimers over other unwanted end-products such as homodimers. Knobs and holes are described further herein.
[0286] The use of knobs into holes as a method for producing multispecific antibodies and / or one-armed antibodies and / or immunoadhesins is well known in the art. See U.S. Patent No. 5,731,168, granted March 24, 1998, assigned to Genentech, PCT Publication No. WO2009089004, published July 16, 2009, assigned to Amgen, and U.S. Patent Publication No. 2009 / 0182127, published July 16, 2009, assigned to Novo Nordisk A / S. See also Marvin and Zhu, Acta Pharmacologica Sincia (2005) 26(6):649-658 and Kontermann (2005) Acta Pharacol. Sin., 26:1-9. A brief discussion is provided herein.
[0287] A "bulge" refers to at least one amino acid side chain that protrudes from the interface of a first polypeptide and can therefore be positioned in a compensatory cavity in an adjacent interface (i.e., the interface of a second polypeptide), thereby stabilizing heteromultimers, for example, thereby favoring heteromultimer formation over homomultimer formation. The bulge can be present in the original interface or can be synthetically introduced (e.g., by modifying the nucleic acid encoding the interface). Typically, the nucleic acid encoding the interface of the first polypeptide is modified to encode the bulge. To achieve this, the nucleic acid encoding at least one "original" amino acid residue in the interface of the first polypeptide is replaced with a nucleic acid encoding at least one "import" amino acid residue having a side chain volume larger than the original amino acid residue. It will be understood that there can be more than one original residue and the corresponding imported residue. The upper limit for the number of original residues to be replaced is the total number of residues in the interface of the first polypeptide. The side chain volumes of various amino acid residues are shown in the table below. Table 6: Amino acid properties TIFF2024156655000009.tif159170 a The molecular weight of the amino acid minus the molecular weight of water. Value taken from Handbook of Chemistry and Physics, 43rd ed. Cleveland, Chemical Rubber Publishing Co., 1961. b Values from AAZamyatnin, Prog. Biophys. Mol. Biol., 24:107-123, 1972. c Values from C. Chothia, J. Mol. Biol. 105:1-14, 1975. Writable surface area is defined in Figures 6-20 of this reference.
[0288] Preferred import residues for forming a bulge are generally naturally occurring amino acid residues, preferably selected from arginine (R), phenylalanine (F), tyrosine (Y), and tryptophan (W). Tryptophan and tyrosine are most preferred. In one embodiment, the original residue for forming a bulge has a small side chain volume, such as alanine, asparagine, aspartic acid, glycine, serine, threonine, or valine. Exemplary amino acid substitutions in the CH3 domain for forming a bulge include, but are not limited to, a T366W substitution.
[0289] A "cavity" refers to at least one amino acid side chain that is recessed from the interface of a second polypeptide and thus accommodates a corresponding protuberance on the interface of an adjacent first polypeptide. The cavity may be present in the original interface or may be synthetically introduced (e.g., by modifying the nucleic acid encoding the interface). Typically, the nucleic acid encoding the interface of the second polypeptide is modified to encode the cavity. To achieve this, the nucleic acid encoding at least one "original" amino acid residue in the interface of the second polypeptide is replaced with DNA encoding at least one "import" amino acid residue having a smaller side chain volume than the original amino acid residue. It will be understood that there may be more than one original residue and the corresponding imported residue. The upper limit for the number of original residues to be replaced is the total number of residues in the interface of the second polypeptide. The side chain volumes of various amino acid residues are shown in Table 2 above. The imported residues preferred for forming the cavity are typically naturally occurring amino acid residues, preferably selected from alanine (A), serine (S), threonine (T), and valine (V). Most preferred are serine, alanine, or threonine. In one embodiment, the original residue for forming the cavity has a large side chain volume, such as tyrosine, arginine, phenylalanine, or tryptophan. Exemplary amino acid substitutions in the CH3 domain for generating a cavity include, but are not limited to, T366S, L368A, and Y407A substitutions.
[0290] An "original" amino acid residue is one that is replaced by an "import" residue, which may have a smaller or larger side chain volume than the original residue. The import amino acid residue may be a naturally occurring or non-naturally occurring amino acid residue, but is preferably a naturally occurring amino acid residue. A "naturally occurring" amino acid residue is a residue that is encoded by the genetic code and is listed in Table 2 above. A "non-naturally occurring" amino acid residue refers to a residue that is not encoded by the genetic code but can be covalently linked to an adjacent amino acid residue(s) in a polypeptide chain. Examples of non-naturally occurring amino acid residues are norleucine, ornithine, norvaline, homoserine, and other amino acid residue analogs, such as those described in Ellman et al., Meth. Enzym. 202:301-336 (1991). To generate such non-naturally occurring amino acid residues, the procedures of Noren et al. Science 244:182 (1989) and Ellman et al. (see above) can be used. Briefly, this involves chemical activation of suppressor tRNA with a non-naturally occurring amino acid residue, followed by in vitro transcription and translation of the RNA. The methods provided herein involve replacement of at least one original amino acid residue, although more than one original residue may be replaced. Usually, no more than the total residues in the interface of the first or second polypeptide contain the original amino acid residue being replaced. Typically, the replaced original residue is "buried". "Buried" means that the residue is essentially inaccessible to solvent. Generally, the imported residue is not a cysteine to prevent possible oxidation or mispairing of disulfide bonds.
[0291] The protuberance is "positionable" in the cavity, which means that the spatial location of the protuberance and the cavity at the interface of the first and second polypeptides, respectively, and the size of the protuberance and the cavity are such that the protuberance can be positioned in the cavity without significantly disrupting the normal association of the first and second polypeptides at the interface.Since protuberances such as Tyr, Phe, and Trp typically do not extend perpendicularly from the axis of the interface and do not have a preferred conformation, the alignment of the protuberance with the corresponding cavity relies on the modeling of the protuberance / cavity pair based on three-dimensional structure, such as that obtained by X-ray crystallography or nuclear magnetic resonance (NMR).This can be achieved using techniques that are widely accepted in the art.
[0292] By "original or template nucleic acid" is meant a nucleic acid encoding a polypeptide of interest that can be "modified" (i.e., engineered or mutated) to encode a bulge or cavity. The original or starting nucleic acid can be a naturally occurring nucleic acid or can include a nucleic acid that has been previously modified (e.g., a humanized antibody fragment). "Modifying" a nucleic acid means that the original nucleic acid is mutated by insertion, deletion, or replacement of at least one codon that encodes a desired amino acid residue. Usually, the codon encoding the original residue is replaced with a codon encoding the imported residue. Techniques for genetically modifying DNA in this manner are reviewed in Mutagenesis: a Practical Approach, MJ McPherson, Ed., (IRL Press, Oxford, UK. (1991) and include, for example, site-directed mutagenesis, cassette mutagenesis, and polymerase chain reaction (PCR) mutagenesis. By mutating the original / template nucleic acid, the original / template polypeptide encoded by the original / template nucleic acid is correspondingly modified accordingly.
[0293] A protuberance or cavity may be "introduced" into the interface of a first or second polypeptide by synthetic means, for example, by recombinant techniques, in vitro peptide synthesis, the techniques for introducing non-naturally occurring amino acid residues described above, enzymatic or chemical coupling of peptides, or some combination of these techniques. The protuberance or cavity "introduced" is thus "non-naturally occurring" or "non-natural", meaning that it is not present in the natural or original polypeptide (e.g., a humanized monoclonal antibody).
[0294] In general, the imported amino acid residues to form the ridge have a relatively small number of "rotamers" (e.g., about 3-6). A "rotamer" is an energetically favorable conformation of an amino acid side chain. The number of rotamers for various amino acid residues is reviewed in Ponders and Richards, J. Mol. Biol. 193:775-791 (1987).
[0295] In one embodiment, the first Fc polypeptide and the second Fc polypeptide contact / interact at an interface. In some embodiments where the first Fc polypeptide and the second Fc polypeptide contact at an interface, the interface (sequence) of the second Fc polypeptide comprises a protuberance (also referred to as a "knob") that can be positioned within a cavity (also referred to as a "hole") of the interface (sequence) of the first Fc polypeptide. In one embodiment, the first Fc polypeptide is modified from the template / original polypeptide to encode a cavity, or the second Fc polypeptide is modified from the template / original polypeptide to encode a protuberance, or both. In one embodiment, the first Fc polypeptide is modified from the template / original polypeptide to encode a cavity, and the second Fc polypeptide is modified from the template / original polypeptide to encode a protuberance. In one embodiment, the interface of the second Fc polypeptide comprises a protuberance that can be positioned within a cavity of the interface of the first Fc polypeptide, and the cavity or the protuberance, or both, are introduced into the interface of the first Fc polypeptide and the second Fc polypeptide, respectively. In some embodiments where the first Fc polypeptide and the second Fc polypeptide contact at an interface, the interface of the first Fc polypeptide (sequence) comprises a protuberance that can be positioned within a cavity of the interface (sequence) of the second Fc polypeptide. In one embodiment, the second Fc polypeptide is modified from the template / original polypeptide to encode a cavity, or the first Fc polypeptide is modified from the template / original polypeptide to encode a protuberance, or both. In one embodiment, the second Fc polypeptide is modified from the template / original polypeptide to encode a cavity, and the first Fc polypeptide is modified from the template / original polypeptide to encode a protuberance. In one embodiment, the interface of the first Fc polypeptide comprises a protuberance positionable within a cavity in the interface of the second Fc polypeptide, and the protuberance or cavity, or both, are introduced into the interfaces of the first Fc polypeptide and the second Fc polypeptide, respectively.
[0296] In one embodiment, the bulge and the cavity each comprise a naturally occurring amino acid residue. In one embodiment, the Fc polypeptide comprising the bulge is generated by replacing an original residue from the interface of the template / original polypeptide with an imported residue having a larger side chain volume than the original residue. In one embodiment, the Fc polypeptide comprising the bulge is generated by a method comprising a step in which a polynucleotide encoding an original residue from the interface of the polypeptide is replaced with a polynucleotide encoding an imported residue having a larger side chain volume than the original residue. In one embodiment, the original residue is threonine. In one embodiment, the original residue is T366. In one embodiment, the imported residue is arginine (R). In one embodiment, the imported residue is phenylalanine (F). In one embodiment, the imported residue is tyrosine (Y). In one embodiment, the imported residue is tryptophan (W). In one embodiment, the imported residue is R, F, Y or W. In one embodiment, the bulge is generated by replacing two or more residues of the template / original polypeptide. In one embodiment, the Fc polypeptide comprising a bulge comprises a replacement of the threonine at position 366 with tryptophan (amino acid numbering according to the EU numbering scheme of Kabat et al. (pp. 688-696 in Sequences of proteins of immunological interest, 5th ed., Vol. 1 (1991; NIH, Bethesda, MD)).
[0297] In some embodiments, an Fc polypeptide comprising a cavity is generated by replacing an original residue at the interface of a template / original polypeptide with an imported residue having a smaller side chain volume than the original residue. For example, an Fc polypeptide comprising a cavity can be generated by a method comprising a step in which a polynucleotide encoding an original residue from the interface of a polypeptide is replaced with a polynucleotide encoding an imported residue having a smaller side chain volume than the original residue. In one embodiment, the original residue is a threonine. In one embodiment, the original residue is a leucine. In one embodiment, the original residue is a tyrosine. In one embodiment, the imported residue is not a cysteine (C). In one embodiment, the imported residue is an alanine (A). In one embodiment, the imported residue is a serine (S). In one embodiment, the imported residue is a threonine (T). In one embodiment, the imported residue is a valine (V). A cavity can be generated by replacing one or more original residues of a template / original polypeptide. For example, in one embodiment, the Fc polypeptide comprising a cavity comprises a replacement of two or more original amino acids selected from the group consisting of threonine, leucine, and tyrosine. In one embodiment, the Fc polypeptide comprising a cavity comprises two or more import residues selected from the group consisting of alanine, serine, threonine, and valine. In some embodiments, the Fc polypeptide comprising a cavity comprises a replacement of two or more original amino acids selected from the group consisting of threonine, leucine, and tyrosine, where the original amino acids are replaced with import residues selected from the group consisting of alanine, serine, threonine, and valine. In some embodiments, the replaced original amino acids are T366, L368, and / or Y407. In one embodiment, the Fc polypeptide comprising a cavity comprises a replacement of the threonine at position 366 with a serine (amino acid numbering according to the EU numbering scheme of Kabat et al., supra). In one embodiment, the cavity-containing Fc polypeptide comprises a substitution of the leucine at position 368 with an alanine (amino acid numbering according to the EU numbering scheme of Kabat et al., supra).In one embodiment, the cavity-containing Fc polypeptide comprises a replacement of the tyrosine at position 407 with a valine (amino acid numbering according to the EU numbering scheme of Kabat et al., supra). In one embodiment, the cavity-containing Fc polypeptide comprises two or more amino acid replacements selected from the group consisting of T366S, L368A, and Y407V (amino acid numbering according to the EU numbering scheme of Kabat et al., supra). In some embodiments of these antibody fragments, the bulge-containing Fc polypeptide comprises a replacement of the threonine at position 366 with a tryptophan (amino acid numbering according to the EU numbering scheme of Kabat et al., supra).
[0298] In one embodiment, the antibody comprises Fc mutations constituting the "knob" and "hole" as described in WO2005 / 063816. For example, the hole mutations can be one or more of T366A, L368A, and / or Y407V in the Fc polypeptide and the knob mutation can be T366W in an IgG1 or IgG4 backbone. The skilled artisan can make equivalent mutations in other immunoglobulin isotypes. Furthermore, the skilled artisan will readily appreciate that it is preferred that the two half antibodies used for bispecificity are of the same isotype.
[0299] CrossMab technology Schaefer et al. (Roche Diagnostics GmbH) describe a method for expressing two heavy chains and two light chains from two existing antibodies as a human bivalent bispecific IgG antibody without the use of artificial linkers (PNAS (2011) 108 (27): 11187-11192 and US2009 / 0232811). The method involves exchanging one or more heavy and light chain domains within the antigen-binding fragment (Fab) of a bispecific antibody half (CrossMab). The correct association of light chains and their cognate heavy chains is achieved by exchanging heavy and light chain domains within the antigen-binding fragment (Fab) of a bispecific antibody half. This "crossover" retains the antigen-binding affinity but makes the two arms different so that mispairing of light chains can no longer occur. See WO2009 / 080251, WO2009 / 080252, WO2009 / 080253, WO2009 / 080254, WO2010 / 115589, WO2010 / 136172, WO2010 / 145792, and WO2010 / 145793, each of which is incorporated by reference in its entirety. These recent advances, resulting from the development of methodologies such as "Knobs into holes" (KiH) or "CrossMab" technology expression of multispecific antibodies, may still result in the undesired formation of product-specific impurities specifically associated with their production. These product-specific impurities may include, for example, 1 / 2 antibodies (containing a single heavy / light chain pair), 3 / 4 antibodies (containing a complete antibody lacking a single light chain), or product 5 / 4 antibodies (containing an additional heavy or light chain variable domain).
[0300] BiTE technology Another format used for bispecific T cell engager (BiTE) molecules (e.g., Wolf et al. (2005) Drug Discovery Today 10:1237-1244) is based on single chain variable fragment (scFv) modules. scFvs consist of the light and heavy chain variable regions of an antibody fused via a flexible linker, which generally allows proper folding so that the regions can bind the cognate antigen. BiTEs link the different specificities of two scFvs in tandem on a single chain. This configuration precludes the generation of molecules with two copies of the same heavy chain variable region. In addition, the linker configuration is designed to ensure the correct pairing of the respective light and heavy chains.
[0301] Other bispecific antibody formats Strop et al. (Rinat-Pfizer Inc.) describe a method to generate stable bispecific antibodies by separately expressing and purifying two antibodies of interest and then mixing them together under specific redox conditions (J. Mol. Biol. (2012) 420:204-19).
[0302] Other heterodimerization domains that strongly favor the formation of heterodimers over homodimers can be incorporated into the present multispecific antigen-binding proteins. Illustrative examples include, but are not limited to, WO2007 / 147901 (Kjaergaard et al.-Novo Nordisk, describing ionic interactions), WO2009089004 (Kannan et al.-Amgen, describing electrostatic steering effects), and WO2010 / 034605 (Christensen et al.-Genentech, describing coiled coils). See also, for example, Pack, P. & Plueckthun, A., Biochemistry 31, 1579-1584 (1992), describing leucine zippers, or Pack et al., Bio / Technology 11, 1271-1277 (1993), describing helix-turn-helix motifs. The phrases "heteromultimerization domain" and "heterodimerization domain" are used interchangeably herein. In certain embodiments, a multispecific antigen binding protein comprises one or more heterodimerization domains.
[0303] Zhu et al. (Genentech) engineered mutations at the VL / VH interface of a diabody construct consisting of a variant domain antibody fragment completely lacking the constant domain to generate a heterodimeric diabody (Protein Science (1997) 6:781-788). Similarly, Igawa et al. (Chugai) also engineered mutations at the VL / VH interface of a single chain diabody to promote selective expression and inhibit conformational isomerization of the diabody (Protein Engineering, Design & Selection (2010) 23:667-677).
[0304] U.S. Patent Publication No. 2009 / 0182127 (Novo Nordisk, Inc.) describes the generation of bispecific antibodies by modifying amino acid residues at the Fc interface and CH1:CL interface of a light-heavy chain pair that reduce the ability of one light chain to interact with the heavy chain of the other pair.
[0305] Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, and the other to biotin. Such antibodies have been proposed, for example, to target immune system cells to unwanted cells (US Pat. No. 4,676,980) and to treat HIV infection (WO91 / 00360, WO92 / 200373, and EP03089). Heteroconjugate antibodies can be made using any convenient cross-linking method. Suitable cross-linking agents are well known in the art and are disclosed in US Pat. No. 4,676,980, along with several cross-linking techniques.
[0306] Techniques for generating bispecific antibodies from antibody fragments are also described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describes a method in which an intact antibody is proteolytically cleaved to produce F(ab') fragments. 2 A procedure is described to generate Fab' fragments that are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The generated Fab' fragments are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is reconverted to the Fab'-thiol by reduction with mercaptoethylamine and mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The generated bispecific antibody can be used as an agent for the selective immobilization of enzymes.
[0307] Various techniques for producing and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then reoxidized to form the antibody heterodimers. This method can also be used for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) provides an alternative mechanism for making bispecific antibody fragments. The fragments contain a heavy chain variable domain (VH) connected to a light chain variable domain (VL) by a linker that is too short to allow pairing between the two domains on the same chain. Thus, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments using single-chain Fv (scFv) dimers has also been reported. See Gruber et al., J. Immunol. 152:5368 (1994).
[0308] Reviews of various bispecific and multispecific antibodies are provided in Klein et al., (2012) mAbs 4:6, 653-663, Spiess et al. (2015) "Alternative molecular formats and therapeutic applications for bispecific antibodies." Mol. Immunol. Published online January 27, 2015, doi:10.1016 / j.molimm.2015.01.003, and Kontermann et al. (2015) Drug Discovery Today 20, 838-847.
[0309] Polynucleotides, Vectors, Host Cells, and Recombinant Methods Multispecific antibodies for use in the purification methods described herein may be obtained using methods well known in the art, including recombinant methods. The following sections provide guidance regarding these methods.
[0310] Polynucleotides "Polynucleotide" or "nucleic acid," used interchangeably herein, refer to polymers of nucleotides of any length, and include DNA and RNA.
[0311] Polynucleotides encoding polypeptides can be obtained from any source, including, but not limited to, cDNA libraries prepared from tissues that are believed to carry polypeptide mRNA and express it at detectable levels.Thus, polynucleotides encoding polypeptides can be conveniently obtained from cDNA libraries prepared from human tissues.Polypeptide-encoding genes can also be obtained from genomic libraries or by known synthetic procedures (e.g., automated nucleic acid synthesis).
[0312] For example, a polynucleotide can encode an entire immunoglobulin molecule chain, such as a light chain or a heavy chain. A complete heavy chain includes a heavy chain variable region (V H ), as well as the heavy chain constant region (C H ), which typically contains three constant domains: H 1. C H 2, and C H 3; and the "hinge" region. In some cases, the presence of constant regions is desirable.
[0313] Other polypeptides that can be encoded by the polynucleotides include antigen-binding antibody fragments, such as single domain antibodies ("dAbs"), Fvs, scFvs, Fab's, and F(ab's). 2 , as well as "minibodies." Minibodies are (typically) H 1 and C K or C LMinibodies are bivalent antibody fragments in which domains have been truncated. Minibodies are smaller than conventional antibodies, so they should achieve good tissue penetration in clinical / diagnostic applications, but are bivalent and must retain higher binding affinity than monovalent antibody fragments such as dAbs. Thus, unless the context dictates otherwise, the term "antibody" as used herein encompasses not only all antibody molecules, but also antigen-binding antibody fragments of the type discussed above. Preferably, each framework region present in the encoded polypeptide contains at least one amino acid substitution with respect to the corresponding human receptor framework. Thus, for example, the framework region may contain a total of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions with respect to the receptor framework region.
[0314] Suitably, the polynucleotides described herein may be isolated and / or purified. In some embodiments, the polynucleotide is an isolated polynucleotide.
[0315] The term "isolated polynucleotide" is intended to indicate that a molecule has been removed or separated from its normal or natural environment, or has been produced in a manner that is not present in its normal or natural environment. In some embodiments, the polynucleotide is a purified polynucleotide. The term purified is intended to indicate that at least some contaminating molecules or substances have been removed.
[0316] Preferably, the polynucleotides are substantially purified such that the related polynucleotide constitutes the predominant (ie, most abundant) polynucleotide present in the composition.
[0317] Expression of polynucleotides The following description is primarily directed to the production of polypeptides by culturing cells transformed or transfected with vectors containing polypeptide-encoding polynucleotides. Of course, it is contemplated that alternative methods well known in the art can be used to prepare polypeptides. For example, the appropriate amino acid sequence or portions thereof can be produced by direct peptide synthesis using solid-phase techniques (see Stewart et al., Solid-Phase Peptide Synthesis WH Freeman Co., San Francisco, Calif. (1969); Merrifield, J. Am. Chem. Soc. 85:2149-2154 (1963)). In vitro protein synthesis can be performed using manual techniques or automated. Automated synthesis can be achieved, for example, using an Applied Biosystems Peptide Synthesizer (Foster City, Calif.) using the manufacturer's instructions. Various portions of a polypeptide can be chemically synthesized separately and combined using chemical or enzymatic methods to produce the desired polypeptide.
[0318] The polynucleotides described herein are inserted into an expression vector(s) for the production of a polypeptide. The term "control sequence" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. Control sequences include, but are not limited to, promoters (e.g., naturally associated or heterologous promoters), signal sequences, enhancer elements, and transcription termination sequences.
[0319] A polynucleotide is "operably linked" when it is placed into a functional relationship with another polynucleotide sequence. For example, a presequence or secretory leader nucleic acid is operably linked to a polypeptide nucleic acid if it is expressed as a preprotein involved in the secretion of the polypeptide, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of that sequence, or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the nucleic acid sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. Enhancers, however, do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
[0320] For antibodies, the light and heavy chains can be cloned in the same or different expression vectors. The nucleic acid segments encoding the immunoglobulin chains are operably linked to control sequences in the expression vector(s) that ensure the expression of immunoglobulin polypeptides.
[0321] For CrossMab containing four different polypeptide chains, four expression valence sets are used. They can be cloned in two or four different expression vectors. Each nucleic acid segment encoding an immunoglobulin chain is operably linked to a control sequence in the expression vector(s) that ensures the expression of the immunoglobulin polypeptide. When two or more expression valence sets are contained on the same expression vector, they can be organized unidirectionally or bidirectionally.
[0322] Vectors containing polynucleotide sequences (e.g., variable heavy and / or variable light chain encoding sequences and any expression control sequences) can be transferred into host cells by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, while calcium phosphate treatment, electroporation, lipofection, biolistics, or viral-based transfection can be used for other cellular hosts. (See generally, Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Press, 2nd ed., 1989). Other methods used to transform mammalian cells include polybrene, protoplast fusion, liposomes, electroporation, and microinjection. For the generation of transgenic animals, transgenes can be microinjected into fertilized oocytes or integrated into the genome of embryonic stem cells and the nuclei of such cells transferred to enucleated oocytes.
[0323] vector The term "vector" includes expression vectors, as well as transformation vectors and shuttle vectors.
[0324] The term "expression vector" means a construct capable of in vivo or in vitro expression.
[0325] The term "transformation vector" refers to a construct that can be transferred from one host to another, which can be of the same species or of a different species. If the construct can be transferred from one host to another, such as from an Escherichia coli plasmid to a bacterium such as a Bacillus genus, then the transformation vector is sometimes referred to as a "shuttle vector." It can also be a construct that can be transferred from an E. coli plasmid to an Agrobacterium to a plant.
[0326] The vector can be transformed into a suitable host cell as described herein to provide expression of the polypeptide. A variety of vectors are publicly available. The vector can be, for example, a plasmid, a cosmid, a viral particle, or a phage. The appropriate nucleic acid sequence can be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. The construction of a suitable vector containing one or more of these components uses standard ligation techniques known to those skilled in the art.
[0327] The vector may be, for example, a plasmid, virus or phage vector provided with an origin of replication, optionally a promoter for the expression of the polynucleotide, and optionally a regulator of the promoter. The vector may contain one or more selectable marker genes well known in the art.
[0328] These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA.
[0329] For the generation of multispecific antibodies, the nucleic acid(s) encoding the multispecific antibody (or arms of the multispecific antibody, i.e., heavy / light chain pairs) are typically isolated and inserted into a replicable vector for further cloning, amplification, and / or expression. DNA encoding the antibody is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of specifically binding to genes encoding the heavy and light chains of the antibody). Many vectors are available. The choice of vector will depend in part on the host cell to be used. It will be understood that constant regions of any isotype, including IgG, IgM, IgA, IgD, and IgE constant regions, can be used for this purpose, and that such constant regions can be obtained from any human or animal species.
[0330] host cell The host cell can be, for example, a bacterial cell, a yeast cell or other fungal cell, an insect cell, a plant cell, or a mammalian cell.
[0331] Genetically engineered transgenic multicellular host organisms can be used to produce the polypeptides. The organisms can be, for example, transgenic mammalian organisms (e.g., transgenic goat or mouse strains).
[0332] Suitable prokaryotes include, but are not limited to, eubacteria, such as gram-negative or gram-positive organisms, e.g., Enterobacteriaceae, such as E. coli. Various strains of E. coli are publicly available, such as E. coli K12 strain MM294 (ATCC 31,446), E. coli X1776 (ATCC 31,537), E. coli strain W3110 (ATCC 27,325), and K5 772 (ATCC 53,635). Other suitable prokaryotic host cells include Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli, e.g., B. subtilis and B. licheniformis (e.g., B. licheniformis 41P), Pseudomonas, e.g., P. aeruginosa, and Streptomyces. These examples are illustrative and not limiting. Strain W3110 is one particularly preferred host or parent host, as it is a common host strain for fermentation of recombinant polynucleotide products. Preferably, the host cell secretes minimal amounts of proteolytic enzymes.For example, strain W3110 can be modified to affect genetic mutations in genes encoding polypeptides that are endogenous to the host, examples of such hosts include E. coli W3110 strain 1A2 with the intact tonA genotype, E. coli W3110 strain 9E4 with the intact tonA ptr3 genotype, E. coli W3110 strain 27C7 (ATCC 55,244) with the intact genotype tonA ptr3phoA E15(argF-lac) 169degP ompT kan', E. coli W3110 strain 37D6 with the intact genotype tonA ptr3phoA E15(argF-lac) 169degP ompT rbs7ilvG kan', E. coli W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant degP deletion mutation, and E. coli strains with mutant periplasmic proteases. Alternatively, in vitro methods of cloning, such as PCR or other nucleic acid polymerase reactions, are suitable. In some embodiments, the prokaryotic host cell (e.g., E. coli host cell) expresses one or more chaperones to facilitate antibody folding and assembly. In some embodiments, the chaperone is one or more of FkpA, DsbA, or DsbC. In some embodiments, the chaperone is expressed from an endogenous chaperone gene. In some embodiments, the chaperone is expressed from an exogenous chaperone gene. In some embodiments, the chaperone gene is an E. coli chaperone gene (e.g., the E. coli FkpA gene, the E. coli DsbA gene, and / or the E. coli DsbC gene).
[0333] In these prokaryotic hosts, one can create an expression vector, which typically contains expression control sequences compatible with the host cell (e.g., an origin of replication). In addition, there may be any number of different well-known promoters, such as the lactose promoter system, the tryptophan (trp) promoter system, the beta-lactamase promoter system, or the lambda phage promoter system. The promoter typically controls expression, optionally has an operator sequence, and has ribosome binding site sequences, etc., for initiating and completing transcription and translation.
[0334] Eukaryotic microbes can be used for expression. Eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for polypeptide-encoding vectors. Saccharomyces cerevisiae is a commonly used lower eukaryotic host microorganism. Others include Schizosaccharomyces pombe; Kluyveromyces hosts such as K. lactis (MW98-8C, CBS683, CBS4574), K. fragilis (ATCC12,424), K. bulgaricus (ATCC16,045), K. wickeramii (ATCC24,178), K. waltii (ATCC56,500), K. drosophilarum (ATCC36,906), K. thermotolerans, and K. marxianus; yarrowia (EP402,226); Pichia pastoris; Candida; Trichoderma reesia; Neurospora crassa; Schwanniomyces occidentalis; and filamentous fungi such as Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts such as A. nidulans and A. niger. Methylotrophic yeasts are suitable herein and include yeasts capable of growth on methanol selected from the genera Hansenula, Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodotorula. Saccharomyces is a preferred yeast host with a suitable vector having expression control sequences (e.g., promoters), origins of replication, termination sequences, etc., as desired. Exemplary promoters include 3-phosphoglycerate kinase and other glycolytic enzymes. Inducible yeast promoters include, among others, alcohol dehydrogenase, isocytochrome C, and enzymes involved in maltose and galactose utilization.
[0335] In addition to microorganisms, mammalian tissue cell cultures may also be used to express and produce polypeptides as described herein, and are preferred in some instances (see Winnacker, From Genes to Clones VCH Publishers, NY, NY (1987)). For some embodiments, eukaryotic cells may be preferred, as several suitable host cell lines capable of secreting heterologous polypeptides (e.g., intact immunoglobulins) have been developed in the art, including CHO cell lines, various Cos cell lines, HeLa cells, preferably myeloma cell lines, or transformed B-cells or hybridomas. In some embodiments, the mammalian host cells are CHO cells.
[0336] In some embodiments, the host cell is a vertebrate host cell. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed with SV40 (COS-7, ATCC CRL1651); human embryonic kidney lines (293 cells or 293 cells subcloned for growth in suspension culture); baby hamster kidney cells (BHK, ATCC CCL10); Chinese hamster ovary cells / -DHFR (CHO or CHO-DP-12 lines); mouse Sertoli cells; monkey kidney cells (CV1 ATCC CCL70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL2); canine kidney cells (MDCK, ATCC CCL34); buffalo rat hepatocytes (BRL3A, ATCC CRL1442); human lung cells (W138, ATCC CCL75); human hepatocytes (Hep G2, HB8065); mouse mammary tumor (MMT060562, ATCC CCL51); TRI cells; MRC5 cells; FS4 cells; and a human liver cancer line (Hep G2).
[0337] Production of multispecific antibodies using prokaryotic host cells Vector construction Polynucleotide sequences encoding the polypeptide components of the multispecific antibodies purified according to the methods provided herein can be obtained using standard recombinant techniques. The desired polynucleotide sequences can be isolated and sequenced from antibody producing cells, such as hybridoma cells. Alternatively, the polynucleotides can be synthesized using a nucleotide synthesizer or PCR techniques. Once obtained, the sequences encoding the polypeptides (two or more heavy chains and / or two or more light chains) are inserted into a recombinant vector capable of replicating and expressing heterologous polynucleotides in a host cell, such as an E. coli cell. Many vectors available and known in the art can be used for the purposes of the methods and compositions provided herein. The selection of an appropriate vector depends primarily on the size of the nucleic acid to be inserted into the vector and the particular host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification or expression of heterologous polynucleotides, or both) and its compatibility with the particular host cell in which it resides. Vector components generally include, but are not limited to, an origin of replication, a selectable marker gene, a promoter, a ribosome binding site (RBS), a signal sequence, the heterologous nucleic acid insert, and a transcription termination sequence.
[0338] Generally, plasmid vectors containing replicon and control sequences derived from a species compatible with the host cell are used in connection with these hosts. The vector usually carries a replication site, as well as marking sequences capable of providing phenotypic selection in transformed cells. For example, E. coli is typically transformed using pBR322, a plasmid derived from an E. coli species. pBR322 contains genes encoding ampicillin (Amp) and tetracycline (Tet) resistance, and thus provides an easy means for identifying transformed cells. pBR322, its derivatives, or other microbial plasmids or bacteriophages, may also contain, or be modified to contain, promoters that can be used by the microorganism for expression of endogenous proteins. Examples of pBR322 derivatives used for the expression of specific antibodies are described in detail in Carter et al., U.S. Pat. No. 5,648,237.
[0339] In addition, phage vectors containing replicon and control sequences compatible with the host microorganism can be used as transforming vectors in connection with these hosts. For example, bacteriophage such as GEM™-11 can be utilized in generating recombinant vectors that can be used to transform susceptible host cells such as E. coli LE392.
[0340] An expression vector may contain two or more promoter-cistron pairs, one encoding each of the polypeptide components. A promoter is a non-translated regulatory sequence located upstream (5') of a cistron that regulates its expression. Prokaryotic promoters are typically divided into two classes, inducible and constitutive promoters. Inducible promoters are promoters that initiate increased levels of transcription of the cistron under their control in response to a change in culture conditions, e.g., the presence or absence of a nutrient or a change in temperature.
[0341] A large number of promoters recognized by a variety of potential host cells are well known. The selected promoter may be operably linked to the cistron DNA encoding the light or heavy chain by removing the promoter from the source DNA by restriction enzyme digestion and inserting the isolated promoter sequence into a vector. Either the native promoter sequence or many heterologous promoters may be used to induce amplification and / or expression of the target gene. In some embodiments, heterologous promoters are utilized because heterologous promoters generally result in greater transcription and higher yields of the expressed target gene compared to the native target polypeptide promoter.
[0342] Suitable promoters for use with prokaryotic hosts include the PhoA promoter, the -lactamase and lactose promoter systems, the tryptophan (trp) promoter system, and hybrid promoters, such as the tac or trc promoter. However, other promoters functional in bacteria, such as other known bacterial or phage promoters, are also suitable. Their nucleotide sequences have been published, allowing one skilled in the art to operably ligate them into the cistrons encoding the target light and heavy chains, using linkers or adapters to provide any necessary restriction sites (Siebenlist et al. (1980) Cell 20:269).
[0343] The translation initiation region (TIR) is a major determinant of the overall translation level of a protein. The TIR comprises a polynucleotide encoding a signal sequence, extending from immediately upstream of the Shine-Dalgarno sequence to approximately 20 nucleotides downstream of the start codon. Generally, the vector comprises a TIR, and TIRs and variant TIRs are known in the art, and methods for generating TIRs are known in the art. A series of nucleic acid sequence variants can be made with a range of translation strengths, thereby providing a convenient means to adjust this factor for optimal secretion of many different polypeptides. The use of reporter genes fused to these variants, such as PhoA, provides a method for quantification of the relative translation strength of different translation initiation regions. Variant or mutant TIRs can be provided in a plasmid vector background, thereby providing a set of plasmids into which genes of interest can be inserted and their expression measured to establish an optimal range of translation strength for maximum expression of the mature polypeptide. Variant TIRs are disclosed in USP 8,241,901.
[0344] In one embodiment, each cistron in the recombinant vector contains a secretory signal sequence component that directs translocation of the expressed polypeptide across the membrane. In general, the signal sequence may be a component of the vector or may be part of the target polypeptide DNA that is inserted into the vector. The selected signal sequence should be one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. In the case of prokaryotic host cells that do not recognize and process the signal sequence native to the heterologous polypeptide, the signal sequence is replaced by a prokaryotic signal sequence. Such sequences are well known in the art. In addition, the vector may contain a signal sequence selected from the group consisting of alkaline phosphatase, penicillinase, Lpp, or heat-stable enterotoxin II (STII) leader, LamB, PhoE, PelB, OmpA, and MBP.
[0345] In one aspect, one or more polynucleotides (e.g., expression vectors) collectively encode the antibody. In one embodiment, a single polynucleotide encodes the light chain of the antibody and a separate polynucleotide encodes the heavy chain of the antibody. In one embodiment, a single polynucleotide encodes the light and heavy chains of the antibody. In some embodiments, one or more polynucleotides (e.g., expression vectors) collectively encode the one-arm antibody. In one embodiment, a single polynucleotide encodes (a) the light and heavy chains of the one-arm antibody, and (b) the Fc polypeptide. In one embodiment, a single polynucleotide encodes the light and heavy chains of the one-arm antibody, and a separate polynucleotide encodes the Fc polypeptide. In one embodiment, separate polynucleotides encode the light chain component of the one-arm antibody, the heavy chain component of the one-arm antibody, and the Fc polypeptide, respectively. Production of one-arm antibodies is described, for example, in WO2005063816.
[0346] Suitable prokaryotic host cells for expressing antibodies include Archaebacteria and Eubacteria, such as gram-negative or gram-positive bacteria. Examples of useful bacteria include Escherichia (e.g., E. coli), Bacilli (e.g., B. subtilis), Enterobacteria, Pseudomonas species (e.g., P. aeruginosa), Salmonella typhimurium, Serratia marcescans, Klebsiella, Proteus, Shigella, Rhizobia, Vitreoscilla, or Paracoccus. In one embodiment, gram-negative cells are used. In one embodiment, E. coli cells are used as host cells. Exemplary E. coli strains include strain W3110 (Bachmann, Cellular and Molecular Biology, vol. 2 (Washington, DC: American Society for Microbiology, 1987), pp. 1190-1219, ATCC Accession No. 27,325) and its derivatives, including strain 33D3 having the genotype W3110ΔfhuA(ΔtonA)ptr3lacIq lacL8ΔompTΔ(nmpc-fepE)degP41kanR (U.S. Pat. No. 5,639,635), and strains 63C1 and 64B4. In some embodiments, the E. coli strain is a W3110 derivative designated 62A7 (ΔfhuA(ΔtonA)ptr3, lacIq, lacL8, ompTΔ(nmpc-fepE)ΔdegP ilvG repaired). Other strains and derivatives thereof are also suitable, such as E. coli 294 (ATCC 31,446), E. coli B, E. coli λ1776 (ATCC 31,537), and E. coli RV308 (ATCC 31,608). These examples are illustrative and not limiting. Methods for constructing derivatives of any of the above bacteria with defined genotypes are known in the art and are described, for example, in Bass et al., Proteins, 8:309-314 (1990).Generally, it is necessary to select a suitable bacterium by considering the replicability of the replicon in the bacterial cell. For example, when using a well-known plasmid such as pBR322, pBR325, pACYC177, or pKN410 to provide the replicon, E. coli, Serratia, or Salmonella species can be suitably used as the host. Typically, the host cell should secrete only a minimal amount of proteolytic enzymes, and it may be desirable to incorporate additional protease inhibitors into the cell culture.
[0347] To improve the production yield and quality of polypeptides in bacterial culture, bacterial cells can be modified. For example, to improve the proper assembly and folding of secreted antibody polypeptides, bacterial host cells can contain additional vectors expressing chaperone proteins, such as FkpA protein and Dsb proteins (DsbB, DsbC, DsbD, and / or DsbG), which can be used to co-transform host prokaryotic cells. It has been demonstrated that chaperone proteins facilitate the proper folding and dissolution of heterologous proteins produced in bacterial host cells.
[0348] Multispecific antibody production Host cells are transformed with the above-described expression vectors and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
[0349] Transformation means introducing DNA into a prokaryotic host so that the DNA is replicable either as an extrachromosomal element or by chromosomal integrant. Depending on the host cell used, transformation is performed using standard techniques appropriate for such cells. Generally, a calcium treatment using calcium chloride is used for bacterial cells that contain substantial cell wall barriers. Another method of transformation uses polyethylene glycol / DMSO. Yet another technique used is electroporation.
[0350] The prokaryotic cells used to produce the polypeptide are grown in a medium known in the art and suitable for culturing the selected host cell. An example of a suitable medium is Luria Broth (LB) containing necessary nutrient supplements. In some embodiments, the medium also contains a selection agent selected based on the construction of the expression vector to selectively allow the growth of prokaryotic cells containing the expression vector. For example, ampicillin is added to the medium to grow cells expressing an ampicillin resistance gene.
[0351] In addition to carbon, nitrogen, and inorganic phosphate sources, any necessary supplements may also be included at appropriate concentrations introduced alone or in mixtures with other supplements or media, such as complex nitrogen sources. Optionally, the culture medium may contain one or more reducing agents selected from the group consisting of glutathione, cysteine, cystamine, thioglycolate, dithioerythritol, and dithiothreitol.
[0352] The prokaryotic host cells are cultured at a suitable temperature. For E. coli growth, for example, preferred temperatures are in the range of about 20° C. to about 39° C., more preferably in the range of about 25° C. to about 37° C., and even more preferably about 30° C. The pH of the medium can be any pH in the range of about 5 to about 9, depending mainly on the host organism. For E. coli, the pH is preferably about 6.8 to about 7.4, more preferably about 7.0.
[0353] When an inducible promoter is used in the expression vector, protein expression is induced under conditions suitable for the activation of the promoter. In one embodiment, the PhoA promoter is used to control the transcription of the polypeptide. Thus, the transformed host cell is cultured in a phosphate-limited medium for induction. Preferably, the phosphate-limited medium is CRAP medium (see, for example, Simmons et al., J.Immunol.Methods (2002), 263:133-147), or the medium described in WO2002 / 061090. Various other inducers can be used according to the vector construction used, as known in the art.
[0354] In one embodiment, the expressed polypeptide is secreted into the periplasm of the host cell and recovered therefrom. Protein recovery typically involves disruption of the microorganism, generally by means such as osmotic shock, sonication, or lysis. Once the cells are disrupted, cell debris or whole cells can be removed by centrifugation or filtration. The protein is further purified, for example, by affinity resin chromatography. Alternatively, the protein can be transported to the culture medium and isolated therein. The cells can be removed from the culture, and the culture supernatant filtered and concentrated for further purification of the produced protein. The expressed polypeptide can be further isolated and identified using commonly known methods such as polyacrylamide gel electrophoresis (PAGE) and Western blot assays.
[0355] In one aspect, antibody pro...
Claims
1. 1. A method for purifying a multispecific antibody from a composition comprising said multispecific antibody and impurities, said multispecific antibody comprising a plurality of arms, each arm comprising a VH / VL unit, said method comprising sequential steps of: a) subjecting said composition to capture chromatography to produce a capture chromatography eluate; b) subjecting the capture chromatography eluate to a first mixed-mode chromatography to produce a first mixed-mode eluate; c) subjecting the first mixed mode eluate to a second mixed mode chromatography to produce a second mixed mode eluate; d) collecting the fractions comprising said multispecific antibodies, The method, wherein the method reduces the amount of product specific impurities in the composition.
2. 2. The method of claim 1, wherein the capture chromatography eluate is subjected to ion exchange or HIC chromatography prior to the first mixed-mode chromatography.
3. 1. A method for purifying a multispecific antibody from a composition comprising said multispecific antibody and impurities, said multispecific antibody comprising multiple arms, each arm comprising a VH / VL unit, each arm of said multispecific antibody being produced separately, said method comprising the steps of: a) subjecting each arm of the multispecific antibody to capture chromatography to produce a capture eluate for each arm of the multispecific antibody; b) forming a mixture comprising a capture eluate of each arm of said multispecific antibody under conditions sufficient to produce a composition comprising said multispecific antibody; c) subjecting the composition comprising the multispecific antibody to a first mixed-mode chromatography to produce a first mixed-mode eluate; d) subjecting the first mixed mode eluate to a second mixed mode chromatography to produce a second mixed mode eluate; e) collecting the fractions comprising said multispecific antibodies, The method, wherein the method reduces the amount of product specific impurities in the composition.
4. 4. The method of claim 3, wherein the composition comprising the multispecific antibody is subjected to ion exchange or HIC chromatography prior to the first mixed-mode chromatography.
5. The method according to any one of claims 1 to 4, wherein the capture chromatography is affinity chromatography.
6. The method of claim 5, wherein the affinity chromatography is Protein L chromatography, Protein A chromatography, Protein G chromatography, Protein A and Protein G chromatography.
7. The method of claim 5 or claim 6, wherein the affinity chromatography is Protein A chromatography.
8. The method according to any one of claims 1 to 7, wherein the capture chromatography is performed in bind and elute mode.
9. The method of any one of claims 1 to 8, wherein the first mixed-mode chromatography and the second mixed-mode chromatography are consecutive.
10. The method of any one of claims 1 to 9, wherein the first mixed-mode chromatography is a mixed-mode anion exchange chromatography.
11. The method of any one of claims 1 to 10, wherein the second mixed-mode chromatography is a mixed-mode cation exchange chromatography.
12. The method of any one of claims 1 to 9, wherein the first mixed-mode chromatography is a mixed-mode cation exchange chromatography.
13. The method of any one of claims 1 to 10 and 12, wherein the second mixed mode chromatography is a mixed mode anion exchange chromatography.
14. The method of any one of claims 1 to 13, wherein the first mixed-mode chromatography is performed in bind-and-elute mode.
15. The method of claim 14, wherein the elution is a gradient elution.
16. The method of any one of claims 1 to 13, wherein the first mixed-mode chromatography is performed in flow-through mode.
17. The method of any one of claims 1 to 16, wherein the second mixed-mode chromatography is performed in bind-and-elute mode.
18. 18. The method of claim 17, wherein the elution is a gradient elution.
19. The method of any one of claims 1 to 16, wherein the second mixed-mode chromatography is performed in flow-through mode.
20. 20. The method of any one of claims 1 to 19, further comprising ultrafiltering the second mixed-mode eluate.
21. 21. The method of claim 20, wherein the ultrafiltration comprises, sequentially, a first ultrafiltration, a diafiltration, and a second ultrafiltration.
22. 22. The method of any one of claims 7 to 21, wherein the Protein A chromatography comprises Protein A linked to agarose.
23. The Protein A chromatography 22. The method of any one of claims 7 to 21, which is MAbSelect™, MAbSelect™ SuRe and MAbSelect™ SuRe LX, Prosep-VA, Prosep-VA Ultra Plus, Protein A Sepharose Fast Flow, or Toyopearl Protein A chromatography.
24. 24. The method of any one of claims 7 to 23, wherein the Protein A chromatography uses one or more of a Protein A equilibration buffer, a Protein A loading buffer, or a Protein A wash buffer, wherein the equilibration buffer, loading buffer, and / or wash buffer is at about pH 7 to about pH 8.
25. 25. The method of claim 24, wherein the Protein A equilibration buffer is at about pH 7.
7.
26. 26. The method of claim 24 or claim 25, wherein the Protein A equilibration buffer comprises about 25 mM Tris and about 25 mM NaCl.
27. The method of any one of claims 24 to 26, wherein the Protein A chromatography is washed with an equilibration buffer after loading.
28. The method of any one of claims 7 to 27, wherein the multispecific antibody is eluted from the Protein A chromatography by pH step elution.
29. The method of any one of claims 7 to 28, wherein the multispecific antibody is eluted from the Protein A by applying a Protein A elution buffer having a low pH to the Protein A chromatography.
30. 30. The method of claim 29, wherein the Protein A elution buffer comprises about 150 mM acetic acid, about pH 2.
9.
31. The Protein A eluates were pooled and the OD of the eluates was 280 The method of any one of claims 7 to 30, wherein is greater than about 0.
5.
32. The method of any one of claims 10 to 31, wherein the anion exchange mixed-mode chromatography comprises a quaternary amine and a hydrophobic moiety.
33. 33. The method of claim 32, wherein the anion exchange mixed-mode chromatography comprises a quaternary amine and a hydrophobic moiety linked to highly cross-linked agarose.
34. 34. The method of claim 33, wherein the mixed-mode chromatography is Capto™ Adhere chromatography or Capto™ Adhere ImpRes chromatography.
35. 35. The method of any one of claims 11 to 34, wherein the cation exchange mixed-mode chromatography comprises N-benzyl-n-methylethanolamine.
36. 36. The method of claim 35, wherein the mixed-mode chromatography is Capto™ MMC chromatography or Capto™ MMC ImpRes chromatography.
37. 37. The method of any one of claims 1 to 36, wherein the first mixed-mode chromatography uses one or more of a mixed-mode pre-equilibration buffer, a mixed-mode equilibration buffer, a mixed-mode loading buffer, or a mixed-mode wash buffer, and wherein the mixed-mode pre-equilibration buffer, the mixed-mode equilibration buffer, the mixed-mode loading buffer, and / or the mixed-mode wash buffer are at about pH 6 to about pH 7.
38. 38. The method of any one of claims 1 to 37, wherein the second mixed-mode chromatography uses one or more of a mixed-mode pre-equilibration buffer, a mixed-mode equilibration buffer, a mixed-mode loading buffer, or a mixed-mode wash buffer, and wherein the mixed-mode pre-equilibration buffer, the mixed-mode equilibration buffer, and / or the mixed-mode wash buffer are at about pH 5 to about pH 8.
39. 39. The method of claim 37 or claim 38, wherein the mixed mode pre-equilibration buffer, the mixed mode equilibration buffer, and / or the mixed mode wash buffer are at about pH 6.
5.
40. 40. The method of any one of claims 37 to 39, wherein the mixed-mode pre-equilibration buffer comprises about 500 mM acetate.
41. The method of any one of claims 37 to 40, wherein the mixed-mode equilibration buffer comprises about 50 mM acetate.
42. The method of any one of claims 37 to 41, wherein the first mixed-mode chromatography is washed with a wash buffer after loading.
43. The method of any one of claims 37 to 42, wherein the second mixed-mode chromatography is washed with a wash buffer after loading.
44. The method of any one of claims 15 and 18 to 43, wherein the multispecific antibody is eluted from the first mixed-mode chromatography by a pH gradient.
45. 45. The method of any one of claims 15 and 18 to 44, wherein the multispecific antibody is eluted from the first mixed mode chromatography by applying a mixed mode elution buffer having a low pH to the mixed mode ion exchange chromatography.
46. The method of any one of claims 15 and 18 to 45, wherein the multispecific antibody is eluted from the second mixed-mode chromatography by a pH gradient.
47. The method of any one of claims 15 and 18 to 46, wherein the multispecific antibody is eluted from the second mixed mode chromatography by applying a mixed mode elution buffer having a low pH to the mixed mode exchange chromatography.
48. 48. The method of any one of claims 2 and 4 to 47, wherein the ion exchange chromatography involves a quaternary amine.
49. 49. The method of claim 48, wherein the ion exchange chromatography is anion exchange chromatography, the anion exchange chromatography comprising a quaternary amine linked to cross-linked agarose.
50. 50. The method of claim 49, wherein the mixed-mode anion exchange chromatography is CaptoAdhere chromatography.
51. 51. The method of any one of claims 48-50, wherein the anion exchange chromatography uses one or more of anion exchange pre-equilibration buffer, anion exchange equilibration buffer, or anion exchange loading buffer, and the anion exchange pre-equilibration buffer, the anion exchange equilibration buffer, and / or the anion exchange loading buffer are at about pH 6 to about pH 8.
52. 52. The method of claim 51, wherein the anion exchange pre-equilibration buffer, the anion exchange equilibration buffer, and / or the anion exchange load is at about pH 6.
5.
53. 53. The method of claim 51 or claim 52, wherein the anion exchange pre-equilibration buffer comprises about 50 mM Tris, 500 mM sodium acetate.
54. 54. The method of any one of claims 51 to 53, wherein the anion exchange equilibration buffer comprises about 50 mM Tris.
55. 55. The method of any one of claims 51 to 54, wherein the anion exchange chromatography is washed with anion exchange equilibration buffer after loading.
56. The method of any one of claims 51 to 55, wherein the multispecific antibody is eluted from the anion exchange chromatography by a salt gradient.
57. The method of any one of claims 51 to 56, wherein the multispecific antibody is eluted from the anion exchange chromatography by applying an anion exchange elution buffer having an increasing salt concentration to the anion exchange chromatography.
58. 58. The method of claim 57, wherein the anion exchange elution buffer comprises about 50 mM Tris, 100 mM sodium acetate at about pH 8.
5.
59. The anion exchange eluates are pooled and the OD of the eluates is 280 The method of any one of claims 51 to 58, wherein is greater than about 0.5 to about 2.
0.
60. The method of any one of claims 1 to 59, wherein the arms of the multispecific antibody are produced in a cell.
61. 61. The method of claim 60, wherein the cell is a prokaryotic cell.
62. 62. The method of claim 61 , wherein the prokaryotic cell is an E. coli cell.
63. 63. The method of claim 61 or claim 62, wherein the cells are engineered to express one or more chaperones.
64. 64. The method of claim 63, wherein the chaperone is one or more of FkpA, DsbA, or DsbC.
65. 63 or 64, wherein the chaperone is an E. coli chaperone. The method according to
66. The method of any one of claims 1 to 60, wherein the cell is a eukaryotic cell.
67. 67. The method of claim 66, wherein the eukaryotic cell is a yeast cell, an insect cell, or a mammalian cell.
68. 68. The method of claim 66 or claim 67, wherein the eukaryotic cell is a CHO cell.
69. The method of any one of claims 60 to 68, wherein the cells are lysed prior to capture chromatography to produce a cell lysate comprising the multispecific antibody or an arm of the multispecific antibody.
70. 70. The method of claim 69, wherein the cells are lysed using a microfluidizing agent.
71. 71. The method of claim 69 or claim 70, wherein polyethyleneimine (PEI) is added to the cell lysate prior to chromatography.
72. 72. The method of any one of claims 1-71, wherein the method reduces the amount of any one of host cell proteins (HCPs), leached Protein A, nucleic acids, cell culture media components, or viral impurities in the composition.
73. The method of any one of claims 1 to 72, wherein the multispecific antibody is a bispecific antibody.
74. 74. The method of claim 73, wherein the bispecific antibody is a knob-in-hole (KiH) bispecific antibody.
75. The method of claim 73 or claim 74, wherein the bispecific antibody is a CrossMab bispecific antibody.
76. The method of any one of claims 1 to 75, wherein the fraction comprises at least about 95% multispecific antibodies.
77. 77. The method of any one of claims 1-76, wherein the product specific impurities are one or more of unpaired antibody arms, antibody homodimers, aggregates, high molecular weight species (HMWS), low molecular weight species (LMWS), acidic variants, or basic variants.
78. 78. The method of claim 77, wherein the fraction comprises about 5% or less of the non-paired antibody arms.
79. 79. The method of claim 77 or claim 78, wherein the fraction comprises about 5% or less antibody homodimers.
80. 80. The method of any one of claims 77-79, wherein the fraction contains about 2% or less aggregates or high molecular weight species (HMWS).
81. 81. The method of any one of claims 77-80, wherein the fraction comprises about 2% or less LMWS.
82. 82. The method of any one of claims 77 to 81, wherein the fraction comprises about 50% or less of the acidic variant.
83. 83. The method of any one of claims 77 to 82, wherein the fraction comprises about 35% or less of basic variants.
84. The method of any one of claims 77 to 83, wherein the fraction comprises about 5% or less of 3 / 4 antibodies.
85. The fraction is a) at least about 95% to about 100% multispecific antibodies; b) about 1% to about 5% or less of the non-paired antibody arms; c) about 1% to about 5% or less antibody homodimers; d) about 1% or about 2% HMWS or less; e) about 1% or about 2% LMWS or less; and f) comprising about 5% or less of 3 / 4 antibodies.
86. A composition comprising a multispecific antibody purified by the method of any one of claims 1 to 85.
87. A composition comprising a multispecific antibody purified by the method of any one of claims 1 to 85 for the treatment of cancer or eye disease.
88. 1. A method for purifying an Fc region-containing heterodimeric polypeptide by a multi-step chromatography method, said method comprising an affinity chromatography step followed by two different multimodal ion exchange chromatography steps, Thereby, the Fc region-containing heterodimeric polypeptide is purified.
89. The multi-step chromatography method comprises: i. an affinity chromatography step followed by a multimodal anion exchange chromatography step followed by a multimodal cation exchange chromatography step; or ii. The method of claim 88, comprising a step of affinity chromatography followed by a step of multimodal cation exchange chromatography followed by a step of multimodal anion exchange chromatography.
90. 90. The method of any one of claims 88 to 89, wherein the multi-step chromatography method comprises an affinity chromatography step followed by a multimodal anion exchange chromatography step followed by a multimodal cation exchange chromatography step.
91. 91. The method of any one of claims 88 to 90, wherein the multi-step chromatography method comprises exactly three chromatographic steps.
92. 92. The method according to any one of claims 89 to 91, wherein the multimodal anion exchange chromatography step is carried out in flow-through mode.
93. 93. The method of any one of claims 89 to 92, wherein in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity value of less than 7 mS / cm.
94. 94. The method according to any one of claims 89 to 93, wherein in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity value ranging from about 6 mS / cm to about 2 mS / cm.
95. 95. The method of any one of claims 89 to 94, wherein in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity value of about 4.5 mS / cm.
96. 96. The method of any one of claims 89 to 95, wherein the multimodal anion exchange chromatography step is carried out at a pH of about 7.
97. 97. The method of any one of claims 89 to 96, wherein in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in a solution having a conductivity of about 4.5 mS / cm and a pH of about 7.
98. 98. The method of any one of claims 89 to 97, wherein in the multimodal anion exchange chromatography step, the Fc region-containing heterodimeric polypeptide is applied in the range of about 100 g to about 300 g per liter of chromatography material.
99. 99. The method of any one of claims 89 to 98, wherein the multimodal anion exchange chromatography material is a multimodal strong anion exchange chromatography material.
100. 100. The method of any one of claims 89 to 99, wherein the multimodal anion exchange chromatography material has a matrix of high flux agarose, multimodal strong anion exchange as ligand, an average particle size of 36-44 μm, and an ionic capacity of 0.08-0.11 mmol Cl- / mL of medium.
101. 101. The method of any one of claims 89 to 100, wherein the multimodal cation exchange chromatography medium is a multimodal weak cation exchange chromatography medium.
102. 102. The method of any one of claims 89 to 101, wherein the multimodal cation exchange chromatography medium has a matrix of high flux agarose, multimodal weak cation exchange as ligand, average particle size of 36-44 μm, and ionic capacity of 25-39 μmol / mL.
103. 103. The method of any one of claims 89 to 102, wherein the multimodal anion exchange chromatography step is performed in bind and elute mode.
104. 104. The method of any one of claims 88 to 103, wherein the affinity chromatography is Protein A affinity chromatography, or Protein G affinity chromatography, or single chain Fv ligand affinity chromatography, or a chromatography step using CaptureSelect chromatography material, or a chromatography step using CaptureSelect FcXL chromatography material.
105. 105. The method of any one of claims 88 to 104, wherein the affinity chromatography step is a Protein A chromatography step.
106. A method according to any one of claims 88 to 105, wherein the affinity chromatography step is a chromatography step using CaptureSelect™ chromatography material.
107. The method of any one of claims 88 to 106, wherein said Fc region-containing heterodimeric polypeptide is an antibody, a bispecific antibody, or an Fc-fusion protein.
108. The method of any one of claims 88 to 107, wherein the Fc region-containing heterodimeric polypeptide is a bispecific antibody.
109. The method according to any one of claims 90 to 108, wherein the Fc region-containing heterodimeric polypeptide is a CrossMab.
110. The Fc region-containing heterodimeric polypeptide is a) heavy and light chains of a first full-length antibody that specifically binds a first antigen; and b) a bispecific antibody comprising a modified heavy chain and a modified light chain of a full-length antibody that specifically binds a second antigen, wherein the constant domains CL and CH1 are replaced by each other.
111. The method of any one of claims 108 to 110, wherein the bispecific antibody binds ANG2 and VEGF.
112. The method of any one of claims 108 to 110, wherein the CrossMab binds ANG2 and VEGF.
113. The method of any one of claims 108 to 112, wherein the bispecific antibody is vanucizumab.
114. 113. The method according to any one of claims 108 to 112, wherein said bispecific antibody comprises a first antigen-binding site comprising SEQ ID NO: 1 as the heavy chain variable domain (VH) and SEQ ID NO: 2 as the light chain variable domain (VL), and a second antigen-binding site comprising SEQ ID NO: 3 as the heavy chain variable domain (VH) and SEQ ID NO: 4 as the light chain variable domain (VL).
115. The method of any one of claims 108 to 112, wherein the bispecific antibody comprises a first heavy chain having the amino acid sequence of SEQ ID NO: 9, and a second heavy chain having the amino acid sequence of SEQ ID NO: 10, and a first light chain having the amino acid sequence of SEQ ID NO: 11, and a second light chain having the amino acid sequence of SEQ ID NO:
12.
116. 113. The method according to any one of claims 108 to 112, wherein said bispecific antibody comprises a first antigen-binding site comprising SEQ ID NO: 5 as the heavy chain variable domain (VH) and SEQ ID NO: 6 as the light chain variable domain (VL), and a second antigen-binding site comprising SEQ ID NO: 7 as the heavy chain variable domain (VH) and SEQ ID NO: 8 as the light chain variable domain (VL).
117. The method of any one of claims 108 to 112, wherein the bispecific antibody comprises a first heavy chain having the amino acid sequence of SEQ ID NO: 13, and a second heavy chain having the amino acid sequence of SEQ ID NO: 14, and a first light chain having the amino acid sequence of SEQ ID NO: 15, and a second light chain having the amino acid sequence of SEQ ID NO:
16.
118. The method of any one of claims 108 to 117, wherein the purified Fc region-containing heterodimeric polypeptide comprises about 5% or less of 3 / 4 antibodies.
119. 1. A method for purifying a bispecific antibody that binds ANG-2 and VEGF by a multi-step chromatography method, the method comprising an affinity chromatography step followed by a multimodal anion exchange chromatography step followed by a multimodal cation exchange chromatography step, thereby purifying said bispecific antibody that binds ANG-2 and VEGF; the bispecific antibody comprises a first antigen-binding site comprising SEQ ID NO: 1 as the heavy chain variable domain (VH) and SEQ ID NO: 2 as the light chain variable domain (VL), and a second antigen-binding site comprising SEQ ID NO: 3 as the heavy chain variable domain (VH) and SEQ ID NO: 4 as the light chain variable domain (VL); or a first antigen-binding site comprising SEQ ID NO:5 as the heavy chain variable domain (VH) and SEQ ID NO:6 as the light chain variable domain (VL), and a second antigen-binding site comprising SEQ ID NO:7 as the heavy chain variable domain (VH) and SEQ ID NO:8 as the light chain variable domain (VL).
120. The bispecific antibody that binds ANG-2 and VEGF, a) the heavy chain and the light chain of a first full-length antibody comprising the first antigen-binding site; and b) the constant domains CL and CH1 are replaced by each other, the modified heavy chain and the modified light chain of a full-length antibody comprising the second antigen-binding site.
121. 1. A composition comprising a bispecific antibody, wherein the composition comprises at least about 95% bispecific antibody.
122. The composition of claim 121, wherein the composition comprises about 5% or less unpaired antibody arms.
123. The composition of claim 121 or 122, wherein the composition comprises about 5% or less antibody homodimers.
124. A composition comprising a CrossMab antibody, wherein the composition comprises at least 95% CrossMab antibody.
125. 125. The composition of any one of claims 121-124, wherein the composition contains about 2% or less aggregates or high molecular weight species (HMWS).
126. The composition of any one of claims 121-125, wherein the composition comprises about 2% or less of low molecular weight species (LMWS).
127. 127. The composition of any one of claims 121 to 126, wherein the composition comprises about 50% or less of acidic variants.
128. 128. The composition of any one of claims 121 to 127, wherein the composition comprises about 35% or less of a basic variant.
129. The composition of any one of claims 121 to 128, wherein the composition comprises about 5% or less 3 / 4 antibodies.
130. The composition, a) at least about 95% to about 100% multispecific antibodies; b) about 1% to about 5% or less of the non-paired antibody arms; c) about 1% to about 5% or less antibody homodimers; d) about 1% or about 2% HMWS or less; e) about 1% or about 2% LMWS or less; and f) The composition of claim 121 or claim 122, comprising about 5% or less of 3 / 4 antibodies.
131. The composition of any one of claims 121 to 130, wherein the bispecific antibody binds ANG-2 and VEGF.
132. The bispecific antibody that binds ANG-2 and VEGF, a) the heavy chain and the light chain of a first full-length antibody comprising the first antigen-binding site; and b) the constant domains CL and CH1 are replaced by each other, the modified heavy chain and the modified light chain of a full-length antibody comprising the second antigen-binding site.
133. 1. A composition comprising a bispecific antibody that binds ANG-2 and VEGF, said composition comprising about 5%, about 4%, about 3%, about 2%, or about 1% or less of 3 / 4 antibody.
134. The bispecific antibody that binds ANG-2 and VEGF, a) the heavy chain and the light chain of a first full-length antibody comprising the first antigen-binding site; and The composition of claim 133, comprising the modified heavy chain and the modified light chain of a full-length antibody comprising the second antigen-binding site, wherein the constant domains CL and CH1 are replaced by each other.
135. 135. The composition of claim 133 or 134, wherein the composition is obtained using the method of claim 119.
136. Use of the method according to any one of claims 88 to 118 for the purification of an Fc-containing heterodimeric polypeptide.
137. Use of the method according to any one of claims 88 to 118 for the reduction of Fc-containing heterodimeric polypeptide related impurities.
138. 121. An Fc-containing heterodimeric polypeptide obtainable by the method of any one of claims 88 to 118, or a bispecific antibody binding ANG-2 and VEGF obtainable using the method of any one of claims 119 to 120, for the manufacture of a medicament for said treatment of cancer or an eye disease.
139. 121. An Fc-containing heterodimeric polypeptide obtainable from the method of any one of claims 88 to 118, or a bispecific antibody binding ANG-2 and VEGF obtainable using the method of any one of claims 119 to 120, for use in said treatment of cancer or an eye disease.
140. 1. A method for producing an Fc-containing heterodimeric polypeptide, comprising: i. culturing a cell comprising a nucleic acid encoding an Fc-containing heterodimeric polypeptide; ii. recovering the Fc-containing heterodimeric protein from the cells or culture medium; iii. Purifying said Fc-containing heterodimeric polypeptide by the method of any one of claims 88 to 118, thereby producing said Fc-containing heterodimeric polypeptide.
141. A method for producing a bispecific antibody binding ANG-2 and VEGF obtained using a method according to any one of claims 119 to 120, comprising the steps of: i. culturing a cell containing nucleic acid encoding the bispecific antibody; ii. recovering the bispecific antibody from the cells or the culture medium; iii. purifying the bispecific antibody by the method of any one of claims 119-120, thereby producing said bispecific antibody that binds ANG-2 and VEGF.
Citation Information
Patent Citations
Dual variable domain immunoglobulins and their use
JP2009504191A
Bispecific antigen-binding protein
JP2012530088A
Bispecific bivalent anti-VEGF / anti-ANG-2 antibody
JP2013526848A
Activatable bispecific antibodies
JP2013538204A
Methods and apparatus for chromatographic purification
JP2014534055A
